INTERNATIONAL CARTILAGE REGENERATION INTERNATIONAL ... · 16.15 Opening Ceremony & Award Session...

&

International Cartilage Regeneration & Joint Preservation Society International Cartilage Regeneration& Joint Preservation Society

I N T E R N AT I O N A L C A R T I L A G E R E G E N E R AT I O N & J O I N T P R E S E R V A T I O N S O C I E T Y

INTERNATIONAL CARTI LAGE REGENERATION & JOINT PRESERVATION SOCIETY

INTERNATIONAL CARTILAGE REGENERATION & JOINT PRESERVATION SOCIETY

I N T E R N A T I O N A L C A R T I L A G E R E G E N E R A T I O N & J O I N T P R E S E R V A T I O N S O C I E T Y

INTERNAT IONAL CART I L AGEREGENER AT ION

JO INT PRESERVAT ION SOCIE T Y &I NTERNAT I O NAL CART I L AGE

REGEN ER AT I O NJO I NT PRESERVAT I O N SO C I E T Y

&INTERNATIONAL CARTILAGEREGENERATION

JOINT PRESERVATION SOCIETY

International Cartilage Regeneration&

Joint Preservation Society

1

International Cartilage Regeneration& Joint Preservation Society

ww.cartilage.org

Final Pocket Programme

#ICRSWORLDCONGRESS

P R O G R A M M E O V E R V I E W

Time Saturday, October 56.006.156.306.457.00 Registration7.157.307.458.008.158.308.459.009.159.309.4510.0010.1510.3010.4511.0011.1511.3011.4512.00 ICRS Meets AAC – Arthroscopy Assoc. of Canada12.1512.3012.4513.00 Next Generation: Promoting Collaboration

in Joint Preservation13.1513.3013.4514.0014.15 News in

Cartilage Imaging?

Rehabilitation Update

Clinical Trials in 201914.30

14.4515.0015.15 Coffee Break / Poster Viewing / Exhibition15.3015.4516.0016.15 Opening Ceremony & Award Session16.3016.4517.00 Honorary Lectures17.1517.3017.4518.00 Welcome Reception18.1518.3018.4519.0019.1519.30

Time Sunday, October 66.00 3rd ICRS Fun Run for Healthy Joints6.156.306.457.007.157.30 Grant Writing

101Joint Preserva-tion of the Hip

Women in the ICRS7.45

8.008.158.30 Post Traumatic Osteoarthritis:

A Preventable Disease?8.459.009.159.309.45 Best & Worst Ex-

periences in Pre-clinical and Clini-cal Joint Repair

Biologics Animal Models in Cartilage Repair

10.0010.1510.3010.45 Coffee Break / Poster Viewing / Exhibition11.0011.1511.30 Anika Arthrex Newclip

Technics’11.4512.0012.1512.30 Regen Lab Zimmer

BiometGeistlich Surgery

JRF Ortho12.4513.00 AlloSource13.1513.30 Cell Based

Therapies in the Knee

Clinical Mis-cellaneous – Part 1

Translatio-nal OA – Part 1

Basic Science Cartilage

13.4514.0014.1514.3014.4515.0015.15 Whole Joint

PreservationICRS NextGen Pain

15.3015.4516.0016.15 Coffee Break/Exhibition/Intermission16.3016.4517.00 Clinical Hip

& AnkleBasic Science OA

Translation-al Meniscus

Biologics17.1517.3017.4518.0018.1518.3018.4519.0019.1519.30 President’s Dinner at Vancouver Club

Time Monday, October 76.006.156.306.457.007.157.30 Cartilage

Repair in the Foot & Ankle

Clinical Trial Design

Joint Preserva-tion of the Knee7.45

8.008.158.30 Stem Cells Without the Hype8.459.009.159.309.45 Joint Loading &

Cartilage HealthTargeting the Cartilage

Big Data10.0010.1510.30

16.00 Spine/Disc CartilageMechanics &Biotribology

Meniscus 201916.1516.3016.4517.00 Coffee Break/Exhibition/Intermission17.15

10.45 Coffee Break/Exhibition/Intermission11.0011.15 Clinical Trials Biomaterials Translational

OA - Part 2Allografts

11.3011.4512.0012.1512.3012.4513.00 Aesculap –

Restoring Cartilage Form & Function

Vericel – Cartilage Restoration

Smith & Nephew – Expanding the Continuum

CartiHeal – The Story of the Agili-C Implant

13.1513.3013.4514.0014.15 Joint

PreservationBasic Science – Stem Cells

Translation-al Science

Clinical Miscellaneous– Part 2

14.3014.4515.0015.1515.3015.45

17.30 ICRS General Assembly17.4518.0018.1518.3018.4519.0019.1519.30 Canadian Farewell Party

Time Tuesday, October 86.006.156.306.457.007.157.307.458.00 Cost Effective Strategies for Joint Preservation8.158.308.459.00 Cartilage Regeneration – Mini Battlefi eld9.159.309.4510.00 Coffee Break/Exhibition/Intermission10.1510.30 Joint Pres-

ervation 2Imaging Stem Cells

& BiologicsOsteoarthri-tis Animal Studies

10.4511.0011.1511.3011.4512.0012.15 Methods to

Assess Cartilage Repair Success or Failure

Subchondral Bone In 2019

Biomaterials / Bioprinting / Bioengineering

12.3012.4513.0013.15 Adjourn

Session Room Location:

Plaza B/C (Floor Level 2)

Regency (Floor Level 3)

Exhibition Area (Floor Level 3)

Georgia (Floor Level 2)

Plaza A (Floor Level 2)

&







JO INT PRESERVAT ION SOCIE T Y &INTERNAT I O NAL CART I L AGE

REGEN ER AT I O NJO INT PRESERVAT I O N SO C I E T Y





5

F L O O R P L A N

UPDN

UP

UPDN

UP

UPUP

DN

UP DN

8 R8 RDN DN

DN UP UPUPUP27 R 5 R 27 R27 R27 R

DN

7

8

13

DN8R

DN8R

UP

STAGE STAGE STAGE

GEORGIAPLAZA APLAZA B/C

DNDN

UP

13R

UP

13R

DN

13RDN

DN 28

DN13R

ELEV 11

SLOPE

DN12R

C REG

ISTR

ATIO

N

ENTRANCE

MEE

TIN

GS

FUTU

REC

CC

C

QUICKSCAN

MAINENTRANCE

COLLAGEN

GEISTLICH

REGENLAB

ARTHREX

SMITH &NEPHEW

JRFORTHO VERICEL

ZIMMER-BIOMET

AESCULAP

CARTIHEAL

CO

FFEE

OSSUR

ALLOSOURCE

LIFENET

CONMED

FINCERAMICA

MEDI GMBH

GENESISORGANO-

COFFEE

ANIKA THERAPEUTICS

BIOMOMENTUM

8 12

9

6

7 13 14 15

23

22

17

5

4

3

2

1

11

10

18

19 20

21

26 27 28BIOGEND

REGENCY

LIPOGEMS

ON

NEWCLIP

ORTEQ

E-PO

STER

S

CERTIFICATESOF ATTENDANCE

PRINCE OFWALES

SPEAKER LOUNGE

OXFORD

SPEAKER READY

STAGE

TECH

29 30 31 32

ICRS

DJOINCREDIWEAR OLIGOMEDIC

24 25

33

SAGE

ASPECT

IB LAB

POSTER EXHIBITION

LEVEL 3

LEVEL 2

BAR / RESTAURANT

EXHIBITOR / DHLHELP DESK

E X H I B I T O R L I S T A – Z

Companies A - Z Booth Nr.Aesculap, Inc. 18AlloSource 7Anika Therapeutics 15Arthrex 14Aspect Biosystems 31BioGend 28Biomomentum 23Cartiheal 11Collagen 1CONMED Orthopedics 9DJO Canada 30Finceramica 8Geistlich Pharma AG 4ICRS Patient Registry 27Image Biopsy Lab 25Incrediwear 29JRF Ortho 12Life Net Health 20Lipogems USA, LLC 3medi GmbH & Co. KG 13Newclip Technics 5OligoMedic Inc 32ON Foundation 26Organogenesis 22Orteq Sports Medicine 6Össur Americas, Inc 2Regen Lab SA 19SAGE Publlications 33Smith & Nephew Inc. 21Vericel Corporation 17Zimmer - Biomet 10

&













9

Now in MEDLINECALL FOR PAPERS

Submit your paper athttp://mc.manuscriptcentral.com/cart

CARTILAGE (CART) is a peer-reviewed quarterlyjournal on the musculoskeletal system with particularattention to cartilage repair, development, function,degeneration, transplantation, and rehabilitation. Aimedat researchers and clinicians involved in cartilagebiology and repair, CART publishes full length originalmanuscripts on all types of cartilage including articular,nasal, auricular, tracheal/bronchial, and intervertebraldisc fibrocartilage. This journal is a member ofthe Committee on Publication Ethics (COPE).

Editor-in-ChiefMats Brittberg, MD, PhDGothenburg University, Sweden

Impact Factor: 2.961Ranking: 18/76 in OrthopedicsSource: 2018 Journal Impact Factor, Journal Citation Reports (Web of Science Group, 2019)

Indexed in MEDLINE/PubMed

journals.sagepub.com/home/car

CARTILAGE (CART)CART)CART isjournal on the musculoskeletalattention to cartilage repair,degeneration, transplantation,at researchers and cliniciansbiology and repair, CARTmanuscripts on all typesnasal, auricular, tracheal/bronchial,

journals.sagepub.com/home/car

1. Appropriate Use Criteria for Hyaluronic Acid in the Treatment of Knee Osteoarthritis in the United States by Arup K. Bhadra, Roy Altman, Vinod Dasa, Karen Myrick, Jeffrey Rosen, Vijay Vad, Peter Vitanzo, Michelle Bruno, Hillary Kleiner, Caryn Just

2. Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis by Roy D. Altman, Vinod Dasa, Jun Takeuchi

3. Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial by Laszlo Hangody, Robert Szody, Piotr Lukasik, Wojciech Zgadzaj, Endre Lénárt, Eva Dokoupilova, Daniela Bichovsk, Agnes Berta, Gabor Vasarhelyi, Andrea Ficzere, György Hangody, Gary Stevens, Miklos Szendroi

4. Long-term Effect of Injection Treatment for Osteoarthritis in the Knee by Orthokin Autologous Conditioned Serum by Danial Zarringam, Joris E. J. Bekkers, Daniel B. F. Saris

5. Evaluation and Management of Osteochondral Lesions of the Talus by Christopher A. Looze, Jason Capo, Michael K. Ryan, John P. Begly, Cary Chapman, David Swanson, Brian C. Singh, Eric J. Strauss

6. Imaging of Folate Receptor Expressing Macrophages in the Rat Groove Model of Osteoarthritis: Using a New DOTA-Folate Conjugate by Huub M. de Visser, Nicoline M. Korthagen, Cristina Müller, Ruud M. Ramakers, Gerard C. Krijger, Floris P. J. G. Lafeber, Freek J. Beekman, Simon C. Mastbergen, Harrie Weinans

7. Three-Dimensional Bioprinting and Its Potential in the Field of Articular Cartilage Regeneration by Vivian H. M. Mouser, Riccardo Levato, Lawrence J. Bonassar, Darryl D. D’Lima, Daniel A. Grande, Travis J. Klein, Daniel B. F. Saris, Marcy Zenobi-Wong, Debby Gawlitta, Jos Malda

8. Cartilage Quality (dGEMRIC Index) Following Knee Joint Distraction or High Tibial Osteotomy by Nick J. Besselink, Koen L. Vincken, L. Wilbert Bartels, Ronald J. van Heerwaarden, Arno N. Concepcion, Anne C. A. Marijnissen, Sander Spruijt, Roel J. H. Custers, Jan-Ton A. D. van der Woude, Karen Wiegant, Paco M. J. Welsing, Simon C. Mastbergen, Floris P. J. G. Lafeber

9. Human Articular Chondrocytes Retain Their Phenotype in Sustained Hypoxia While Normoxia Promotes Their Immunomodulatory Potential by Claire Mennan, John Garcia, Helen McCarthy, Sharon Owen, Jade Perry, Karina Wright, Robin Banerjee, James B. Richardson, Sally Roberts

10.Osteochondritis Dissecans: Etiology, Pathology, and Imaging with a Special Focus on the Knee Joint by Juergen Bruns, Mathias Werner, Christian Habermann

Top 10 Most-Read Articles from CARTILAGE

&













13

Schedule at a Glance .................Front Cover Fold Out

Floor Plans ................................Front Cover Fold Out

Oranization ........................................................ 14

History & Awards .......................................... 15–17

AV Centre/Slide Room ........................................ 18

General Information A–Z ................................ 19–23

Scientifi c Programme..................................... 26–62Saturday ............................................................. 26Sunday ............................................................... 29Monday .............................................................. 46Tuesday .............................................................. 62

Poster Exhibition .......................................... 72–100

Exhibitor & Sponsor Guide .......................... 101–116

C O N T E N T SBerlinGermany May 26–29, 2021

16th World Congressof the International Cartilage Regeneration & Joint Preservation Society


Mark your agenda!

www.cartilage.org

&













15O R G A N I Z AT I O N

Congress Organizing Offi ceCartilage Executive Offi ce GmbHSpitalstrasse 190 – House 3CH-8623 Wetzikon ZH, SwitzerlandPhone: +41 44 503 73 [email protected]

Congress Venue/HotelHyatt Regency Vancouver655 Burrard StreetBC V6C 2R7 Vancouver, CanadaPhone: +1 604 683 1234 www.vancouver.regency.hyatt.com

Hyatt Convention Service ManagerDarin Lee, Event Planning [email protected]

Offi ce & Registration DesksThe ICRS Congress Secretariat and Registration Desks are located at Level 2 of the Hyatt Convention Centre.

Opening Hours:Friday Oct 04 16.00 – 18.30Saturday Oct 05 09.00 – 18.30Sunday Oct 06 07.15 – 18.30Monday Oct 07 07.15 – 18.30Tuesday Oct 08 07.45 – 14.00

AV Centre / Speaker Ready RoomThe Speaker Ready Room is located on Floor 4 of the HyattConvention Centre.

Opening Hours:Friday Oct 04 16.00 – 18.30Saturday Oct 05 08.00 – 18.30Sunday Oct 06 07.00 – 18.30Monday Oct 07 07.00 – 18.30Tuesday Oct 08 07.30 – 14.00

H I S T O RY

Past ICRS World Congresses1997 – 1st World Congress Freiburg, Switzerland; Roland Jakob

1998 – 2nd World Congress Boston, USA; Alan Grodzinsky

2000 – 3th World Congress Gothenburg, Sweden; Lars Peterson

2002 – 4th World Congress Toronto, Canada; Shawn O’Driscoll

2004 – 5th World Congress Gent, Belgium; Rene Verdonk

2006 – 6th World Congress San Diego, USA; Bert Mandelbaum, Bill Bugbee

2007 – 7th World Congress Warsaw, Poland; Jaroslaw Deszczynski, Jacek Kruczynski; Konrad Slynarski2009 – 8th World Congress Miami, USA; Jack Farr, Tom Minas2010 – 9th World Congress Sitges / Barcelona, Spain; Ramon Cugat, Pedro Guillen

2012 – 10th World Congress Montreal, Canada; Michael Buschmann, Patrick Lavigne

2013 – 11th World Congress Izmir / Turkey; Mehmet Binnet, Didem Kocazi

2015 – 12th World Congress Chicago / USA; Brian Cole, Susan Chubinskaya

2016 – 13th World Congress Sorrento / Italy; Stefano Della Villa, Donato Rosa

2018 – 14th World Congress Macao / SAR China; Yingfang Ao

Past ICRS Presidents1997 – 1998 Roland Jacob, Switzerland 1999 – 2000 Alan Grodzinsky, USA 2000 – 2001 Lars Peterson, Sweden 2002 – 2003 Shawn O’Driscoll, USA 2004 – 2005 Ernst Hunziker, Switzerland 2006 – 2007 Mats Brittberg, Sweden2008 – 2009 Bert Mandelbaum, USA2009 – 2010 Lisa Fortier, USA2011 – 2012 Daniël Saris, USA2012 – 2013 Anthony Hollander, UK2014 – 2015 Chris Erggelet, CH2015 – 2016 Norimasa Nakamura, JP2016 – 2018 Kenneth Zaslav, USA 2018 – 2019 Alberto Gobbi, IT (current)

&













17

Honorary Fellows2007 Grodzinski Alan, US2007 Jakob Roland, CH2007 Peterson Lars, SE2009 Brittberg Mats, SE2012 Minas Tom, US2012 Nehrer Stefan, AT2015 Chubinskaya Susan, US2016 Mandelbaum Bert, US2016 Kandel Rita, CA2018 Fortier Lisa, US2018 Nixon Alan, US2018 McIlwright Wayne, US2019 Cugat Ramon, ES2019 Guillen Pedro, ES

ICRS Lifetime Award2004 Peterson Lars, SE2006 Gross Allan, CA2007 Caplan Arnold, US2009 Steadman Richard, US2010 Brittberg Mats, SE2012 Buckwalter Joseph, US2013 Poole A. Robin, CA2015 Bentley George, UK2016 Sandell Linda, USA2018 Jakob Roland, CH2019 Lindahl Anders, SE

ICRS Award for Excellence in Cartilage Research2004 R. Dorotka et al, AT2006 M. Randolph et al, UK2007 G. Van Osch et al, NL2009 A. Yayon, et al, Israel2010 A. Aszody, et al, DE2012 X, Cui et al, US2013 S. Zhu et al, China2015 W. Wei et al, NL2016 K. Sivasubramaniyan et al, NL2018 Y. Chen et al, China

Best Rated Abstracts2007 K. Nakagawa et al, Japan2007 C. Moser et al, Germany2009 J.F. Harrington et al, USA2010 S. D’Arcy et al, Ireland2012 G. Van Den Akker, NL2013 N. Nakamura et al, Japan2015 S. Grässel et al, Germany2016 H. Fujie et al, Japan2018 G. Hu et al, China2019 G. Merkely et al, USA

AWA R D W I N N E R S I C R S S O C I E T Y

ICRS Executive BoardPresident: Gobbi Alberto, Milano, IT 1st Vice President: Minas Tom, West Palm Beach, US2nd Vice President: Kon Elizaveta, Milan, ITSecretary General: Grande Daniel, Manhasset, USTreasurer: Lattermann Christian, USPast President: Zaslav Ken, Richmond, US

ICRS General Board• Biant Leela, Edinburgh, GB• Brittberg Mats, Göteborg, SE• Cole Brian, Chicago, US• Decker Rebekah, San Diego, US• Getgood Alan, Ontario, US• Gobbi Alberto, Milano, IT• Gomoll Andreas, New York, US• Grande Daniel, Manhasset, US• Hurtig Mark, Guelph, CA• Kon Elizaveta, Milano, IT• Lane John, San Diego, US• Lattermann Christian, Lexington, US• Mandelbaum Bert, Santa Monica, US• Marlovits Stefan, Vienna, AT• McCormack Robert, Vancouver, CA• Minas Tom, Chestnut Hill, US• Nehrer Stefan, Krems, AT• Papacostas Emmanuel, Thessaloniki, GR• Sherman Seth, Columbia, US• Vonk Lucienne, Utrecht, NL• Zaslav Ken, Richmond, US

ICRS 2019 Congress Co-Chairs• Hurtig Mark, Guelph, CA• McCormack Robert, Vancouver, CA

Scientifi c Programme Committee• Getgood Alan, Ontario, US (Co-Chair)• Vonk Lucienne, Utrecht, NL (Co-Chair)• Chubinskaya Susan,Chicago, US• Lattermann Christian, Lexington, US• Krych Aaron, Rochester, US• Roberts Sally, Shropshire, UK• Snow Martyn, Bromsgrove, UK• Stoddart Martin, Davos, CH

ICRS Executive Offi ceCartilage Executive Offi ce GmbHSpitalstrasse 190 – House 3CH-8623 Wetzikon ZH, SwitzerlandPhone: +41 44 503 73 70Email: [email protected]

&













19AV CENTRE/SPEAKER’S READY ROOM

The Speaker Ready Room “Prince of Wales” is located on the Third Floor of the Hyatt Convention Centre close to the Registration Area.

Instructions for Presenters: The offi cial congress language is English. If English is not your native language, we recommend that you have your presentation proof-read by a native speaker if possible. Presentations must be provided on a USB-Memory Stick to be uploaded on our central server. It is mandatory to deliver presentations to the Speaker Ready Room at least 3 hours prior to the respective session. In case you have an early morning session, presentations must be uploaded the day before. The computers in the server room are equipped with Microsoft Windows 10 and Microsoft Offi ce 2016. If you use Macintosh, please convert your keypoint presentation or your PowerPoint Presentation for MAC into PowerPoint for PC Windows format.

Please embed the videos into you PowerPoint Presentation. The following video formats are recommended: .mp4, .mpeg2, .wmv. Please use only common and widespread encodings (codecs), preferably in their newest version. If you have any doubt, please contact the Speaker Ready Room 4 hours before your presentation. Our staff will have enough time to verify and adapt your presentation if needed. Do not use special fonts which are not part of the standard PowerPoint package, as this will cause prob-lems while uploading your fi le. Such presentations cannot be edited in the Speaker Centre. The requested presentation format for your Slides is 16:9.

Important: It will not be possible to use your own laptop or your USB-stick for your presentation in the session rooms. If a presenter has included videos into the PPT presentations, she/he should make sure that the movies run on the most commonly used video software with Windows compatible codec. File names of the presentation fi le should include the presenter’s name and the presentation number. To avoid any compatibility problems, please do not use special characters (e.g. Ö, Ø, ñ, ε, ®) to name your presentation. The presentation material remains the property of the speakers and will only be re-used by ICRS with the speaker’s permission. Without formal per-mission, your presentation data will be defi nitely deleted after the congress.

Financial Disclosure: All Presenters must include their Financial Disclosure Statement. We request all presenters to cooperate in this by declaring any commercial role or confl icts of interests in the related research on the fi rst slide of their PP Presentations or on the posters for poster presentations.

Speaking Time Free Papers: 6 Minutes + 3 DiscussionIt is essential that all podium presenters respect the given speaking time in order not to delay the entire congress schedule. Session Moderators will in-terrupt presentations in case of exceeding the speaking time of 6 Minutes.

Submit Your Publication to our Journal “Cartilage”We encourage authors to submit full manuscripts to our peer reviewed jour-nal “Cartilage” ISSN 1947-6043 (now indexed at PUBMED), which publish-es full-length original manuscripts on all types of cartilage including articular, nasal, auricular, tracheal/bronchial, and intervertebral disc fi brocartilage. Manuscripts on clinical and laboratory research are welcome. Instructions to authors for submissions are available at http://cart.sagepub.com.

GENERAL INFORMAT ION A -Z

Awards & Honours ICRS 2019 (Opening Ceremony)Saturday, Oct. 05 from 17.15 – 18.00 in the Main Auditorium

The following scientifi c awards will be presented:• 1 x Overall Best Rated Abstract• 2 x Poster Award Magna Cum Laude• 2 x Poster Award Cum Laude• 2 x Poster Certifi cate of Merit• 1 x ICRS Lifetime Award• 1 x James Richardson Award• 1 x Young Investigator’s Award (US$ 1000.00)• 1 x ON Orthoregeneration Award (US$ 1000.00)• 1 x ICRS Excellence in Cartilage Research (US$ 3000)

Badges, Bags – Scan & GoParticipants are required print out their offi cial congress registration confi rmation / barcode or have it ready on a mobile device. Upon arrival, participants should scan their barcode at the Scan & Go sta-tion and a badge will be printed automatically. The personalized badge is not transferrable and it is the admission to the congress. Delegates can then check-in at the appropriate registration desk to pick up their extra vouchers and the congress bags.

Badge Replacement: Please do not forget or lose your badge. In case of loss, a replacement badge will only be provided against an administrative charge of € 50.00. Name changes will be charged with € 100.00 each.

Certifi cate of AttendancePlease use one of the dedicated workstations to print out your certifi -cate of attendance. You can also print your certifi cate at home after the congress by accessing your ICRS online account. This year you are requested to fi ll in a short meeting survey of every session you have attended, before you can print out your certifi cate of attendance.

CME Credits (Maximum of 22 Credits)The ICRS 2019 World Congress Vancouver is an accredited Group Learning Activity (Section 1) as defi ned by the Maintenance of Certifi cation program of The Royal College of Physicians and Surgeons of Canada, and approved by The Canadian Orthopae-dic Association. The ICRS event is accredited for a maximum of 22 Section 1 CME credits. Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

• AMA PRA Category 1 Credit™ DesignationThrough an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credit™. Information on the process and cost to con-vert Royal College MOC credit to AMA credit can be found on the AMA website at https://www.ama-assn.org/education/cme/agreement-royal-college-physicians-surgeons-canada

&













21

• UEMS – ECMEC®Live educational activities recognized by the Royal College of Phy-sicians and Surgeons of Canada as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medi-cal Specialists (UEMS) eligible for ECMEC®.https://www.uems.eu/areas-of-expertise/cme-cpd/eaccme/mutu-al-recognition-with-canada

How can I obtain CMEs for ICRS 2019?ICRS uses a digital session evaluation system. Visit sessions and evaluate them immediately afterwards either on one of the termi-nals or via your smart phone, tablet or laptop through the ICRS 2019 Congress App.

When is the deadline for completing evaluations?Make sure to submit your evaluations immediately after each ses-sion during the congress! Online evaluation of the sessions is possi-ble until October 25, 2019. No evaluation is possible and no CME credits can be obtained after this date for sessions which were not evaluated on time.

Credit Cards / Cash MachinesAll major credit cards are widely accepted. Bank cash machines (ATM) can be found easily and debit cards are also widely used. If you are using a foreign card at a bank machine, your money will be disbursed in Canadian Dollars.

CurrencyThe currency in Canada is the Canadian Dollar. 1 $CAD ≈ 0.75 US$ ≈ 0.67 € Euros (Date of printing, Aug 2019)

DisclaimerICRS and the congress organizer cannot accept any liability for the acts of any suppliers to this meeting nor of the safety of any attend-ee while in transit to or from this event. Participants are strongly advised to carry proper travel and health insurance as the ICRS cannot accept liability for any accidents or injuries that may occur. Information in this programme is subject to change without prior notice. For updated information, please visit frequently our con-gress website at www.cartilage.org.

Electricity, Weights and Measures• Electricity: 220 volts 60 hz• Weights: Kilo/Gramm system• Measures: Metric system

Health CareSpecial vaccinations are not required for entry into Canada but an individual travel & health insurance is highly recommended be-cause health insurance plans often do not extend full coverage for medical services received outside the country of residence.


Industry ExhibitionA technical industry exhibition will take place at the Hyatt Con-vention Centre. It will be open every day throughout the meeting and exhibitors from around the world will present a wide range of orthopaedic and cartilage repair related products. Participants are encouraged to take advantage of this unique opportunity to be updated with the most recent advances and latest news from our industry partners.

IntermissionsDuring intermissions, coffee, tea and refreshments will be served in the exhibition area as a courtesy of the ICRS.

Internet/WLANAs a special courtesy, ICRS will provide free WLAN Hot Spots and a public Internet corner to all attendees and exhibitors.

LanguageThe offi cial congress language is English. No simultaneous trans-lation will be provided.

Members’ General Assembly (for ICRS Members only)Monday, Oct 07 from 17.30–18.30 at Regency Ballroom

All present ICRS members are expected to attend the ICRS General Member’s Assembly. Retired Members and Corporate Members have no right to vote, but are most welcome to attend.

Meals, Snacks & RefreshmentsSeveral restaurants & bars in the hotel and adjacent shopping cen-ter will be at your service subject to their opening hours. Delegates may purchase meals and drinks against payment. No offi cial lunch will be provided by the congress organizer. Industry Satellite Symposia organizers will offer lunch boxes during their symposia. During intermissions, coffee, tea and refreshments are served in the exhibition area as a courtesy of the ICRS.

Opening Ceremony & Awards SessionSaturday Oct. 05 from 16.15 – 17.00 in the Main Auditorium

Phones Please turn-off or set your mobile phone to “silent-mode” during all scientifi c sessions.

Photos/RecordingTaking photos or video/audio recording during the scientifi c pre-sentations or from the poster area is strictly prohibited. Note that a vast majority of the speakers’ presentations, posters and all offi -cially recorded sessions will become available online after the con-gress on the ICRS website in the members’ area. Therefore, there is no need to take pictures during the sessions or from poster exhibits.


&













23

Scientifi c Poster ExhibitsSaturday, Oct 05 from 15.15 – 16.15 in the Poster AreaSunday, Oct 06 from 10.45 – 12.30 in the Poster Area

Computer stations will be available for viewing about 250 elec-tronic scientifi c poster exhibits. The electronic system offers greater fl exibility and provides enhanced opportunities for communica-tion. The ability to use moving images, to link to related websites, to search quickly the whole of the scientifi c exhibition for specifi c topics in seconds, to e-mail entire exhibits to one’s-self or to a col-league and to access the exhibit from any internet-linked computer in the world are amongst its many advantages besides the post congress availability of the presentations during many years.

In addition to the full electronic poster session, available through the dedicated computer stations, the authors were asked to bring also a traditional paper posters by reserving a poster wall in ad-vance. Approximately 120 posters are located in the poster area.

Abstracts of all posters can be found on our website and on the electronic poster viewing system onsite. All congress participants are strongly encouraged to join the poster session. To facilitate discussions and networking, all poster presenters are required to stay near their poster boards during this session. Authors should encourage a lively discussion with interested participants. The pre-senters should introduce themselves as poster presenters and be well prepared to answer questions and initiate discussions.

Security / Badge ControlThe safety of all congress attendees is of utmost importance to our society. The ICRS and the Hyatt Vancouver have taken security precautions to ensure the maximum possible safety for all partici-pants. Identity check controls may occur at any time by the securi-ty staff. Congress badges are personalized, not transferable and guarantee individual access to different sections of the event. For organizational and security reasons, badges have to be worn all the time at the congress venue.

SmokingThe ICRS World Congress is a non-smoking congress. Smoking is not permitted at the Hyatt Hotel and its Conference Centre except in designated smoking areas.


Social Networking Events

Welcome Reception – Saturday, Oct 05 from 18.00 – 19.30Exhibit Area – The Welcome Reception is offered by the ICRS

3rd ICRS Fun Run for Healthy Joints (3-4 km)Sunday, Oct 06 from 06.00–0645Participants wanting to get off the treadmill and take their workout outside can join the ICRS Fun Run led by members of the HYATT Regency Vancouver management team. Runners meet at 6:00 AM in the Lobby for a four-mile jog. Price per Person: € 10.00 (partly sponsored by Hyatt) (incl. T-shirt, towels and a refreshing juice)

Presidents Dinner – Sunday, Oct 06 from 19.30 – midnightVancouver Club – Upon invitation only – Walking Distance 10 Min

Canadian Night (Farewell Party)Monday, Oct 07 from 19.45 – midnightBrewhall, 97 E 2nd Ave. VancouverMeeting Point: 19.15, Hyatt Lobby Back EntranceBus Departure: 19.30 Ticket price: € 90.00

TippingCanada, like the USA, has a strong culture of tipping. Gratuities are seldom included in Canadian restaurants. It is customary to tip approx-imately 15-20% on the total bill. Tipping at hotels does not stop with the porter who brings baggage to a guest room. Doorman, Chamber-maid, Concierge, Valet, they all expect a few CAD for their services


&













25

The Future of Joint Repair

CartiHeal is pleased to invite you toa lunch symposium

The Story of the Agili-C™ Implantfrom Bench to Bedside

Lunch boxes will be available for attendees

Hyatt Regency Vancouver - Plaza A Room Monday, October 7th 2019 | 12:30pm - 1:30pm

ModeratorsDr. Andreas Gomoll & Dr. Seth Sherman

SpeakersDr. K. Zaslav (Richmond, USA)The science: Osteochondral remodelling using aragonite-based implants

Prof. P. Verdonk (Antwerp, Belgium)Best practices: Agili-C™ surgical technique

Dr. E. Kon (Bologna, Italy)Clinical outcomes: Treating focal lesions, osteochondral defects and osteoarthritis using Agili-C™

Q&ADr. Andreas Gomoll & Dr. Seth Sherman

October 6th 2019Sunday, 12:30–13:30 Room “Georgia”

Matthias Steinwachs, Zurich/Switzerland

Fabio Sciarretta, Rome/Italy

Tomasz Piontek, Poznan/Poland

ICRS 2019 World Congress Vancouver

Innovative Cartilage Regeneration Techniques with Chondro-Gide®

Geistlich Lunch

Symposium

&













27S AT U R D AY, O C T O B E R 5 , 2 019

07:00 - 08:30 ICRS Committee Meetings Room: TurnerICRS Editorial Board Breakfast Meeting

08:45 - 10:00 ICRS Committee Meetings Room: Lord ByronICRS Executive Board Meeting

10:15 - 12:00 ICRS Committee Meetings Room: TurnerICRS General Board Meeting

12:00 - 13:00 Plenary Session Room: Georgia1.0 ICRS Meets AAC – Arthroscopy Assoc. of Canada Moderators: Alan Getgood/CA, Robert McCormack/CA

1.0.1 The Patient Perspective P. Dowling/Vancouver, CA

1.0.2 Stem Cell Tourism - The Scientist’ Perspective R. Krawetz, Calgary/CA

1.0.3 Stem Cell Tourism - The Clinican’ Perspective J. Chahal, Toronto/CA

1.0.4 Discussion & Take Home Points

13:00 - 14:00 Plenary Session Room: Regency2.0 Next Generation: Promoting Collaboration in Joint Preservation Moderators: Lars Peterson/SE, Seth Sherman/US

Objective: Upon completion of this session, participants will understand the benefi ts of collaboration between clinicians, scientists and industry.

2.0.1 A Joint Effort: Clinical and Research Collaboration to Treat and Understand Knee Pathologies A. Yanke, H. Huddleston, Chicago/US

2.0.2 Bridging the Bed-Bench Gap: Scientist Perspective R. Decker, San Diego/US

2.0.3 Innovating Joint Preservation - An Industry Perspective S. Kili, London/GB

S AT U R D AY, O C T O B E R 5 , 2 019

14:15 - 15:15 Special Session Room: Plaza B&C3.1 What’s New in Cartilage Imaging? Moderators: Goetz Welsch/DE, Stefan Marlovits/AT

Objective: After attending this session, attendees will have an update on the current status of imaging and where future research is heading.

3.1.1 Quantitative MRI V. Pedoia, San Francisco/US

3.1.2 Is there a Role for Nuclear Imaging? F. Kogan, Stanford/US

3.1.3 Multi-modal Evaluation of Cartilage & Bone in Acute Knee Injury S. Boyd, A. Kroker, B. Besler, J. Bhatla, M. Shtil, P. Salat, N. Mohtadi, R. Walker, S. Manske, Calgary/CA

14:15 - 15:15 Special Session Room: Plaza A3.2 Rehabilitation Update Moderators: Matthias Steinwachs/CH, Timothy Hewett/US

3.2.1 Prevention Strategies: Current Trends & Knowledge Using the Experiences of ACL Research K. Webster, Melbourne/AU

3.2.2 Does Blood Flow Restriction have a Role? C. Jacobs, Lexington/US

3.2.3 Can we Accelerate Rehab? L. Snyder-Mackler, Newark/US

14:15 - 15:15 Special Session Room: Georgia3.3 Clinical Trials in 2019 Moderators: Philipp Niemeyer/DE, Emmanuel Papacostas/GR

Objective: In this session, participants will learn the results of clinical trials that have been completed in 2018/ beginning 2019

3.3.1 Neocart D. Crawford, Portland/US

3.3.2 Prospective, Randomized Trial to Compare Autologous Chon- drocyte Implantation with Spheroid Technology vs. Microfracture P. Niemeyer, Munich/DE

3.3.3 Regeneration of Articular Cartilage Lesions using Nasal Chondrocyte-Based Engineered Cartilage Grafts I. Martin, M. Mumme, Basel/CH

&













29

15:15 - 16:15 Coffee Break / Poster Viewing / Exhibition

16:15 - 17:00 Plenary Session Room: Regency4.0 Opening Ceremony and Award Session

17:00 - 18:00 Plenary Session Room: Regency5.0 Honorary Lectures5.0.1 Monoclonal Antibodies Against Glycosaminoglycan & Proteoglycan Epitopes & Neoepitopes: Science, Luck & Magic B. Caterson, Cardiff/GB

5.0.2 Horses and Humans: Building a Translational Research Program in Osteoarthritis and Cartilage Repair W. McIlwraith, Fort Collins/US

18:00 – 19:30 Social Event Room: Exhibition Area5.9 Welcome Reception All participants, industry representatives and accompanying persons are invited to join this welcome cocktail in the Exhibit Area. The welcome reception is offered to you by the ICRS. After the cocktail, participants have free time for their own leisure to discover Vancouver and enjoy one of the many nice Restaurants, Bars & Clubs.

S AT U R D AY, O C T O B E R 5 , 2 0 1 9 S U N D AY, O C T O B E R 6 , 2 0 1 9

06.00 – 06.45 Social Event Outdoor6.0 3rd ICRS Fun Run for Healthy Joints (3-4 km) Participants wanting to get off the treadmill and take their workout outside can join the ICRS Fun Run led by members of the HYATT Regency Vancouver management team. Runners meet at 5:45 AM in the Lobby for a four-mile jog returning by 6:45 AM. Price per Person: € 10.00 (partly sponsored by Hyatt) (incl. T-shirt, towels and a refreshing Juice)

07:30 – 08:30 Instructional Course Room: Plaza A6.1 Grant Writing 101 Moderators: Norimasa Nakamura/JP, Anthony Hollander/GB Objective: In this instructional course, participants will get advise how to write a successful grant application6.1.1 Consortium-Based Grants E. Kon, Milano/IT6.1.2 Research Grants L. Fortier, Ithaca/US6.1.3 Do’s & Dont’s in Grant Writing D. Grande, Manhasset/US

07:30 - 08:30 Instructional Course/Workshop Room: Plaza B&C6.2 Joint Preservation of the Hip Moderators: Aaron Krych/US, Jas Chahal/CA Objective: In this case-based round-the-table instructional course, anonymised patient cases and treatments of joint problems in the hip will be interactively discussed6.2.1 Case Based Roundtable I. Wong, Halifax/CA6.2.2 Case Based Roundtable A. Krych, Rochester/US6.2.3 Case Based Roundtable C. Erggelet, Zurich/CH

07:30 - 08:30 Instructional Course/Workshop Room: Georgia6.3 Women in the ICRS Moderators: Lucienne Vonk/NL, Susan Chubinskaya/US Objective: The goal of this course is to identify problems with female diversity and inclusion in the orthopaedic fi eld, to provide females with advise on female leadership and to identify whether females participating this event feel that sessions on female leadership should be offered more often6.3.1 Thriving in a Male-Dominated Environment S. Chubinskaya, Chicago/US6.3.2 Challenges & Opportunities of Female Orthopaedic Surgeons C. Lee, Sacramento/US6.3.3 Challenges & Opportunities of Female Veterinarians L. Goodrich, Fort Collins/US

&













31S U N D AY, O C T O B E R 6 , 2 0 1 9

08:30 - 09:30 Plenary Session Room: Regency7.0 Post Traumatic Osteoarthritis: A Preventable Disease? Moderators: Alan Getgood/CA, Stefan Lohmander/SE

Description: Participants of this session will learn and understand biomarkers and molecular targets for osteoarthritis and learn on promising new treatments

7.0.1 Molecular Targets T. Appleton, London/CA

7.0.2 Biomarkers A. Mobasheri, Oulu/FN

7.0.3 Challenging Treatment Paradigms/Novel Treatments C. Lattermann, Boston/US


09:45 - 10:45 Special Session Room: Regency8.1 My Best & Worst Experiences in Preclinical and Clinical Joint Repair Moderators: Brian Cole/US, Anders Lindahl/SE

Objective: In this session participants will learn from senior scientists and clinicians what they have done very well and what they would do differently if they could re-do something

8.1.1 A Scientist Perspective S. Lohmander, Lund/SE

8.1.2 A Scientist’s Best & Worst Experiences Related to Cell Therapy for Joint Preservation S. Roberts1, J.H. Kuiper2, C. Mennan1, 1Shropshire/ GB, 2Oswestry/GB

8.1.3 A Scientist Perspective B. Johnstone, Portland/US

8.1.4 A Clinician Perspective D.B. Saris, Rochester/US

8.1.5 A Clinician Perspective T. Spalding, Coventry/GB

8.1.6 A Clinician Perspective - “Experience is the Hardest Teacher, it gives you the Test First and the Lesson After” - Oscar Wilde W. Bugbee, La Jolla/US

S U N D AY, O C T O B E R 6 , 2 0 1 9

09:45 - 10:45 Special Session Room: Georgia8.2 Biologics Moderators: Martin Stoddart/CH, Lucienne Vonk/NL

Objective: Participants of this session will learn the current status and scientifi c results of using antibodies, cytokines, PRP, bone marrow and adipose tissue stromal vascular fraction concentrates, and exosomes

8.2.1 Antibodies & Cytokines O. Jeon, Baltimore/US

8.2.2 PRP, BMC, SVF G. Filardo, A. Roffi , A. Di Martino, L. Andriolo, Bologna/IT

8.2.3 Extracellular Vesicles from Mesenchymal Stem Cells: Results & Perpectives Towards an Acellular Therapy in Rheumatic Diseases D. Noel, Montpellier/FR

09:45 - 10:45 Special Session Room: Plaza A8.3 Animal Models in Cartilage Repair Moderators: Mark Hurtig/CA, David Frisbie/US

Objective: Attendees of this session will learn on small and large animal models that are used to research cartilage repair (with the 3R’s in mind)

8.3.1 Are Rodent Models Relevant? F. Beier, London/CA

8.3.2 What is the Best Large Animal Model? F. Henson, Cambridge/GB

8.3.3 α10hi MSCs Decrease Synovial Membrane Long Term Expres- sion of TIMP-2 and NFκB Following Articular Injury L. Fortier, M. Delco, M. Cercone, L. Becktell, M. Okudaira, M. Goodale, L. Seewald, Ithaca/US

10:45-11:30 Coffee Break / Poster Viewing / Exhibition

&













33

11:30 - 12:15 Industry Satellite Symposium Room: Plaza B&C9.1 Anika – Preservation & Regeneration: A Joint Approach Moderator: Sanjay Anand/GB

9.1.1 CINGAL: Preservation of Movement with a Combination Therapy for OA Pain S. French, Calgary/CA

9.1.2 HYALOFAST: One-Step Cartilage Regeneration from Science to Practice S. Anand, Cheadle/GB

9.1.3 HYALOFAST: Arthroscopic Implantation in a Limited Access Location: Surgical Technique K. Slynarski, Warszawa/PL

11:30 - 12:15 Industry Satellite Symposium Room: Georgia9.2 Arthrex Innovations: Emerging Techniques for Treating Complex Cartilage Pathology Moderator: Adam Anz/US

9.2.1 Addressing Bone Marrow Lesions with the IntraOsseous BioPlasty™ Technique A. Anz, Gulf Breeze/US

9.2.2 Cartilage Restoration with BioCartilage® Extracellular Matrix and the GraftNet™ Device B. Cole, Chicago/US

9.2.3 Innovations in Meniscus Repair for Cartilage Preservation A. Krych, Rochester/US

9.2.4 Q&A / Discussion

11:30 - 12:15 Industry Satellite Symposium Room: Plaza A9.3 Newclip Technics’ Solutions Around Knee Osteotomies Moderators: Kristian Kley/DE, Matthieu Ollivier/FR

9.3.1 Planning of Osteotomies: HTO/DFO/Double Level K. Kley, Hannover/DE

9.3.2 Patient Specifi c Instrumentation for HTO and DFO: Presentation & Key Points of the Surgical Techniques M. Ollivier, Marseille/FR

S U N D AY, O C T O B E R 6 , 2 0 1 9

12:30 -13:30 Industry Satellite Symposium Room: Georgia9.4 Geistlich Surgery - Innovative Cartilage Regeneration Techniques with Chondro-Gide®

Moderator: Matthias Steinwachs/CH

9.4.1 Platelet rich plasma (PRGF®) enhanced AMIC® in the knee M. Steinwachs1, M. Mumme2, 1Zürich/CH, 2Basel/CH

9.4.2 LIPO-AMIC F. Sciarretta, Rome/IT

9.4.3 Membrane Induced Meniscus Regeneration with Chondro-Gide T. Piontek1, K. Ciemniewska-Gorzela2, 1Poznan/PL, 2Poznań/PL

12:30 - 13:00 Industry Satellite Symposium Room: Plaza B&C9.5 Regen Lab - Platelet Rich Plasma (PRP) and HA Combination in Osteoarthritis & Sport Medicine Moderators: Alberto Gobbi/IT, Bert Mandelbaum/US

9.5.1 Adipose Tissue Vs. Cellular Matrix A. Gobbi, Milano/IT

9.5.2 Medical Treatment Update in OA & Sports Medicine B. Mandelbaum, Santa Monica/US

13:00 - 13:30 Industry Satellite Symposium Room: Plaza B&C9.6 AlloSource® – Solving Long Term (2-Year) Storage of Viable Cartilage: ProChondrix® CR

9.6.1 Does Cryopreservation of a Thin Osteochondral Allograft Provide the Necessary Components for Repair of Superfi cial Cartilage Defects? P. Stevens, Centennial/US

S U N D AY, O C T O B E R 6 , 2 0 1 9

&













35

12:30 - 13:30 Industry Satellite Symposium Room: Plaza A9.7 JRF Ortho - The Case for OCA’s: Outcomes, Uses, and Economics 9.7.1 Presentation 1 W. Bugbee, La Jolla/US

9.7.2 Presentation 2 S. Sherman, Redwood City/US

9.7.3 Presentation 3 T. Spalding, Coventry/GB

12:30 -13:30 Industry Satellite Symposium Room: Regency9.8 Zimmer Biomet - Early Intervention Strategies: Bridging the Gap in the Continuum of Care Moderator: Jennifer Woodell-May/US

9.8.1 Treatment of Knee Osteoarthritis with the APS Kit: The Japanese Experience M. Sato, Kanagawa/JP

9.8.2 The Treatment of Chronic, Symptomatic Bone Marrow Lesions of the Knee, using the Subchondroplasty® Procedure C. Hajnik, Encinitas/US

S U N D AY, O C T O B E R 6 , 2 0 1 9

13:30 - 15:00 Free Paper Session Room: Regency10.1 Cell Based Therapies in the Knee Moderators: Daniel BF Saris/US, Stefan Nehrer/AT10.1.1 Hypertension Increases Graft Failure Rate After Autologous Chondrocyte Implantation G. Merkely1, J. Ackermann1, A. Gomoll2, 1Boston/US, 2New York/US

10.1.2 High rate of failure after matrix-assisted autologous chondrocyte transplantation in osteoarthritic knees at 15 years’ follow-up. L. Andriolo, A. Sessa, I. Romandini, D. Reale, A. Di Martino, S. Zaffagnini, G. Filardo, Bologna/IT10.1.3 Long-term results and prognostic factors after Matrix-assisted Autologous Chondrocyte Transplantation for knee cartilage lesions F. Perdisa, L. Andriolo, A. Poggi, D. Reale, R. De Filippis, A. Di Martino, S. Zaffagnini, G. Filardo, Bologna/IT10.1.4 Long-term results of matrix-assisted autologous chondrocytes transplantation combined with bone grafting for JOCD L. Andriolo, F. Perdisa, A. Poggi, A. Roffi , A. Di Martino, S. Zaffagnini, G. Filardo, Bologna/IT10.1.5 Neuromuscular Control and Strength 1-year following Autolo-

gous Chondrocyte Implantation (ACI) and 5-Year Patient-Report-ed Outcomes

J. Howard1, C. W Conley2, C. Lattermann3, 1Boone/US, 2Lexington/US, 3Boston/US10.1.6 Autologous chondrocyte implantation for bipolar chondral

lesions in the patellofemoral compartment T. Ogura1, G. Merkely2, T. Bryant3, T. Minas4, 1Funabashi/JP, 2Boston/US, 3Chestnut Hill/US, 4West Palm Beach/US10.1.7 Long-term clinical outcome of Matrix-assisted Autologous Chon-

drocyte Implantation (MACI) in the knee P. Guillen, I. Guillen-Vicente, E. Rodriguez Iñigo, D. Perez-Perez, M. Guillen-Vicente, T. Fernandez-Jaen, S. Abelow, J.M. Lopez-Alcorocho, Madrid/ES10.1.8 Etiology of Cartilage Lesions Does Not Affect Clinical Outcomes

of Patellofemoral Autologous Chondrocyte Implantation A. Mestriner1, J. Ackermann2, G. Merkely3, P. Galvao1, A. Gomoll4, 1Sao Paulo/BR, 2Chestnut Hill/US, 3Boston/US, 4New York/US10.1.9 The short-term outcomes of autologous chondrocyte implantation

associated with an atelocollagen-based scaffold R. Akagi1, A. Watanabe1, Y. Kato2, Y. Kimura3, T. Morikawa1, M. Saito1, S. Kitahara4, S. Kimura1, S. Yamaguchi1, S. Ohtori1, T. Sasho1, 1Chiba/JP, 2Kamogawa/JP, 3Matsudo/JP, 4Narashino/JP10.1.10 Trochlear Dysplasia Does Not Affect the Outcomes of Patellofem-

oral Autologous Chondrocyte Implantation A. Mestriner1, J. Ackermann2, F. Ambra1, C.E. Franciozi1, F. Faloppa1, A. Gomoll3, 1Sao Paulo/BR, 2Chestnut Hill/US, 3New York/US

S U N D AY, O C T O B E R 6 , 2 0 1 9

&













37

13:30 - 15:00 Free Paper Session Room: Plaza B&C10.2 Clinical Miscellaneous - Part 1 Moderators: John Lane/US, Emmanuel Papacostas/GR10.2.1 Subchondral Insuffi ciency Fractures of the Knee: High Rates of

Surgical Management and Conversion to Arthroplasty A. Pareek, C. Parkes, C. Bernard, C. Camp, M. Stuart, D.B. Saris, A. Krych, Rochester/US

10.2.2 The Effect of Affect: Does a Patient’s Outlook Infl uence Their Recovery?

T. Hopkins1,2, S. Roberts1,2, J. Richardson1,2, J. Wales1, B. Linklater- Jones1, J.M. Williams1, J.H. Kuiper1,2, 1Oswestry/GB, 2Stoke-on-Trent/GB

10.2.3 Prospective Evaluation of a Fresh Amniotic Membrane for the Treatment of Cartilage Defects

S. Tabet1, K. Kimmerling2, K. Mowry2, N. Munson1, 1Albuquerque/US, 2Birmingham/US

10.2.4 The SIFK Score: A Validated Predictive Model for Arthroplasty Progression after Subchondral Insuffi ciency Fractures of the Knee

A. Pareek, C. Parkes, C. Bernard, M. Abdel, D.B. Saris, A. Krych, Rochester/US

10.2.5 Histological Assessment and Grading of Cartilage Damage at the Time of Patient Undergoing a Total Knee Replacement

A. Goyal, M. Vora, N. Shah, C. Shah, M. Shah, Ahmedabad/IN

10.2.6 Post-Arthroscopy Spontaneous Osteonecrosis/Subchondral Insuf-fi ciency Fractures of the Knee: Etiology and Clinical Outcomes

L.A. Barras, A. Pareek, C. Parkes, C. Camp, M. Stuart, D.B. Saris, A. Krych, Rochester/US

10.2.7 Three dimensional knee kinematics and kinetics in ACL-defi cient patients with and without MMPHT during level walking

S. Ren, Y. Yu, H. Shi, H. Huang, Y. Ao, Beijing/CN

10.2.8 Magnetic Resonance Quantifi cation of Meniscus Vascularity in Pediatric Versus Adult Knees

K. Lin1, N. Gadinsky1, C. Klinger1, J. Dyke1, S. Rodeo1, D. Green1, P. Fabricant1, K. Shea2, L. Lazaro1, 1New York/US, 2Stanford/US

10.2.9 The Public Perception of Microfracture Surgery: A Cohort Study Comparing the General Public and Elite Athletes

E. Haunschild1, D. Wang2, P. Fabricant3, K. Jones1, 1Los Angeles/US, 2Orange/US, 3New York/US

10.2.10 Modelling and predicting the long-term clinical outcome of Autologous Chondrocyte Implantation

J.H. Kuiper1,2, M. Dugard1, J.M. Williams2, C. Kuiper2, P. Harrison2, S. Roberts1, J. Richardson1, 1Newcastle-under-Lyme/GB, 2Oswestry/G

S U N D AY, O C T O B E R 6 , 2 0 1 9

13:30 - 15:00 Free Paper Session Room: Georgia10.3 Translational OA - Part 1 Moderators: Frank Beier/CA, Ivan Martin/CH10.3.1 Wnt Pathway Modulation via CLK2 and DYRK1A Inhibition by

Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis

V. Deshmukh, S. Kennedy, A. O’Green, C. Bossard, M. Ibanez, T. Seo, L. Lamangan, C. Barroga, J. Tambiah, J. Hood, Y. Yazici, San Diego/US

10.3.2 Lorecivivint (SM04690): An Intra-articular Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment - Phase 2b Patient-Reported Outcomes Y. Yazici1, J. Bergfeld2, M. Jones2, C. Swearingen1, A. Difrancesco1, J. Tambiah1, S. Kennedy1, C. Lattermann3, 1San Diego/US, 2Cleveland/US, 3Boston/US10.3.3 Design of a mutant protein with enhanced Type II collagen

gelatin binding capacity, for use in targeting therapeutics to cartilage lesions

A. Hollander, A. Dabbadie, L.-Y. Lian, A. Salerno, Liverpool/GB10.3.4 A small molecule GPI-1046 protects against cartilage degener-

ation X. Xu, D. Shi, Q. Jiang, Nanjing/CN10.3.5 Intra-articular knee injection of mesenchymal stem cells for de-

generative osteoarthritis improved the knee function at 3-years follow up

M. Iosifi dis1, I. Melas1, T. Kyriakidis2, A. Fylaktou1, E. Michalopoulos3, C. Stavropoulos-Giokas3,1Thessaloniki/GR, 2Brussels/BE, 3Athens/GR

10.3.6 Bone Mineral Density is more closely associated with the de-velopment of knee osteoarthritis in women than men: National Health Examination

S.H. Jeon1, M.S. Kim2, 1Incheon/KR, 2Seoul/KR

10.3.7 REG-O3 Chimeric Peptide combining Growth Hormone and Somatostatin sequences slows down Traumatic Knee Osteoar-thritis Progression in Rat

R. Montjean1, S. Escaich1,2, R. Paolini1, C. Carelli1, Y. Henrotin3,4, C. Vêtu1, 1Romainville/FR, 2Saint-Cloud/FR, 3Liège/BE, 4Marche-en-Famenne/BE

10.3.8 Can osteoarthritis biomarkers monitor clinical improvement? E. Antonioli1, R. Ravagnani-Campedelli1, F. Bruno Dias De Oliveira2, S. Agarwal3, M. Ferretti1, 1São Paulo/BR, 2Sao Paulo/BR, 3Sao Paulo/US

10.3.9 Molecular biomarkers for use in diagnosing early stage knee osteoarthritis J. Convill, T. Freemont, G. Tawy, L. Biant, Manchester/GB

10.3.10 Metabolomic profi le and metabolic syndrome in patients with knee osteoarthritis: a sub-group analysis.

E. Sousa, M. Pacheco Junior, D. Aguiar, R. Aguiar, G. Dos Santos Junior, Rio De Janeiro/BR

S U N D AY, O C T O B E R 6 , 2 0 1 9

&













39

13:30 - 15:00 Free Paper Session Room: Plaza A10.4 Basic Science Cartilage Moderators: Susan Chubinskaya/US, Daniel Grande/US10.4.1 Over-Confl uence of expanded mesenchymal stem cells amelio-

rates their chondrogenic capacity in 3D cartilage tissue engi-neering

W. Kafi enah1, D. Tucker1, A. Hollander2, A. Blom1, K. Still1, 1Bristol/GB, 2Liverpool/GB

10.4.2 Design of chondro-instructive hydrogels for high-throughput 3D-biofabrication of cartilage tissue modules

G. Lindberg, K. Lim, G. Hooper, T. Woodfi eld, Christchurch/NZ

10.4.3 Design and evaluation of electrospun structured polycaprolac-tone biomaterials for annulus fi brosus repair

C. Le Visage1, M. Gluais1, J. Clouet1, M. Fusellier1, C. Decante1, C. Moraru1, M. Dutilleul1, J. Veziers1, J. Lesoeur1, D. Dumas2, J. Abadie1, A. Hamel1, E. Bord1, S.Y. Chew3, J. Guicheux1, 1Nantes/FR, 2Vandoeuvre/FR, 3Singapore/SG

10.4.4 Magnetic levitational bioassembly of cartilage in Space A. Gryadunova, V. Parfenov, S. Petrov, E. Bulanova, E. Koudan, Y. Khesuani, V. Mironov, Moscow/RU

10.4.5 Cartilage-on-chip: mimicking the complex mechanical stimula-tion present in articular cartilage

C.A. Paggi, B. Venzac, J. Leijten, L. Moreira, S. Le Gac, M. Karperien, Enschede/NL

10.4.6 The mechanism of spontaneous calcium signalling in chondro-cytes and its regulation in cartilaginous matrix metabolism

X. Gong, G. Li, Y. Huang, C. Chen, L. Yang, Chongqing/CN

10.4.7 The Natural Repair of Articular Cartilage in Humans: An Immunohistological Study S. Roberts1, J. Garcia1, H.S. McCarthy1, B. Tins2, P. Gallacher1, P. Jermin1, J. Richardson1, J.H. Kuiper1, 1Oswestry/GB, 2Stoke-on-Trent/GB

10.4.8 Identifi cation of M9 high-mannose glycan regulating hypertro-phy in articular cartilage

K. Homan, T. Onodera, J. Furukawa, H. Hanamatsu, R. Hishimura, K. Wooyoung, M. Hamasaki, L. Xu, N. Iwasaki, Sapporo/JP

10.4.9 The concentration-dependent effect of CoCr ions and particles on osteoarthritic chondrocytes

C. Stotter1, C. Bauer1, V. Jeyakumar1, E. Niculescu-Morzsa1, S. Bojana2, M. Rodríguez Ripoll2, T. Klestil3, F. Franek2, S. Nehrer1, 1Krems/AT, 2Wiener Neusatdt/AT, 3Baden/AT

10.4.10 The role of biaxial sliding and cyclic uniaxial compression on solute transport in articular cartilage

K. Culliton, P. Beaule, A. Speirs, Ottawa/CA

S U N D AY, O C T O B E R 6 , 2 0 1 9

15:15 - 16:15 Special Session Room: Regency11.1 Whole Joint Preservation Moderators: Ignacio Dallo/AR, John Lane/US Objective: attendees of this session will learn how other tissues in a joint are affected by damaged cartilage and the other way around and how to deal with this in terms of patient care and basic science

11.1.1 ACL & Cartilage - Optimized Strategic Planning to Treat These Combined Lesions

N. Nakamura, Osaka/JP11.1.2 Meniscus & Cartilage A. Krych, Rochester/US11.1.3 Patellofemoral Joint S. Sherman, Redwood City/US

15:15 - 16:15 Special Session Room: Plaza B&C11.2 ICRS NextGen - It Takes 2 To Make A Thing Go Right : Surgeon-Scientist Collaboration Moderators: Rebekah Decker/US, Luis Tirico/BR Objective: Participants of this session will learn the perspective from both a scientist and a clinician on orthobiologics for early osteoarthritis, scaffolds that are used for cartilage repair and how to treat the subchondral bone.11.2.1 Orthobiologics for Early OA - The Scientist’s Perspective T. McCarrel, Gainesville/US11.2.2 Orthobiologics for Early OA - The Surgeon’s Perspective E. Strauss, New York/US11.2.3 Scaffolds for Cartilage Repair - The Scientist’s Perspective F. Taraballi, P. McCulloch, E. Tasciotti, Houston/US11.2.4 Scaffolds for Cartilage Repair - The Surgeon’s Perspective F. De Caro, V. Condello, A. Russo, M. Collarile, R. Orlandi, V. Madonna, Bergamo/IT11.2.5 Treating the Subchondral Bone - The Scientist’s Perspective J. Patel, J. Carey, R. Mauck, Philadelphia/US11.2.6 Treating the Subchondral Bone - The Surgeon’s Perspective L. Tirico, São Paulo/BR

15:15 - 16:15 Special Session Room: Georgia11.3 Pain Moderators: Frank Beier/CA, Tom Minas/US Objective: Attendees will learn in this session where pain comes from, how it affects outcomes and strategies to reduce pain.11.3.1 Pain - Where is it Coming From? D. Walsh, Notthingham/GB11.3.2 How Pain Affects Outcomes D. Flanigan, Columbus/US11.3.3 Mechanisms of Joint Pain Reveal New Targets A.-M. Malfait, Chicago/US

S U N D AY, O C T O B E R 6 , 2 0 1 9

&













41

16:15 - 17:00 Coffee Break/Exhibition/Intermission 17:00 - 18:30 Free Paper Session Room: Plaza B&C12.1 Clinical Hip & Ankle Moderators: Ivan Wong/CA, Vikas Kanduja/GB12.1.1 Is Microfracture Necessary? Acetabular Chondrolabral

Debridement Exhibits Similar Outcomes to Microfracture: A Multi-Center Analysis

M. Hevesi1, C. Bernard1, D. Hartigan1, B. Levy1, B. Domb2, A. Krych1, 1Rochester/US, 2Westmont/US12.1.2 Cartilage register of german speaking countries-4 year results

of the module Hip S. Fickert1, W. Zinser2, C. Sobau3, J. Weber4, 1Straubing/DE, 2Dinslaken/DE, 3Pforzheim/DE, 4Regensburg/DE12.1.3 Can a Biopolymer Scaffold Injected Arthroscopically Restore

Articular Cartilage and Delay Hip Osteoarthritis? I. Wong, R. John, Halifax/CA12.1.4 Radiologic and Demographics Risk Factors for Labral Reconstruc-

tion versus Repair in Primary Hip Arthroscopy. A Predictive Model B. Domb, D. Maldonado, J. Chen, A. Lall, Des Plaines/US12.1.5 24 months after arthroscopic matrix-associated ACT of the hip

–signifi cant improvement of PROs and MRI using an injectable hydrogel

S. Fickert1, H. Brettschneider2, S. Trattnig3, S. Landgraeber4, A. Hartmann2, M. Dienst5, J. Schröder6, K.-P. Günther2, 1Straubing/DE, 2Dresden/DE, 3Vienna/AT, 4Essen/DE, 5München/DE, 6Berlin/DE12.1.6 Ankle Instability in the Setting of an Osteochondral Lesion of the

Talus: Results from an International Consensus Meeting N.A. Smyth1, C. Murawski2, I.C.G. On Cartilage Repair Of The Ankle2, 1Baltimore/US, 2Pittsburgh/US12.1.7 Scaffold-Based Treatment Results in Arthroscopic Cartilage

Repair of the Ankle Osteochondral Lesions A. Yıldırım, M. Ozer, Konya/TR12.1.8 Autologous Osteochondral Transplantation for large osteochon-

dral lesions of the talus is a viable option in an athletic population A. Ramasamy1, A. Nguyen2, M. Walsh2, L. McMenemy1, J. Calder1, 1London/GB, 2Eq/GB12.1.9 Reducing scan time for full ankle MRI examination by 45%

using combined compressed sensing and parallel imaging. O. Baur1, C. Den Harder1, R. Hemke1, F. Farid Mojtahedi2, F. Smithuis1, E. De Weerdt3, A. Nederveen1, M. Maas1, 1Amsterdam/NL, 2Ubbergen/NL, 3Eindhoven/NL12.1.10 Treatment of Chondral Lesions in the ankle by High-Density

Autologous Chondrocyte Implantation: Two-Year follow-up I. Guillen-Vicente, E. Rodriguez Iñigo, R. Caballero, M. Guillen-Vicente, M. Casqueiro, T. Fernandez-Jaen, S. Abelow, J.M. Lopez-Alcorocho, P. Guillen, Madrid/ES

S U N D AY, O C T O B E R 6 , 2 0 1 9

17:00 - 18:30 Free Paper Session Room: Plaza A12.2 Basic Science OA Moderators: Caroline Hoemann/US, Brian Johnstone/US12.2.1 Attenuation of the knee osteoarthritis progression by administra-

tion of SIRT1 activator SRT2104 in mice N. Miyaji, T. Matsushita, T. Tanaka, Y. Nakanishi, T. Yamamoto, Y. Hiroshima, T. Yamashita, K. Ibaraki, K. Nagai, D. Araki, N. Kanzaki, Y. Hoshino, R. Kuroda, Kobe/JP

12.2.2 A small molecule promotes cartilage extracellular matrix gener-ation and inhibits osteoarthritis development

Y. Shi, X. Hu, C. Cao, J. Wang, Y. Ao, Beijing/CN

12.2.3 Modulation of Infl amed Synovium and its Residing MacrophagesImproves in vitro Migration of Mesenchymal Stromal Cells

M.A. Wesdorp, S. Capar, K. Sivasubramaniyan, G. Van Osch, Y. Bastiaansen-Jenniskens, Rotterdam/NL

12.2.4 Transcriptional profi ling of murine macrophages stimulated with cartilage fragments reveals a novel mechanism for osteoarthritis

M. Hamasaki, M.A. Terkawi, T. Onodera, K. Homan, G. Matsumae, Y. Tian, H. Alhasan, T. Ebata, N. Iwasaki, Sapporo/JP

12.2.5 Low-Intensity Ultrasound Attenuates IL-6 and TNFα-induced Cat-abolic Effects and Repairs Chondral Fissures in Osteochondral Explants

A. Subramanian1, N. Sahu2, 1Madison/US, 2Stanford/US

12.2.6 Differential regulation of distinct TGF-beta signaling pathways in articular cartilage: Role of CD109

S. Khanjani, M. Blati, J. L. Ramirez-Garcialuna, A. Philip, Montreal/CA

12.2.7 Activation of Wnt signaling pathway ameliorates deterioration of knee cartilage: an DMM-induced osteoarthritic animal model study D. Zhao, K. Tao, L. Zhang, J. Gao, Q. Liu, R. Li, H. Liu, J. Lin, Beijing/CN

12.2.8 MicroRNA-195 contributes development of osteoarthritis via targeting Smad3

X. Cao1, L. Wei2, X. Wei2, 1TaiYuan/CN, 2Taiyuan/CN

12.2.9 Infl amed macrophages by cartilage fragments elicits typical gene expression signature of endochondral ossifi cation in chondrocytes

T. Onodera, M.A. Terkawi, M. Hamasaki, T. Ebata, Y. Tian, N. Iwasaki, Sapporo/JP

12.2.10 Targeted Inhibition of TAK1 Prevents Infl ammation-Related Cartilage Degradation in Osteoarthritis

J. Cheng, Y. Ao, Beijing/CN

S U N D AY, O C T O B E R 6 , 2 0 1 9

&













43

17:00 - 18:30 Free Paper Session Room: Regency12.3 Translational Meniscus Moderators: Aaron Krych/US, Peter Verdonk/BE12.3.1 Clinical Results of the NUsurface® Implant vs Non-Surg Con-

trols: First 100 Patients from RCT and Single-Arm Observational Study at 12 Months

K. Zaslav1, B. McKeon2, W. Gersoff3, R. Alfred4, R.M. Alley4, R. Edelson5, J. Greenleaf5, C. Keading6, 1Richmond/US, 2Boston/US, 3Denver/US, 4Albany/US, 5Tigard/US, 6Columbus/US12.3.2 Medial Meniscus Posterior Root Tear Treatment: A matched

cohort comparison of non-operative management, partial meniscectomy and repair

N. Kennedy, C. Bernard, A. Tagliero, C. Camp, D.B. Saris, B. Levy, M. Stuart, A. Krych, Rochester/US12.3.3 Medial vs. Lateral Meniscus Root Tears: Is there a difference

in injury presentation, treatment decisions, and surgical repair outcomes?

N. Kennedy, A. Krych, C. Bernard, A. Tagliero, C. Camp, B. Levy, M. Stuart, Rochester/US12.3.4 A Polyurethane Partial Meniscal Implant for Chronic Painfull

Partial Meniscectomy: A 5 Y + Follow Up Evaluation A. Dhollander1, C. Toanen2, E. Bulgheroni3, P. Bulgheroni3, G. Filardo4, S. Zaffagnini4, L. Asplin5, T. Spalding5, J. Monllau6, P. Gelber6, R. Verdonk7, P. Beaufi ls8, N. Pujol8, P. Verdonk9, 1Brasschaat/BE, 2Versaille/FR, 3Varese/IT, 4Bologna/IT, 5Coventry/GB, 6Barcelona/ES, 7Gent/BE, 8Le Chesnay/FR, 9Antwerp/BE12.3.5 Medial meniscus extrusion between intact and posterior root

tear during knee fl exion-extension motion and external load: A Cadaveric Study

T. Suzuki1, S. Yamakawa2, K. Onishi2, V. Musahl2, R. Debski2, 1Sapporo/JP, 2Pittsburgh/US12.3.6 3D bioprinted meniscus tissue-like structure using gene edited iPS

cell-line and chondrocytes induces the cartilage marker ACAN S. Simonsson, C. Lindahl, S. Concaro, M. Brittberg, L. Peterson, A. Lindahl, Gothenburg/SE12.3.7 A novel approach to the treatment of meniscal hoop injuries using

a mesenchymal stem cell-seeded electrospun nanofi brous scaffold K. Shimomura1, B. Rothrauff2, D. Hart3, S. Hamamoto1, M. Kobayashi1, H. Yoshikawa1, R. Tuan2, N. Nakamura1, 1Osaka/JP, 2Pittsburgh/US, 3Calgary/CA12.3.8 A 3D Bioprinted Meniscus with Biomechanical Properties Suit-

able for Surgical Implantation S. Wadsworth1, E. Kapyla1, M.K. Khan1, S. Pan1, R. Nickmanesh1, S. Beyer1, J. Ault2, J. Hwang2, S. Getsios1, T. Mohamed1, 1Vancouver/CA, 2Raynham/US12.3.9 Local Administration of Magnesium Promotes Meniscal Healing Through Homing of Endogenous Stem Cells: A Proof-of-Concept Study Z. Zhang, B. Song, W.-P. Li, Guangzhou/CN12.3.10 Progenitor cells with high chondrogenic potential are present in

the adult human meniscus J. Korpershoek, M. Rikkers, T.S. De Windt, D.B. Saris, M. Tryfonidou, L. Vonk, Utrecht/NL

S U N D AY, O C T O B E R 6 , 2 0 1 9

17:00 - 18:30 Free Paper Session Room: Georgia12.4 Biologics Moderators: Taralyn McCarrel/US, Brian Cole/US12.4.1 Establishment of reactive arthritis mouse model and analysis of

serum exosome-mediated infl ammation induction mechanism M. Ota, Y. Tanaka, D. Kamimura, R. Yamamoto, T. Onodera, M. Murakami, N. Iwasaki, Sapporo/JP12.4.2 Exosomes secreted by mesenchymal stem cells prevent the

progression of osteoarthritis in mice H. Hanai, K. Shimomura, G. Jacob, S. Nakagawa, M. Kobayashi, N. Nakamura, Osaka/JP12.4.3 Platelet-Rich Plasma Powder - dose dependent effects on chon-

drocytes in a standardized model T. Tischer1, M. Kieb2, A. Jonitz-Heincke1, R. Bader1, K. Peters1, O. Hahn1, 1Rostock/DE, 2Berlin/DE12.4.4 Duration effects of a single intra-articular injection of Autologous

Protein Solution (APS) in patients with knee osteoarthritis (OA) E. Kon1, P. Verdonk2, L. Engebretsen3, S. Nehrer4, A. Di Martino5, G. Filardo5, 1Milano/IT, 2Antwerp/BE, 3Oslo/NO, 4Krems/AT, 5Bologna/IT12.4.5 Effect of Autologous Platelet-Rich Plasma and Gelatin Sponge

for Tendon-to-Bone Healing After Rabbit ACLR B. Ren, J. Zheng, Xi’an/CN12.4.6 Brief High Intensity Interval Exercise Increases Platelets and TGF

in Platelet-rich Plasma M. Baria, M. Miller, J. Borchers, W.K. Vasileff, S. Durgam, R. Magnussen, Columbus/US12.4.7 Platelet lysate for cartilage regeneration: Improved redifferentia-

tion after expansion, but opposite effects in 3D culture M. Rikkers1, K. Dijkstra1, R. Levato1, D.B. Saris1,2,3, J. Malda1, L. Vonk1, 1Utrecht/NL, 2Rochester/US, 3Enschede/NL12.4.8 Comparing effi cacy of newer PRP (Chitosan PRP) over PRP

(Platelet rich plasma) in an experimental guinea pig knee osteo-arthritis model

S. Aggarwal, Chandigarh/IN12.4.9 Off-the-shelf allogeneic PRP shows chondrogenic potential after

single administration in 3D mesenchymal progenitor cell culture N. Sinner, M. Endres, J.P. Krüger, Berlin/DE12.4.10 Multiple PRP injection versus Single PRP injection in early OA

knee: An experimental study in a guinea pig early knee OA model

S. Patel, M. Dhillon, T. Bansal, D. Chouhan, Chandigarh/IN 19:30 President’s Dinner at Vancouver Club (Upon Invitation Only)

19:10 Meet: Hyatt Hotel Lobby19:15 Departure - 10 minutes-walk

S U N D AY, O C T O B E R 6 , 2 0 1 9

&













45

Join usFor our lunchtime symposium

Expanding the continuum of care: A full body cartilage solutionMonday 7 October13:00 – 14:00 Plaza BC

SpeakersAlan Getgood, MD (CAN)Martyn Snow, MD (UK)Ivan Wong, MD (CAN)

Visit us at booth #21 to learn more about our cartilage repair portfolio

©2019 Smith+Nephew

TRS19_20745-4_V1_ICRS_VancouverCAN_Oct5-58_FullPage_ProgramAD_r3_0819.indd 1 8/22/19 4:19 PM

autologous culturedchondrocyteson porcinecollagen membrane

©2019 Vericel Corporation. All rights reserved. PP.US.MAC.0872

VISIT US AT ICRS BOOTH 17

James Carey, mdUPenn Sports Medicine Center

David Flanigan, mdOhio State University

Sabrina Strickland, mdHospital for Special Surgery

F E A T U R I N G :

Learn more about MACI at the:

MACI Symposium Monday, October 7th from 1-2pm

Hyatt Regency Vancouver, Room: Georgia 340

Register at: http://bit.ly/MACI_ICRS_2019

&













47M O N D AY, O C T O B E R 7, 2 019

07:30 - 08:30 Instructional Course/Workshop Room: Plaza B&C13.1 Cartilage Repair in the Foot & Ankle Moderators: Richard Ferkel/US, John Kennedy/US Objective: in this case-based round-the-table instructional course, anonymised patient cases and treatments for cartilage damage in the foot and ankle will be interactively discussed 13.1.1 Case Based Roundtable J. Kennedy, New York/US13.1.2 Case Based Round Table G. Kerkhoffs, Amsterdam/NL13.1.3 Case Based Round Table C. Pearce, London/GB

07:30 - 08:30 Instructional Course / Workshop Room: Plaza A13.2 Clinical Trial Design Moderators: Jack Farr/US, Mike McNicholas/GB Objective: in this instructional course, participants will learn how to effectively design a clinical study 13.2.1 What do Regulatory Bodies Want? K. Zaslav, Richmond/US13.2.2 The Challenges of Joint Preservation Trials S. Lyman, New York/US13.2.3 Industry Perspective G. Matthews, Marietta/US

07:30 - 08:30 Instructional Course / Workshop Room: Georgia13.3 Joint Preservation of the Knee Moderators: Brian Cole/US, Norimasa Nakamura/JP Objective: in this case-based round-the-table instructional course, anonymised patient cases and treatments for cartilage damage in the knee joint will be interactively discussed 13.3.1 Case Presentation 1 M. Brittberg, Kungsbacka/SE13.3.2 Case Presentation 2 C. Erggelet, Zurich/CH13.3.3 Case Presentation 3 D.B. Saris, Rochester/US13.3.4 Case Presentation 4 B. Mandelbaum, Santa Monica/US13.3.5 Case Presentation 5 A. Gobbi, Milano/IT13.3.6 Case Presentation 6 S. Nehrer, Krems/AT

M O N D AY, O C T O B E R 7, 2 019

08:30 - 09:30 Plenary Session Room: Regency14.0 Stem Cells Without the Hype Moderators: Andreas Gomoll/US, Daniel Grande/US Objective: In this session, attendees will be updated on the real science of stem cells, what is needed from the regulatory side and their role in joint preservation.

14.0.1 What is the Real Science? M. Stoddart, Davos/CH

14.0.2 What about Regulatory Approval? A. Anz, Gulf Breeze/US

14.0.3 Do they have a Clinical Role in Joint Preservation? M. Snow, Birmingham/GB

09:45 - 10:45 Special Session Room: Georgia15.1 Joint Loading & Cartilage Health Moderators: Alan Getgood/CA, Roland Jakob/CH Objective: In this session participants will learn how (ab)normal mechanical loading affects joint health, how it can be adjusted using osteotomy and joint distraction treatment

15.1.1 How Does Mechanical Load Affect Joint Health? T. Birmingham, London/CA

15.1.2 Re-Alignment Osteotomy K. Kley, Hannover/DE

15.1.3 Knee Joint Distraction R. Custers, Utrecht/NL


09:45 - 10:45 Special Session Room: Plaza B&C15.2 Targeting the Cartilage Moderators: Pedro Guillen/ES, Laurie Goodrich/US Objective: After completion of this session, participants will understand how chondrocytes in cartilage can be targeted by small drugs and they will get an update on the latest gene therapy and microRNA modulation research.

15.2.1 Gene Therapy H. Madry, Homburg/DE

15.2.2 Drug Delivery to Cartilage & Joints for Post-Traumatic OA A. Grodzinsky, Cambridge/US

15.2.3 MicroRNA Modulation for Cartilage Regeneration L. Vonk, Utrecht/NL

&













49

09:45 - 10:45 Special Session Room: Regency15.3 Big Data Moderators: Christian Lattermann/US, Anders Lindahl/SE Objective: In this session an update on the ICRS registry will be given. In addition, the audience will learn how they can use data from registries and also how to maximize data output from performed and future clinical studies

15.3.1 ICRS Patient Registry Update L. Biant, Manchester/GB

15.3.2 What Can We Learn from Registries? T. Spalding, Coventry/GB

15.3.3 Randomized Trials Vs. Cohort Studies E. Kon, Milano/IT

10:45 - 11:15 Coffee Break/Exhibition/Intermission

M O N D AY, O C T O B E R 7, 2 019

11:15 - 12:45 Free Paper Session Room: Georgia16.1 Clinical Trials Moderators: Stephen Lyman/US, Giuseppe Filardo/IT16.1.1 Prospective Comparison of Sham vs. Placebo Injections: Data from a Trial of Lorecivivint, a Wnt Pathway Inhibitor for Knee Osteoarthritis Y. Yazici1, J. Tambiah1, C. Swearingen1, S. Kennedy1, V.Strand2,

B. Cole3, M. Hochberg4, R.R. Bannuru5, T. McAlindon5, 1San Diego/US,2Portola Valley/US, 3Chicago/US, 4Baltimore/US, 5Boston/US

16.1.2 Amniotic Suspension Allograft (ASA) for Treatment of Knee Osteoarthritis in a Randomized Controlled Multi-Center Trial J. Farr1, A. Gomoll2, K. Kimmerling3, K. Mowry3, 1Green-

wood/US, 2New York/US, 3Birmingham/US16.1.3 Five-year follow-up of the IMPACT trial: One-stage cell based cartilage repair using recycled chondrons and allogeneic MSCs T. Saris, T.S. De Windt, E.C. Kester, R. Nizak, L. Vonk,

R. Custers, D.B. Saris, Utrecht/NL16.1.4 Microfracture Versus a Collagen-Augmented Chondrogen- esis Technique for Treating Knee Cartilage Defects: A Ran- domized Controlled Trial M.S. Kim, C.K. Kim, K.Y. Choi, Y. In, Seoul/KR16.1.5 Prospective study comparing PRP combined with Hyaluronic acid and Adipose derived MSC in patients with early OA knee V.K. Muthukumar1, K. Herman1, D. Szwedowski1, A. Gobbi1,2,

1Milan/IT, 2Milano/IT16.1.6 Allogeneic Umbilical Cord Blood-derived MSCs for Knee Osteoar- thritis: Randomized Clinical Trial (with 5-year Follow-up Study) Y.-B. Park1, C.-W. Ha1, J. Kim1, I.-J. Yeo1, M. Kim2, 1Seoul/KR,

2Anyang-si/KR16.1.7 ADSCs vs PRP in patients with knee Osteoarthritis: Prelimi- nary results of a Randomized Controlled Trial. A. Di Martino, L. Andriolo, F. Perdisa, A. Sessa, A. Boffa,

S.A. Altamura, G. Filardo, S. Zaffagnini, Bologna/IT16.1.8 Autologous blood coagulum containing recombinant human BMP 6 accelerates bone healing in a phase I/II study of patients with HTO C. Chiari1, L. Grgevic2, A. Valentinitsch1, E. Nemecek1, K. Staats1,

M. Schreiner1, C. Trost1, T. Bordukalo-Niksic2, F. Kainberger1,M. Milosevic2, S. Martinovic2, M. Peric2, S. Vukicevic2, R. Windhager1,1Vienna/AT, 2Zagreb/HR

16.1.9 Assessment of Dynamic Mechanical Biomarkers to Assist Primary Care Physicians in the Management of Knee Osteo- arthritis: A Cluster RCT A. Cagnin1, M. Choinière1, N.J. Bureau1, M. Durand1, N. Mezghani1,

N. Gaudreault2, N. Hagemeister1, 1Montreal/CA, 2Sherbrooke/CA16.1.10 Diagnostic Scope Vs. Cartilage Procedure: Who Will Progress? T. Southworth, N. Naveen, T. Tauro, B. Cole, A. Yanke, Chicago/US

M O N D AY, O C T O B E R 7, 2 019

&













51

11:15 - 12:45 Free Paper Session Room: Plaza A16.2 Biomaterials Moderators: Daniel Kelly/IE, Jos Malda/NL

16.2.1 Construction of transitional structured tendon complex based three dimensional near fi eld bioelectrospinning technology Y. Long, Gui Yang/CN

16.2.2 A wood-derived biomimetic scaffold for segmental bone reconstruction: Pre-clinical safety and performance assessment in a sheep model E. Kon1, G. Filardo2, F. Perdisa2, J. Shani3, N. Shabshin4,

F. Veronesi2, F. Salamanna2, A. Parrilli2, B. Di Matteo5, M. Marcacci5, S. Sprio6, A. Ruffi ni6, A. Tampieri6, 1Milano/IT,2Bologna/IT, 3Beit Berl/IL, 4Ra’anana/IL, 5Rozzano Milano/IT,6Faenza/IT

16.2.3 Volume-by-volume bioprinting of chondrocytes-alginate bioinks in high temperature thermoplastic scaffolds for cartilage regeneration J.M. Baena, Granada/ES

16.2.4 Structurally and Functionally Optimized Silk Fibroin-Gelatin caffold using 3DP to Repair Cartilage Injury W. Shi, X. Hu, Y. Ao, Beijing/CN

16.2.5 Magneto-responsive hydrogel recapitulates cartilage-like cell distribution in engineered tissue Zlotnick, R. Mauck, Philadelphia/US

16.2.6 Suspended manufacture as a method to produce complex tissue interfaces L. Grover1, M. Snow1, M. Cooke2, S. Jones1, A. Smith3,

1Birmingham/GB, 2Montreal/CA, 3Huddersfi eld/GB

16.2.7 Mechanisms of cell-free cartilage repair using a modifi ed collagen type I matrix and additive fi brin glue P. Roessler, C. Hilgers, W. Masson, E.-M. Haddouti, T.M.

Randau, F.A. Schildberg, Bonn/DE

16.2.8 The Development of an Anisotropic Composite Silk Nanofi bre Bioink for Cartilage Tissue Engineering R. Begum, A.W. Perriman, Bristol/GB

16.2.9 An injectable hydrogel scaffold with Kartogenin-encapsulated nanoparticles for porcine cartilage regeneration – a six months follow-up W. Yan, Q. Jiang, D. Shi, Nanjing/CN

M O N D AY, O C T O B E R 7, 2 019

11:15 - 12:45 Free Paper Session Room: Plaza B&C16.3 Translational OA - Part 2 Moderators: Peter Angele/DE, Norimasa Nakamura/JP

16.3.1 Distinctive long-term migration of adipogenic niche in the rabbit: biological perspectives for osteoarthritis clinical headway G. Desando1, I. Bartolotti1, L. Martini1, N. Nicoli Aldini1,

G. Giavaresi1, M. Fini1, A. Roffi 1, E. Kon2, F. Perdisa1, G. Filardo1, B. Grigolo1, 1Bologna/IT, 2Milano/IT

16.3.2 Syndecan-4 is Increased in Osteoarthritic Knee, but not Hip or Shoulder, Articular Hypertrophic Chondrocytes Y. Henrotin1, C. Sanchez1, C. Lambert1, J.-E. Dubuc2, J. Bertrand3,

T. Pap4, 1Liège/BE, 2Brussels/BE, 3Magdeburg/DE, 4Munster/DE

16.3.3 Long term effi cacy of Micro-fragmented adipose tissue in the treatment of Knee Osteoarthritis N. Heidari1, T. McGuire2, A. Noorani1, A. Wilson1, A. Mahmood1,

A. Cullen1, 1London/GB, 2Winchester/GB

16.3.4 Machine learning predicts rate of cartilage loss: data from the Osteoarthritis Initiative T. Paixao1, H.-P. Dimai2, C. Goetz1, Z. Bertalan1, R. Ljuhar1,

S. Nehrer3, 1Wien/AT, 2Graz/AT, 3Krems/AT

16.3.5 Platelet-rich Plasma for the Treatment of Sport-active Patients with Knee Osteoarthritis: Limited Return to Sport. A. Boffa, S.A. Altamura, L. Andriolo, R. De Filippis, A. Di Martino,

S. Zaffagnini, G. Filardo, Bologna/IT

16.3.6 Rescue Injection of Amniotic Suspension Allograft Improves Pain and Function in Patients with Knee Osteoarthritis A. Gomoll1, J. Farr1, K. Kimmerling2, K. Mowry2, 1New York/US,

2Birmingham/US

16.3.7 Surface modifi cation on biomaterials with synovium-derived mesenchymal stem cells-affi nity peptide for tissue engineering Z. Shao, X. Zhang, Y. Pi, Y. Ao, C. Zhou, H. Chen, Beijing/CN

16.3.8 A novel quantitative metric for joint space width: data from the Osteoarthritis Initiative T. Paixao1, C. Goetz1, Z. Bertalan1, D. Ljuhar2, R. Ljuhar2, S. Nehrer3,

1Wien/AT, 2Vienna/AT, 3Krems/AT

16.3.9 Vitamin D3 inhibits ADAMTS-4 and MMP13 J. Ekholm, S. Concaro, A. Lindahl, C. Brantsing, Göteborg/SE

16.3.10 Comparison of Two Different Cartilage Repair Procedures with Concomitant High Tibial Osteotomy fo Varus Knee Osteoarthritis H.S. Chung, Y.S. Kim, P.K. Chung, Y.G. Koh, Seoul/KR

M O N D AY, O C T O B E R 7, 2 019

&













53

11:15 - 12:45 Free Paper Session Room: Regency16.4 Allografts Moderators: Simon Görtz/US, Luis Tirico/BR

16.4.1 Long-term Survival of Meniscus Allograft Transplantation in an Arthritic Population M. Vessal, K. Stone, S. Hennessy, T. Turek, A. Walgenbach,

E. Huttler, W. Li, L. Do, D. Greene, San Francisco/US

16.4.2 The Effect of BMI on Patient Reported Outcome Scores in Osteochondral Allograft Transplantation T. Southworth1, N. Naveen1, A. Beletsky1, K. Okoroha1,

T. Jildeh2, T. Tauro1, N. Verma1, A. Yanke1, B. Cole1, 1Chicago/US, 2Detroit/US

16.4.3 Patellar Osteochondral Allograft Transplantation Using Femoral Hemicondyle Allografts: Magnetic Resonance and Clinical Outcomes K. Lin1, D. Wang2, A. Burge1, F. Coxe1, M. Pais1, R. Williams Iii1,

1New York/US, 2Orange/US

16.4.4 Which Variables Predict Osteochondral Allograft Failure? W. Bugbee, La Jolla/US

16.4.5 Does Patellar Morphology Matter When Matching Osteochon- dral Allografts for Osteochondral Defects of the Central Ridge of the Patella? K. Patel, J. Grant, A. Ramme, J. Scott, N. Salka, Ann Arbor/US

16.4.6 Predictors of Return to Athletic Activity Following Osteochon dral Allograft Transplantation of the Knee G. Ode, J. Bido, T. Warner, B. Nwachukwu, R. Williams Iii,

New York/US

16.4.7 Osteochondral Allograft Transplantation of the Knee in “Ideal” Candidates: Clinical Outcomes and Graft Survivorship W. Bugbee, La Jolla/US

16.4.8 Cost-effectiveness of allografts: highly effective for osteochondral, more research needed for meniscal allografts. T. Spalding1, P. Verdonk2, L. De Girolamo3, A. Metcalfe1,

N. Waugh1, 1Coventry/GB, 2Antwerp/BE, 3Milano/IT

16.4.9 Clinically Signifi cant Outcome Achievement After Osteochon- dral Allograft Surgery A. Beletsky, T. Southworth, N. Naveen, B. Nwachukwu,

J. Chahla, N. Verma, A. Yanke, B. Cole, Chicago/US

16.4.10 Clinical Results of a Novel 3D Fresh Cartilage Matrix for Focal Articular Cartilage Defects V. Mehta, R. Shriver, Geneva/US

M O N D AY, O C T O B E R 7, 2 019

13:00 - 14:00 Industry Satellite Symposium Room: Regency17.1 Aesculap - Restoring Cartilage Form & Function: An Expanding Landscape

17.1.1 Management of the Cartilage Defect in the Athlete B. Cole, Chicago/US

17.1.2 Innovations in Cartilage Treatment I. Wong, Halifax/CA

13:00 - 14:00 Industry Satellite Symposium Room: Georgia17.2 Vericel - Cartilage Restoration with the MACI Implant: Early US Experience Moderator: David Flanigan/US

17.2.1 A Review of the First 1000 U.S. MACI Patients & Case Study D. Flanigan1, J. Carey2, 1Columbus/US, 2Philadelphia/US

17.2.2 The MACI Patella Clinical Experience & Case Study S. Strickland1, A. Pyne1, A. Burge2, 1New York City/US,

2New York/US

17.2.3 A Consensus on MACI Rehabilitation & Case Study J. Carey1, D. Flanigan2, 1Philadelphia/US, 2Columbus/US

17.2.4 Market Access to MACI & Discussion D. Flanigan, Columbus/US

13:00 - 14:00 Industry Satellite Symposium Room: Plaza B&C17.3 Smith & Nephew - Expanding the Continuum of Care: A Full Body Cartilage Solution Moderator: Alan Getgood/CA

17.3.1 Cartilage Repair in the Hip, Featuring a Liquid Bioscaffold I. Wong, R. John, Halifax/CA

17.3.2 Treating Cartilage Defects in the Knee Utilizing a Liquid Bioscaffold M. Snow, Birmingham/GB

13:00 - 14:00 Industry Satellite Symposium Room: Plaza A17.4 CartiHeal - The Story of the Agili-C Implant; From Bench to Bedside Moderators: Andreas Gomoll/US, Seth Sherman/US

17.4.1 The Science Behind the Agili-C implant K. Zaslav, Richmond/US

17.4.2 Surgical Technique - Lessons Learned from 800 Implantations P. Verdonk1,2,3, 1Gent-Zwijnaarde/BE, 2Antwerp/BE, 3Deurne/BE

17.4.3 Long Term Clinical Outcomes E. Kon, Milano/IT

M O N D AY, O C T O B E R 7, 2 019

&













55

14:15 - 15:45 Free Paper Session Room: Regency18.1 Joint Preservation Moderators: Konrad Slynarski/PL, Alberto Gobbi/IT

18.1.1 Survival Analysis of Medial Open Wedge High Tibial Osteoto- my for Unicompartment Knee Osteoarthritis: Long-term study I.-S. Choi, S. Na, J.K. Seon, E.K. Song, Gwangju/KR

18.1.2 Femoral and Tibial Torsion Measurements Based on EOS Imaging Compared to 3D CT Reconstruction Measurements W. Yan, Q. Jiang, D. Shi, Nanjing/CN

18.1.3 Analysis and quantifi cation of bone healing after open wedge high tibial osteotomy C. Chiari1, E. Nemecek1, A. Valentinitsch1, F. Kainberger1,

G. Hobusch1, A. Kolb1, L. Hirtler1, C. Trost1, S. Vukicevic2, R. Windhager1, 1Vienna/AT, 2Zagreb/HR

18.1.4 Agili-C Implant Provides Knee Joint Function Restoration (a four-year follow-up) P. Verdonk1, E. Kon2, M. Marcacci3, K. Zaslav4, D. Robin-

son5, O. Dulic6, G. Gavrilovic7, J.M. Patrascu8, 1Antwerp/BE, 2Milano/IT, 3Rozzano Milano/IT, 4Richmond/US, 5Pet-ahTikwa/IL, 6Novi Sad/RS, 7Belgrade/RS, 8Timisoara/RO

18.1.5 A treatment for chondral and osteochondral knee defects: clinical results of a biomimetic scaffold implantation at 3 years’ follow-up. F. Perdisa, I. Romandini, L. Andriolo, A. Sessa, A. Di Martino,

S. Zaffagnini, G. Filardo, Bologna/IT

18.1.6 Ideal Donor Site for Osteochondral Autografting of the Distal Femur Using Radius of Curvature: a 3D High-Resolution Scan- ner Comparison P. Massey, M. Lowery, G. Houk, S. Barton, G. Solitro, Shreveport/US

18.1.7 Long-term outcome of the autologous osteochondral transplantation for steroid induced osteonecrosis of the knee K. Nishitani, Y. Nakagawa, M. Kobayashi, S. Kuriyama,

S. Nakamura, S. Matsuda, Kyoto/JP

18.1.8 Long-term Clinical Outcomes of Cartilage Repair in the Knee Using Hyaluronic Acid-based Scaffold with Bone Marrow Aspirate Concentrate. A. Gobbi1, K. Herman2,3, D. Szwedowski3,4, K. Vetri1, 1Mila-

no/IT, 2Katowice/PL, 3Milan/IT, 4Toruń/PL

18.1.9 The Sound of Cartilage: Audiometric Characterization of Cartilage Preparation in Joint Preservation Surgery M. Hevesi, A. Krych, D.B. Saris, Rochester/US

M O N D AY, O C T O B E R 7, 2 019

14:15 - 15:45 Free Paper Session Room: Georgia18.2 Basic Science - Stem Cells Moderators: Roman Krawetz/CA, Martin Stoddart/CH

18.2.1 Articular cartilage-derived progenitors from healthy and osteoarthritic human cartilage show potential for cartilage repair treatment M. Rikkers, J. Korpershoek, S. Van Der Leij, R. Levato, J. Malda,

L. Vonk, Utrecht/NL

18.2.2 Progenitors from Cartilage, Bone Marrow, Infrapatellar fat pad, Synovium, Periosteum – A Quantitative Comparison for Cartilage Repair V.P. Mantripragada, W. Bova, N. Piuzzi, C. Boehm,

N. Obuchowski, R. Midura, G. Muschler, Cleveland/US

18.2.3 Neuromedin B is a new player in cartilage differentiation M. Maumus1, G. Fonteneau1, M. Ruiz1, S. Assou1,

H. Boukahaddaoui1, P. Pastoureau2, F. De Ceuninck2, C. Jorgensen1, D. Noel1, 1Montpellier/FR, 2Suresnes/FR

18.2.4 Nanosecond Pulsed Electric Fields (nsPEFs) Enhanced Stemness of Mesenchymal Stem Cells via downregulation of DNMT1 K. Li, Z. Ge, Beijing/CN

18.2.5 Autophagy drives the therapeutic effect of MSCs in single-stage cell-based cartilage regeneration C.A. Paggi1, Y. Fu1, A. Dudakovic2, C. Galeano Garces2,

M. Hevesi2, D. Galeano Garces1, A. Van Wijnen2, M. Karperien1, 1Enschede/NL, 2Rochester/US

18.2.6 Multiple Nanosecond Pulsed Electric Fields Enhanced Multilineage Differentiation Potential of MSCs during Prolonged In Vitro Culture Z. Ge, J. Chen, Beijing/CN

18.2.7 Regeneration of cartilage from induced pluripotent stem cells in understanding genetic skeletal diseases E. Hyder, Manchester/GB

18.2.8 Modulation of the infl ammatory osteoarthritis environment in presence of MSCs from bone marrow and adipose tissue: an in vitro study F. Veronesi, S. Pagani, G. Filardo, M. Fini, Bologna/IT

18.2.9 Effects of Micronized Matrix Allograft Cartilage on Stem Cell Differentiation T. Reed1, B. Alba2, H. Liang3, D. Grande3, 1North Bellmore/

US, 2New Hyde Park/US, 3Manhasset/US

18.2.10 Mechano-ion-channel activation of TRPV4 promotes cartilage differentiation of MSCs and chondroprogenitors A. El Haj, I. Echevarria, H. Markides, Bimringham/GB

M O N D AY, O C T O B E R 7, 2 019

&













57

14:15 - 15:45 Free Paper Session Room: Plaza B&C18.3 Translational Science Moderators: Adam Anz/US, Lisa Fortier/US

18.3.1 Development of a new technique for directing stem cells to engraft into articular cartilage lesions A. Salerno, A. Dabbadie, L.-Y. Lian, S. Prendergast,

B. Poulet, A. Hollander, Liverpool/GB

18.3.2 In vivo MRI cell tracking of autologous mesenchymal stem cells in an ovine osteochondral defect model. H. Markides1, K. Newell2, H. Rudorf2, L. L. Blokpoel Ferreras3,

J. Dixon3, M. Graves2, J.D. Kaggie2, F. Henson2, A. El Haj1,1Birmingham/GB, 2Cambridge/GB, 3Nottingham/GB

18.3.3 One-step strategy for cartilage repair using Acellular Bone Matrix scaffold in a preclinical mini-pig model L. Dai, Y. Ao, Z. He, X. Hu, Beijing/CN

18.3.4 Osteotransduction of an aragonite-based scaffold by human bone marrow-derived mesenchymal stem cells D. Robinson1, N. Altschuler2, E. Kon3, L. Hangody4,

K. Zaslav5, Á. Berta4, 1PetahTikwa/IL, 2Kfar Saba/IL, 3Milano/IT, 4Budapest/HU, 5Richmond/US

18.3.5 Regeneration of hyaline cartilage in joints using minimally invasive fractional laser procedure V. Baskov1, A. Tokareva1, I. Yaroslavsky2, A. Baskov1,

E. Sobol2, A. Shechter1, V. Andreeva3, A. Kovalenko3, G. Altshuler2, 1Moscow/RU, 2Marlborough/US, 3Fryazino/RU

18.3.6 Therapeutic effects of gefi tinib-encapsulated thermosensitive injectable hydrogel in intervertebral disc degeneration Z. Pan, H. Ouyang, Hangzhou/CN

18.3.7 Injectable gels for cartilage repair: a long-term follow-up study in an equine chondral defect model. S. Both1, R. Vindas Bolanos2, S. Cockelaere3, N. Korthagen3,

B. Zoetebier1, P. Dijkstra1, A. Lindahl4, J. De Grauw3, R. Van Weeren3,M. Karperien1, 1Enschede/NL, 2San Jose/CR, 3Utrecht/NL, 4Gothenburg/SE

18.3.8 Ovine knee cartilage differs in structural and functional properties across articular surfaces B. Nelson, M. Risch, J. Easley, E. McCready, K. McGilvray, K.

Troyer, J. Johnson, J. Kisiday, Fort Collins/US

18.3.9 The results of cartilage damage treatment using growth plate chondrocytes on the growing animal model. R. Tomaszewski, Ł. Wiktor, Katowice/PL

18.3.10 Osteochondritis Dissecans Chondrocytes: A Novel Source for Cartilage Tissue Engineering L. Moncada-Palazuelos, V. Krasnodemsky, O. Sayfan, A. Kapatkin,

B. Filliquist, P.-Y. Chou, D. Marcellin-Little, N. Vapniarski-Arzi, Davis/US

M O N D AY, O C T O B E R 7, 2 019

14:15 - 15:45 Free Paper Session Room: Plaza A18.4 Clinical Miscellaneous - Part 2 Moderators: Kai Mithoefer/US, Jas Chahal/CA

18.4.1 Evaluation of bone marrow MSCs from different sources for the treatment of chondral lesions of the knee in >40-year old patients P. Neckar1, V. Havlas2, P. Bauer2, J. Braniš2, D. Lyková2,

J. Kvízová2, I. Drahorádová2, K. Růžičková2, H. Potočková2,1Usti Nad Labem/CZ, 2Prague/CZ

18.4.2 Allograft Compared with Autograft in Osteochondral Transplan- tation for the Treatment of Osteochondral Lesions of the Talus Y. Shimozono1, E. Hurley2, T. Deyer1, J. Kennedy1,

1New York/US, 2Dublin/IE

18.4.3 Intra-articular and subchondral injection of Bone Marrow concentrate to treat unicompartmental knee OA: results at 12 months follow-up E. Kon1, B. Di Matteo2, A. Nannini1, N. Vitale1, F. Vandenbulcke1,

S. Zaffagnini3, L. Andriolo3, A. Di Martino3, G. Filardo3, 1Milano/IT,2Rozzano Milano/IT, 3Bologna/IT

18.4.4 Cell Identity Assay Result May Correlate with Repair Tissue Quality and Graft Survival in Patients after Carticel J. Ackermann1, G. Merkely1, A. Mestriner2, N. Shah1,

A. Gomoll3, 1Boston/US, 2Sao Paulo/BR, 3New York/US

18.4.5 Performance of PROMIS Instruments in Patients Undergoing ACL Reconstruction Compared to Cartilage Procedures A. Beletsky, B. Nwachukwu, T. Southworth, K. Okoroha, N. Naveen,

B. Forsythe, N. Verma, B. Cole, A. Yanke, Chicago/US

18.4.6 Osteochondral Allograft – Host Interface Mismatch Does Not Affect Reoperation Rates When Using Less Restrictive Graft Matching Criteria K. Jones1, F. Coxe2, D. Wang3, R. Williams Iii2, 1Los Angeles/US,

2New York/US, 3Orange/US

18.4.7 Meniscal Extrusion Does Not Affect Morphologic Changes of Lateral Meniscus Allograft During Midterm Follow-up D. Son, S. Bin, J.M. Kim, Seoul/KR

18.4.8 Effect of the Atlas™ Unicompartmental Knee System on Tibiofemoral Joint Stress During the Stance Phase of Gait A. Gomoll1, A. Ranawat1, O. Morgan2, A. Fragomen1, R. Rozbruch1,

H. Hillstrom1, M. Rajshree1, 1New York/US, 2Chelmsford/GB

18.4.9 A novel radiological texture analysis technique for the assessment of cartilage regeneration following GelrinC treatment V. Juras1, P. Szomolanyi1,2, C. Deniz3, S. Trattnig1, 1Vienna/AT,

2Bratislava/SK, 3New York/US

18.4.10 Outcomes after Microfracture with Traditional Awl vs. Powerpick N. Naveen, T. Tauro, T. Southworth, J. Baker, A. Beletsky,

J. Chahla, N. Verma, A. Yanke, B. Cole, Chicago/US

M O N D AY, O C T O B E R 7, 2 019

&













59

16:00 - 17:00 Special Session Room: Plaza B&C19.1 Spine/Disc Moderators: Sally Roberts/GB, Ali Mobasheri/FN Objective: In this session, the audience will learn on the usage of stem cells and biomaterials for intervertebral disc repair, progenitor cells that can be found in the nucleus pulposus of the intervertebral disc and on the clinical trial in Japan where iPS cells are used for intervertebral disc regeneration.

19.1.1 Exploring Stem Cells & Biomaterials for Regenerative Medicine of Intervertebral Disc: From Clinical Data to Innovative Concepts J. Guicheux, Nantes/FR19.1.2 Progenitor Cells of the Intervertebral Disc D. Chan, Hong Kong/HK19.1.3 Reprogramming the Future of Cell Based Therapy for Interverte- bral Disc Disease D. Sakai, Isehara/JP

16:00 - 17:00 Special Session Room: Georgia19.2 Cartilage Mechanics & Biotribology Moderators: Alan Grodzinsky/US, Markus Wimmer/US Objective: In this session the participants will learn on the current status on cartilage biotribology, how cartilage damage affects the mechanics of the tissue and the role of rehydration and lubrication in cartilage repair

19.2.1 Current Status of Biotribology M. Wimmer1, C. Yuh1, R. Irwin2, T. Shoaib3, R. Espino-

sa-Marzal3, 1Chicago/US, 2Ithaca/US, 3Urbana/US19.2.2 Multimodal Assessment of Zonal Articular Cartilage: Correlation of Mechanics, Structural Organization, and Biochemistry V. Ferguson, Colorado/US19.2.3 Regenerating Cartilage Biomechanics Through Chondroinduction M. Buschmann1, C. Hoemann1, A. Chevrier2, S. Sim3, E. Quenneville3,

M. Garon3, G. Dwivedi4, A. Changoor5, 1Fairfax/US,2Montreal/CA, 3Laval/CA, 4Cambridge/US, 5Toronto/CA

16:00 - 17:00 Special Session Room: Regency19.3 Meniscus 2019 Moderators: William Bugbee/US, Tim Spalding/GB Objective: The lectures in this session will update the audience on meniscus regeneration, how we can enhance it and new research performed on meniscus replacement

19.3.1 Current Status of Meniscus Regeneration D. D’Lima, La Jolla/US19.3.2 Enhancing Meniscus Repair A. Hollander1, A. Blom2, M. Whitehouse2, W. Kafi enah2,

A. Salerno1, 1Liverpool/GB, 2Bristol/GB19.3.3 Meniscus Replacement P. Verdonk, Gent-Zwijnaarde/BE

M O N D AY, O C T O B E R 7, 2 019


17:30 - 18:30 ICRS General Assembly Room: Regency (For Members Only) All present ICRS Members are expected to attend this important session.

19:30 Canadian Farewell Party Brewhall, 97 East 2nd Ave. Vancouver, BC, V5T 1B3 19:15 Meet: Hyatt Lobby, Back Entrance19:30 Bus Departure

Great entertainment for everyone! Join us for a fun evening with good food, beers & drinks in a relaxed and informal party atmosphere. Enjoy live music. Pric/Person: € 90.00 (incl. bus transport, dinner, drinks & entertainment)

M O N D AY, O C T O B E R 7, 2 019

&













61

ReNu® is an innovative, single-injection therapy for the treatment of osteoarthritis symptoms. When used to treat knee osteoarthritis, clinical studies have shown an improvement in pain and function scores for up to 12-months.1,2 ReNu is different. It’s long-lasting OA symptom relief that really goes the distance.

Empowering Healing

www.organogenesis.com

Learn more about ReNu® at our podium presentations.

Amniotic Suspension Allograft (ASA) for Treatment of Knee Osteoarthritis in a Randomized Controlled Multi-Center Trial

Jack Farr, MD | OrthoIndy, Cartilage Restoration Center

Monday, October 7, 2019

11:24 a.m. – 11:33 a.m.

Georgia Ballroom, Hyatt Vancouver

Rescue Injection of Amniotic Suspension Allograft Improves Pain and Function in Patients with Knee Osteoarthritis

Andreas Gomoll, MD | Hospital for Special Surgery

Monday, October 7, 2019

12:00 p.m. – 12:09 p.m.

Plaza Ballroom B and C, Hyatt Vancouver

1. Farr J, Gomoll AH, Yanke AB, Strauss EJ, ASA Study Group, Mowry KC. A randomized controlled single blind study demonstrating superiority of amniotic suspension allograft injection over hyaluronic acid and saline control for modification of knee osteoarthritis symptoms. J Knee Surg. 2019, In press. 2. Vines JB, Aliprantis AO, Gomoll AH, Farr J. Cryopreserved amniotic suspension for the treatment of knee osteoarthritis. J Knee Surg. 2016 Aug;29(6):443–50. doi: 10.1055/s-0035-1569481.

Document No.: ReNu-407 | Revision: Initial Release | Effective Date: 08/26/2019

LONG-LASTING OA SYMPTOM RELIEFTHAT REALLY GOES THE DISTANCE.

© 2019 Arthrex, Inc. All rights reserved. AD1-000052-en-US_A Ad.Arthrex.com/GraftNet

Resect and Collect™The GraftNet device is designed to collect autologous tissue while suctioning or when using an arthroscopic shaver for various applications like bone and cartilage grafting.

GraftNet Autologous Tissue CollectorWhen using the GraftNet autologous tissue collector, gaining access to healthy autograft tissue can be as simple as attaching suction tubing to the shaver handpiece to collect resected tissue.

1. Attach the GraftNet device to suction 2. Attach the GraftNet apparatusto shaver or suction wand

3. Following collection, disassemble the GraftNet tissue collector

4. Withdraw the plunger from the GraftNet device

5. The collected tissue may then be mixed with autolo-gous fluid

&













63T U E S D AY, O C T O B E R 8, 2 019

08:00 - 09:00 Plenary Session Room: Regency21.0 Cost Effective Strategies for Joint Preservation Moderators: Mats Brittberg/SE, Leela Biant/GB Objective: After this session, participants will better understand the importance of cost-effectiveness, learn whether cell therapy is cost-effective and why and what other cheaper options are possible.

21.0.1 Should Cost be a Measure of Success? S. Lyman, I. Wolfe, New York/US21.0.2 Kneeconomics: Cost-Effectiveness Assessment in the Treatment of Articular Cartilage & Osteochondral Defects N. Waugh, Coventry/GB21.0.3 Can we do it Cheaper & Better? Cost Effective Cartilage Repair M. Lind, Aarhus N/DK

09:00 - 10:00 Plenary Session Room: Regency22.0 Cartilage Regeneration – Mini Battlefi eld Moderators: Brian Johnstone/US, Daniel BF Saris/US Objective: In this session 2 speakers ‘battle’ one topic during 4 minutes each, but each of them from a different angle. This will provide more insight and nuance into topics.

22.0.1 ACL Isolated Cartilage Lesion – Leave Alone B. Cole, Chicago/US22.0.2 ACL Isolated Cartilage Lesion – Treat A. Gomoll, New York/US

22.0.3 Realignment Osteotomy Works - That’s All You Need K. Kley, Hannover/DE22.0.4 Realignment Osteotomy Works - Combine with Cartilage Repair K. Slynarski, Warsaw/PL

22.0.5 Cells Only Way to Go T. Minas, West Palm Beach/US22.0.6 Cells not Required E. Kon, Milan, IT

22.0.7 No Role for Stem Cells Outside of Clinical Trials C.T. Vangsness, Jr., Los Angeles/US22.0.8 Stem Cells Should Be Available to All S. Sampson, Los Angeles/US

22.0.9 Marrow Stimulation is Dead R. Williams III, New York,/US22.0.10 Marrow Stimulation is Going Strong K. Mithoefer, Brookline/US

22.0.11 Rehab May be a Better Option E. Roos, Odense/DK22.0.12 Surgery Provides Better Outcomes A. Gobbi, Milano/IT

T U E S D AY, O C T O B E R 8, 2 019


10:30 - 12:00 Free Paper Session Room: Regency23.1 Joint Preservation 2 Moderators: Tom Minas/US, Roel Custers/NL

23.1.1 Clinical study of anatomical ACL reconstruction with adjustable oval shaped bone tunnels: a CT evaluation Z. Liu1, X. Hu2, Y. Ao1, 1Beijing/CN, 2Haidian District/CN

23.1.2 Does Repair of Horizontal Cleavage Meniscus Tears Improve Patient Outcomes? 1 Year Results from Prospective Multi-Center STITCH Trial D. Flanigan1, A. Krych2, A. Anz3, F.W. Gwathmey4, J. Larson1,

G. Loren5, M. Lavery6, L. Jazrawi7, S. Faucett8, L. McIntyre9, P. Kurzweil10, 1Columbus/US, 2Rochester/US, 3Gulf Breeze/US,4Charlottesville/US, 5Winchester/US, 6Greenwood/US, 7New York/US, 8Washington/US, 9Sleepy Hollow/US, 10Long Beach/US

23.1.3 Prospective Evaluation of Particulated Juvenile Articular Carti- lage Allograft in the Treatment of Osteochondral Lesions of the Talus R. Vellinga, R. Taylor, M. Discoll, G. Applegate, R. Ferkel, Van Nuys/US

23.1.4 Outcomes and Survival Rate of Collagen Matrix-Based Meniscus Repair: 4- to 8-year Follow-up Study K. Ciemniewska-Gorzela1,2, T. Piontek1, M. Slomczykowski2,

P. Bąkowski1, 1Poznan/PL, 2Poznań/PL

23.1.5 Improved Osteochondral Allograft Preservation Using Cyclic Hydrostatic Pressure G. Merkely, S. Mizuno, C. Lattermann, Boston/US

23.1.6 Anteromedial Tibial Tubercle Osteotomy improves results of MPFL reconstruction in patients with TT-TG distance of 17-20mm P. Debieux, C. Cohen Kaleka, C.E. Franciozi, Sao Paulo/BR

23.1.7 Tibial tubercle distalization can reduce articular cartilage contact pressures in the patellofemoral joint of patients with patella alta J. Koh1, J. Elias2, T. Jones2, 1Evanston/US, 2Akron/US

23.1.8 The Study on the Clinical Effect of Weight-bearing of Fast-Fix Suture Operation under Arthroscopy of Meniscus Tear J. Chen, Y. Meng, Y. Pan, H. Feng, QingDao/CN

23.1.9 Severe bone marrow edema following prior marrow stimulation technique is a predictor of autologous chondrocyte implantation failure. G. Merkely1, T. Ogura2, T. Bryant1, T. Minas3, 1Boston/US,

2Chiba/JP, 3West Palm Beach/US

&













65

10:30 - 12:00 Free Paper Session Room: Georgia23.2 Imaging Moderators: Stefan Marlovits/AT, Siegfried Trattnig/AT23.2.1 The Suitability of Pre-Operative Magnetic Resonance Imaging In Predicting Accurate Cartilage Defect Sizes For Treatment With Cell Therapy J. Perry1,2, H.S. McCarthy1,2, S. Roberts1,2, P. Gallacher2,

J.B. Richardson1,2, B. Tins1,2, 1Stoke-on-Trent/GB, 2Oswestry/GB23.2.2 The MOCART (Magnetic Resonance Imaging of Cartilage Repair Tissue) 2.0 Knee Score and Atlas S. Trattnig1, S. Marlovits2, M. Raudner1, M. Schreiner2, 1Wien/AT,

2Vienna/AT23.2.3 Discrepancy between T2 mapping MRI and histological anal- yses for zonal composition of mesenchymal stem cell-based cartilage repair tissue K. Shimomura1, H. Hamada1, K. Koizumi1, Y. Yasui1, D. Hart2,

W. Ando1, T. Nishii1, S. Horibe1, H. Yoshikawa1, N. Nakamura1,1Osaka/JP, 2Calgary/CA

23.2.4 The development of a magnetic resonance scoring system for evaluating osteochondral healing in preclinical models – the ‘AMOS’ score. E. Chisari1,2, K. Newell2, J.D. Kaggie2, W. Khan2, F. Henson2,

1Catania/IT, 2Cambridge/GB23.2.5 Elliptical, Stacked, and Single Osteochondral Allograft Transplan- tation for Large Knee Chondral Defects: One-Year MRI Outcomes F. Coxe1, D. Wang2, G. Ode1, A. Elbuluk1, A. Burge1, K. Jones3,

R. Williams Iii1, 1New York/US, 2Orange/US, 3Los Angeles/US23.2.6 Automated detection of Bone Marrow Edemas from MRI: data from the Osteoarthritis Initiative T. Paixao1, A. Stria1, C. Goetz1, R. Ljuhar2, Z. Bertalan1,

1Wien/AT, 2Vienna/AT23.2.7 Cationic contrast enhanced computed tomography characterizes articular cartilage in an equine impact model B. Nelson1, T. Lawson2, J. Makela2, B. Snyder2, M. Hurtig3,

V. Moorman1, M. Grinstaff2, L. Goodrich1, C. Kawcak1, 1Fort Collins/US, 2Boston/US, 3Guelph/CA

23.2.8 Anterior tibiotalar fat pad morphology and signal intensity on MRI are correlated with patient characteristics and joint pathology S. Arnaert1, P. Byttebier2, S. Van Rossom1, E. Vereecke2, I. Jonkers1,

E. Oei3, S.M.A. Bierma-Zeinstra3, R. Lories1, M. Van Middelkoop3,S. Clockaerts1,2, 1Leuven/BE, 2Kortrijk/BE, 3Rotterdam/NL

23.2.9 Computed tomography parameters following osteochondral allograft transplantation do not correlate with patient reported outcomes D. Anderson1, S. Rodeo2, E. Bogner2, J. Wiedrick3, D. Crawford3, 1Rochester/US, 2New York/US, 3Portland/US23.2.10 Apparent Density of osteoarthritic cartilage is infl uenced by integrity of the superfi cial zone in non-equilibrium contrast-enhanced CT C. Flynn, M. Hurtig, Guelph/CA

T U E S D AY, O C T O B E R 8, 2 019

10:30 - 12:00 Free Paper Session Room: Plaza B&C23.3 Stem Cells & Biologics Moderators: Rebekah Decker/US, Martin Lind/DK23.3.1 Co-overexpression of FGF-2 and SOX9 via rAAV gene transfer enhances chondrogenic and metabolic processes in human bone marrow aspirates K. Tao1,2, A. Rey-Rico2, J. Kumar Venkatesan2, G. Schmitt2,

H. Madry3, J. Lin1, M. Cucchiarini2, 1Peking/CN, 2Homburg/Saar/DE, 3Homburg/DE

23.3.2 Chitosan oligomers alter the entire knee microenvironment when IA-injected post-bone marrow stimulation in a chronic defect rabbit model C. Mathieu1, J. Guzman-Morales1, A. Lemay1, S. Desmarais1,

L. Hotz1, G. Chen1, R. McCormack2, P. Chitnis3, M. Lavertu1, C. Hoemann1,3, 1Montreal/CA, 2New Westminster/CA, 3Manassas/US

23.3.3 Intra-articular Injection of Human Synovial Mesenchymal Stem Cells Promotes Cartilage Regeneration in a Canine Osteoarthritis Model H.S. Chung, Y.S. Kim, Y.G. Koh, Y.I. Kim, Seoul/KR23.3.4 Infl uences of antiplatelet therapy on the quality of Platelet-rich plasma (PRP) and effi cacy of the PRP therapy Y. Kobayashi1,2, Y. Saita1, T. Wakayama1, H. Nishio1, S. Fukusato1,

S. Uchino1, H. Ikeda1, M. Nemoto2, K. Kaneko1, 1Tokyo/JP, 2Chiba/JP23.3.5 Characterization of Bone Marrow Aspirate obtained by Marrow Cellution device: the smartest way to collect Bone Marrow B. Di Matteo, M. Viganò, E. Ragni, L. Lovato, E. Kon, L. De Girolamo,

Milano/IT23.3.6 Deleted Ihh in Mesenchyme Promotes Chondrocyte Hypertrophy and Pathological Matrix Calcifi cation J. Sun1, X. Wei1, C. Xiang1, L. Li1, D. Liang1, X. Cao1, L. Wei2,

1Taiyuan/CN, 2Providence/US23.3.7 Return to Sport and Work Following Osteochondral Autograft Transplantation A. Beletsky, W. Skallerud, T. Southworth, N. Naveen, J. Chahla,

B. Nwachukwu, A. Yanke, N. Verma, B. Cole, Chicago/US23.3.8 Anti-coagulation infl uences properties of extracellular vesicles isolated from autologous blood derived products A. De Luna, A. Otahal, O. Kuten, Z. Lacza, S. Nehrer, Krems/AT23.3.9 Microfracture Augmentation with Enzymatic Pretreatment And Growth Factor Functionalized Self-Assembling Peptide Hydrogel Scaffold G. Zanotto1, P. Liebesny2, M. Barrett1, H. Zlotnick3, A. Grodzinsky4,

D. Frisbie1, 1Fort Collins/US, 2Somerville/US, 3Cambridge, Ma/US,4Cambridge/US

23.3.10 Engineering the Damaged Cartilage Interface to Direct Stem Cell Behavior J. Patel, C. Loebel, B. Wise, J. Carey, J. Burdick, R. Mauck, Philadelphia/US

T U E S D AY, O C T O B E R 8, 2 019

&













67

10:30 - 12:00 Free Paper Session Room: Plaza A23.4 Osteoarthritis Animal Studies Moderators: David Frisbie/US, Christian Lattermann/US23.4.1 Allogeneic and autologous equine mesenchymal stem cells elicit comparable responses in both normal and infl amed equine joints A. Colbath, S. Dow, J. Phillips, L. Goodrich, Fort Collins/US23.4.2 Different ways to treat osteoarthritis with mesenchymal stromal cells injection: an animal model E. Antonioli1, F. Bruno Dias De Oliveira2, O. Metropolo Dias2,

J. Gabriel Souza2, M. Ferretti2, 1São Paulo/BR, 2Sao Paulo/BR23.4.3 Evaluation of different intraarticular injection therapies with gait analysis at rat osteoarthritis model C. Caglar, H. Kara, O. Ates, S. Karahan, M. Türk, M. Uğurlu,

Ankara/TR23.4.4 Upregulation of IL-1β, -6 and TNF-α is responsible for the form of post-traumatic osteoarthritis in a porcine model X. Wei1, P. Han1, L. Wei1,2, P. Li1, J. Lu1, L. Li1, 1Taiyuan/CN,

2Providence/US23.4.5 Synovial membrane response to bone marrow stimulation and IA-injections of saline or Synvisc® in a chronic cartilage defect rabbit model C. Mathieu1, J. Guzman-Morales1, A. Lemay1, S. Desmarais1,

G. Chen1, R. McCormack2, M. Lavertu1, C. Hoemann1,3, 1Montreal/CA, 2New Westminster/CA, 3Manassas/US

23.4.6 Amniotic epithelial stem cells (AECs) Vs adipose-derived mesenchymal stem cells (ADSCs): biological treatment for osteoarthritis F. Veronesi1, F. Vandenbulcke2, B. Di Matteo2, E. Kon2, A. Muttini3,

N. Vitale2, M. Fini1, 1Bologna/IT, 2Milano/IT, 3Teramo/IT23.4.7 PPARγ rejuvenation via the promoter demethylation alleviates osteoarthritis in mice X. Zhu, Q. Jiang, Nanjing/CN23.4.8 Diabetes Mellitus Accelerates Progression of Osteoarthritis in Streptozotocin-induced Diabetic Mice X.F. Zheng, H. Wang, H. Hou, J. Li, Q. Teng, D. Michelle,

Guangzhou/CN23.4.9 Gefi tinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment H. Sun, H. Ouyang, Y. Wu, Z. Pan, Hangzhou/CN23.4.10 Evaluation of TRB-N0224, a Chemically Modifi ed Curcumin for Treatment of Osteoarthritis R. Nixon1, J. Coury2, N. Chahine3, D. Grande2, 1Queens/US,

2Manhasset/US, 3New York/US

T U E S D AY, O C T O B E R 8, 2 019

12:15 - 13:15 Special Session Room: Georgia24.1 Methods to Assess Cartilage Repair Success or Failure Moderators: Peter Angele/DE, Ewa Roos/DK Objective: In this session, participants will learn qualitative and quantitative outcome measures and get insight into the societal perspective

24.1.1 The Knee Injury & Osteoarthritis Outcome Score (KOOS). Aspects to Consider in Assessment of Patients Undergoing Cartilage Repair E. Roos, Odense/DK24.1.2 Quantitative Methods S. Trattnig, Wien/AT24.1.3 Aligning Scientists, Researchers, Payors & Policy-Makers Goals to Optimize Access to Patients for Meaningful Innovation: A Health Economist Perspective J. Frappier, Montreal/CA

12:15 - 13:15 Special Session Room: Plaza B&C24.2 Subchondral Bone In 2019 Moderators: Yves Henrotin/BE, Vladimir Bobic/GB Description: This session will provide the current status and an update into the research on the subchondral bone

24.2.1 Edema S. Marlovits, Vienna/AT24.2.2 Subchondral Bone Sclerosis in Knee Osteoarthritis: Association with Cartilage Degeneration D. Findlay1, D. Muratovic1, X.-D.E. Guo2, Y. Hu2, F. Cicuttini3, A. Wluka3,

Y.R. Lee1, J. Kuliwaba1, 1Adelaide/AU, 2New York/US, 3Melbourne/AU24.2.3 The Tidemark C. Hoemann, Manassas/US

12:15 - 13:15 Special Session Room: Plaza A24.3 Biomaterials / Bioprinting / Bioengineering Moderators: Marcel Karperien/NL, Riccardo Levato/NL Objective: In this session, the participants will learn the current status of additive manufacturing, how biomaterials can instruct cells and the benefi ts and mechanism of using decellularized tissue.

24.3.1 Knee Joint-On-A-Chip M. Karperien, Enschede/NL24.3.2 Biomaterials for Cartilage Repair: Are we Heading in the Right Direction? J. Malda, R. Van Weeren, Utrecht/NL24.3.3 Decellularized Tissue Derived Scaffolds for Cartilage & Osteo- chondral Defect Repair D. Kelly, Dublin/IE

13:30 - 14:30 ICRS Committee Meeting Room: TurnerICRS General Board Meeting (New Board 2019-2021)

T U E S D AY, O C T O B E R 8, 2 019

&













69

HYALOFAST® is not approved for use in the United States. HYALOFAST® is a registered trademark of Fidia Farmaceutici S.p.a.

One-step cartilageregeneration made easy

The only entirely hyaluronic acid based scaffold

Easy and fast application in arthroscopy or mini-arthrotomy

Hyaluronic acid is released creating a regenerative micro-environment

Clinically proven hyaline-like cartilage formation

Ultra-pure, non-animal hyaluronan

Safe, highly biocompatible and absorbable

VISIT ANIKA AT BOOTH #15

RegenLab® is a certified global leader in medical device biotechnologies, specializing in Cellular Therapies.

Our products provide expertly designed Medical Devices for the preparation of

autologous platelet rich plasma and cellular therapies which continue to set the

standard for production quality, patient safety, and preparation efficiency.

PRP ® & CELL THERAPY SPECIALISTS

®

P R P ® & C E L L T H E R A P Y S P E C I A L I S T S

®

RegenLab® is a certified global leader in medical device biotechnologies, specializing in Cellular Therapies.

Our products provide expertly designed Medical Devices for the preparation of platelet rich plasma and cellular therapies which continue

to set the standard for production quality, patient safety, and preparation efficiency.

®

Cellular Matrix

Breaking the vicious cycle of osteoarthritis

Platelet Rich Plasma + Hyaluronic Acid

The reproducible bone marrow

concentrate system

RegenKit® A-PRP®

The safe & effective leukocyte-reduced A-PRP for musculoskeletal applications

www.regenlab.com

CellularMatrix CAUTION DeviceLimited by Canadian law and Health Canada and not currently available for use in Canada.

RegenKit® A-PRP®

The safe & effective leukocyte-reduced A-PRP

RegenKit® A-PRP®

A-PRP®

RegenExtracell®

BMC & GLUE

The reproducible bone marrow

concentrate systemconcentrate system

Single Step Preparation of Hyaluronic Acid + Platelet Rich Plasma Combination

Cellular Matrix®

A-PRP & HA

&













71

Biologic approaches to tissue repair and regeneration represent the future in healthcare worldwide.

Aesculap Biologics is leading the way.

Learn more at www.aesculapbiologics.com

Aesculap Biologics, LLC | 866-229-3002 | www.aesculapusa.com

Aesculap Biologics, LLC - a B. Braun company

NOVOCART® 3DFacing a New Frontier in Cartilage Repair

NOVOCART 3D is an investigational product and not approved for use in the U.S. or in Canada outside of the clinical study.

Visit us at Booth 18

ZIMMER BIOMETEARLY INTERVENTION

903.238 Rev A | Copyright © 2019 Zimmer Biomet

* Caution-Investigational Device. Limited by U.S. Law to Investigational Use. Data presented based on European prospective randomized trial; safety and e� ectiveness not yet established in the U.S.

** As measured by WOMAC pain scores reported by patients continuing follow-up through 3 years (n=19) 19 out of the original cohort of 31 patients.

All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its a� liates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.This material is intended for health care professionals. Distribution to any other recipient is prohibited.For indications, contraindications, warnings, precautions, potential adverse e� ects and patient counselling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com for additional product information.Check for country product clearances and reference product specifi c instructions for use.Not intended for surgeons practicing medicine in France.

1. Mine et al. Innervation of nociceptors in the menisci of the knee joint: an immunohistochemical study. Ortho Trauma Surg. 2000 120 (3-4).2. Sowers et al. Associations of Anatomical Measures from MRI with Radiographically Defi ned Knee Osteoarthritis Score, Pain and Physical

Functioning. JBJS Am. 2011; 93:241-251.3. Tofi ghi et al. Setting Reaction Involved in Injectable Cements Based on Amorphous Calcium Phosphate, Key Engineering Materials Vols. Pages

192-195 (2001) Benchtop and animal data is not necessarily indicative of clinical outcomes.4. Hajnik C, et al. One Year Radiographic and Clinical Outcomes of Subchondroplasty for Treatment of Symptomatic Bone Marrow Lesions of the

Knee. ICRS World Congress Macau, 2018.5. Kon E, Engebretsen L , Peter Verdonk P, Nehrer S and Filardo G. “Two-year Clinical Outcomes of An Autologous Protein Solution Injection For

Knee Osteoarthritis.” I CRS 14th World Congress, presented 2018.6. A Multicenter, Double-Blind, Randomized, Placebo [Saline]-Controlled Pilot Study of a Single, Intra-Articular Injection of Autologous Protein

Solution in Patients with Osteoarthritis of the Knee” Clinical Investigation Report – 36 Month, APSS-33-00, Version 1.0. 14 January 2019.

• Treats chronic subchondral bone defects, which are primary cause of joint pain1,2

• Proprietary minimally-invasive injection of AccuFill® BSM; undergoes cell-mediated remodeling as the bone heals3

• Peer-reviewed data demonstrate sustained pain reduction, improved function and quality of life4

The Subchondroplasty®

(SCP®) ProcedurenSTRIDE® APS Kit*

• Autologous anti-infl ammatory injection for the treatment of knee osteoarthritis5

• Signifi cantly improves function in the knee joint associated with OA5

• Signifi cantly reduces pain associated with knee OA upto 3 years6**

BRIDGING THE GAPIN THE CONTINUUM OF CARE

&













73

E P O S / P O S T E R P R E S E N TAT I O N S

Poster Viewing Sessions:Saturday, October 05 from 15:15–16:15Sunday, October 06 from 10:45–12:30

Poster Numbers marked with will bring a traditional wall poster besides their E-poster

P001Comparison of Infl ammation Response in Allogene-ic Immune Reactions Between Human Juvenile and Adult Articular ChondrocytesS. Abe, Asahikawa/JP

P002Characterizing Native and Allograft ACL Tissues: Transcriptional Role and Novel Histologic Validation of SPARC and PRELPM. Hevesi1, W. Van Genechten2, C. Paradise1, C.A. Paggi1, A. Dudakovic1, S. Kakar1, T. Hewett1, A. Krych1, D.B. Saris1, A. Van Wijnen1, 1Rochester/US, 2Ham/BE

P003Outcomes of Salvage Arthrodesis and Arthroplasty for Failed Osteochondral Allograft Transplantation of the Ankle.F. Gaul, C. Barr, S.N. Copp, W. Bugbee, La Jolla/US

P004Effectiveness of Arthroscopic Rotator Cuff Repair with Allogenous Dermal Augmentation in Irrepara-ble Massive Rotator Cuff TearH. Kang, J. Choi, S. Choi, W.Y. Chang, Jeju/KR

P005Interfacial Shear Mechanical Properties of Commer-cially Available Osteochondral AllograftsD. Wang1, K. Culley2, A. Wach2, A. Shields2, T. Chen2, J. Nguyen2, D. Nemirov2, S. Rodeo2, S. Maher2, R. Williams Iii2,1Orange/US, 2New York/US

P006Tissue Adhesive Patch – Cartilage (TAP-C): A Glue Improve Osteochondral Grafts Transplantations for Joint Repair Application.M.-D. Truong1, I.-S. Park1, B.H. Choi2, D.Y. Park1, B.-H. Min1, 1Suwon/KR, 2Incheon/KR

P007Analysis of Defect Size and Ratio to Condylar Size with Respect to Outcomes Following Isolated Osteo-chondral Allograft TransplantationR. Frank1, S. Lee2, D. Christian3, B. Cole3, 1Boulder/US, 2Ann Arbor/US, 3Chicago/US


P008Osteochondritis Dissecans Lesion Location is Highly Concordant with Mechanical Axis DeviationG. Gracitelli1, M. Brown2, W. Bugbee2, 1São Paulo/BR, 2La Jolla/US

P009Predicting Complications and Extended Stay follow-ing Treatment of Chondral LesionsY. Lu, A. Beletsky, B. Patel, T. Southworth, N. Naveen, J. Chahla, B. Forsythe, N. Verma, B. Cole, Chicago/US

P010The Recovery of Bone Marrow Oedema and Carti-lage Lesions in 100 Knees Following First-time Mar-athon RunningA. Hart, J. Henckel, L. Horga, A. Di Laura, A. Fotiadou, London/GB

P011Osteochondritis Dissecans of the Humeral Capitel-lum: Updated Classifi cation Based on Lesion Loca-tionP. Saluan1, J. Kolmodin2, K. Everhart1, 1Cleveland/US, 2Cleveland Heights/US

P012Up-Scale Manufactured Human Mesenchymal Stro-mal Cells Promote Murine Cartilage RegenerationJ. Perry1,2, A.J. Roelofs3, H.S. McCarthy1,2, C. Mennan1,2, K.T. Wright1,2, C. De Bari3, S. Roberts1,2, 1Stoke-on-Trent/GB, 2Oswestry/GB, 3Aberdeen/GB

P013A Novel Early Osteoarthritis Model Exhibits Carti-lage Degeneration After Medial Collateral Ligament Transection Outside CapsuleZ. Liu1, X. Hu2, Y. Ao1, 1Beijing/CN, 2Haidian District/CN

P014Hyaluronan Photocrosslinked Hydrogels for Im-proved Osteochondral Repair: A 1-year Pre-clinical Study on a Mini-pig ModelR. Beninatto1, L. Gao2, C. Barbera1, M. Pavan1, M. Cucchiarini2,D. Galesso1, H. Madry2, 1Abano Terme (pd)/IT, 2Homburg/Saar/DE

P015Unicondylar Reconstruction Using an Aragonite Scaffold in a Caprine ModelE. Kon1, N. Altschuler2, D. Robinson3, K. Zaslav4, J. Shani5, M. Drobnic6, F. De Caro7, B. Di Matteo8, 1Milano/IT, 2Kfar Saba/IL, 3PetahTikwa/IL, 4Richmond/US, 5Beit Berl/IL, 6Ljubljana/SI, 7Bergamo/IT, 8Rozzano Milano/IT

&













75

P016Development and Characterization of a Humanized Mouse Model of OsteoarthritisC. Vinatier, B. Metayer, M. Masson, C. Vignes, J. Lesoeur, J. Veziers, B. Bodic, V. Daguin, F. Haspot, M. Yves, J. Guicheux, Nantes/FR

P017Enhancement of Bone Defects in Rabbits Using a Mixture of Atelocollagen Gel and Bone Marrow Aspirate ConcentrateH.Y. Park, S.J. Kim, J.H. Lee, Uijeongbu-si/KR

P018Growth Plate Chondrocyte Transplantation in the Treatment of Physeal Injury in Rabbits.R. Tomaszewski, Ł. Wiktor, Katowice/PL

P019Experimental Study on the Treatment of Long Bone Non-union with Silk Fibroin (SF)-graphene Oxide (GO) Thin-fi lm Composite (TFC) Membrane.F.Y. Takyi-Appiah1, Y. Zhang2, X. Li1, 1Shijiazhuang/CN, 2Shijiazhaung/CN

P020Amniotic Suspension Allograft Modulates Infl amma-tion in an in vitro Human Synoviocyte ModelK. Mowry, K. Kimmerling, Birmingham/US

P021 Bone Marrow-derived Cells but not Chondrocytes Having a Decisive Role in a New Cartilage Matrix Formation in an 3D ModelN. Andjelkov1, M. Ivarsson2, H. Riyadh1, P. Wretenberg2, 1Västerås/SE, 2Örebro/SE

P022Zipper-stiffness Mechanism of Chondrospheres Tis-sue FusionA. Gryadunova, V. Parfenov, E. Bulanova, E. Koudan, Y. Khesuani, V. Mironov, Moscow/RU

P023Synovial Fluid Biomarker Alternatives: Can Plasma and Urine Samples Shed Light on the Post-Traumatic Intra-Articular Microenvironment?E. Strauss, M. Kingery, A. Clair, U. Anil, L. Kenny, New York/US


P024Tissue Inhibitor of Metalloproteinase as a Synovial Fluid Biomarker of Post-Operative Pain Following ACL ReconstructionE. Strauss, M. Kingery, A. Clair, U. Anil, L. Kenny, New York/US

P025Chronicity of Injury and Synovial Fluid Biomarkers for Meniscal and Anterior Cruciate Ligament InjuriesE. Strauss, B. Kester, M. Kingery, U. Anil, K. Thompson, L. Kenny, New York/US

P026Preoperative Changes in the Biomarker Profi le of the Knee before Anterior Cruciate Ligament Recon-structionE. Strauss, M. Kingery, U. Anil, A. Clair, L. Kenny, New York/US

P027Synovial Fluid Biomarkers in the Osteoarthritic Knee: Differences in Concentration with Progression of Radiographic SeverityE. Strauss, M. Kingery, D. Whitney, D. Klein, T. Rodriguez, L. Kenny, New York/US

P028Anti-Infl ammatory Changes In The Cytokine Pattern of the Osteoarthritic Knee Joint in Response to Hy-peracute Serum TreatmentZ. Lacza1, D. Kardos1, A. Hinsenkamp1, O. Kuten2, I. Hornyák1,1Budapest/HU, 2Krems/AT

P029Behaviour of Osteoarthritis markers in patients with Anterior Cruciate Ligament Reconstruction at 24-monthsA. Olivos Meza1, J. Palos2, C. Landa Solis1, S. Renan León1, F.J. Pérez Jiménez1, B. Olivos1, C. Suarez Ahedo1, A. González Hernández1, C. Ibarra1, 1Mexico City/MX, 2Mexico/MX

P030Coll2-1,a Biomarker of Osteoarthritis, is not Affect-ed by Sampling Conditions, Circadian Rhythm, Sea-sonality and Physical Activity.Y. Henrotin1, A.-C. Hick2, M. Fonck1, B. Costes2, E. Cobraiville1, S. Pirson1, L. Garcia1, B. Cordier2, 1Liège/BE, 2Liege/BE

P031Functional Mimicry of Articular Cartilage Through a Fiber Reinforced Hydrated NetworkA. Moore1, G. Miklosic1, M. Flury1, O. Ovrebo1, R. El Laham1, L. Zharova1, M. Stevens1,2, 1London/GB, 2Stockholm/SE


&













77

P032A Zonal Microstructured Scaffold for Osteochondral Defect RepairA. Moore1, J. Steele1, J.-P. St-Pierre1, S. McCullen1, A. Gormley1,2, C. Horgan1, C. Meinert3, J. Ren3, T. Klein3, S. Saifzadeh3, R. Steck3, M. Woodruff3, M. Stevens1,2, 1London/GB, 2Stockholm/SE,3Brisbane/AU

P033Aptamer-Functionalized Bioscaffold Enhances Carti-lage Repair by Improving Stem Cells Recruitment in Osteochondral DefectsC. Chen, Chongqing/CN

P034Self-assembling of 3D Gelatin Microniches into Functional Constructs for Cartilage RegenerationD. Xing, J. Lin, Y. Du, Beijing/CN

P035Particulated Cartilage Allograft Supports Cell Viabil-ity, Adhesion, and MigrationL. Fortier1, R. Irwin1, J. Commins1, A. Matuska2, M. Delco1, 1Ithaca/US, 2Naples/US

P036Application of Coaxial Electrospinning Technique for Tissue Engineered BoneY. Long, Y. Chuan, Gui Yang/CN

P037Gelatin Scaffold Mimic the Lesion Zone Microenvi-ronment of Knee Osteoarthritis by Regulating Pore Sizes and HardnessY. Zhao, J. Lin, Y. Du, Z. You, D. Xing, Beijing/CN

P038Evaluation of Commercially Available Knee Carti-lage Restoration Techniques Stratifi ed by FDA Ap-proval PathwayS. Sherman1, L. Oladeji1, T. Ray1, B. Hinckel2, J. Farr3, W. Gersoff4, 1Columbia/US, 2San Diego/US, 3Greenwood/US, 4Denver/US

P039Decellularized Articular Cartilage Repopulation Sup-ported by Laser Engraving Technologies.S. Nürnberger1, C. Schneider1, B. Rieder1, A. Teuschl1, J. Zehetner2, C. Keibl1, H. Redl1, S. Wolbank1, 1Vienna/AT, 2Dornbirn/AT


P040The IEIK13 Self-assembling Peptide Hydrogel is Effi cient to Repair Osteochondral Defects in a Non-human Primate ModelE. Perrier-Groult1, A. Dufour1, M. Verset2, A. Cohendet2, M. Buffi er3,M. Rioult3, H. Contamin2, F. Mallein-Gerin1, 1Lyon Cedex/FR, 2Marcy-l‘Etoile/FR, 3Caluire-et-Cuire/FR

P041In Vivo Evaluation of 3D Bioprinted Osteochondral Implants with Hierarchical Fiber Orientation and Cellular DistributionM. De Ruijter1, P. Diloksumpan1, I. Dokter1, H. Brommer1, F.M. Braganca1, R. Levato1, R. Van Weeren1, M. Castilho1,2, J. Malda1, 1Utrecht/NL, 2Eindhoven/NL

P042Mussel Adhesion Protein (MAP) as an Equal Alterna-tive to Fibrin for Scaffold Fixation During Cartilage Repair ProceduresN. Andjelkov1, M. Ivarsson2, H. Riyadh1, P. Wretenberg2, 1Västerås/SE, 2Örebro/SE

P043The Creation of a Novel Synthetic Periosteum Using 3D Bioprinting on a Biologic MatrixD. Kiridly1, P. Swami2, B. Alba1, H. Goodman1, D. Grande2, 1New Hyde Park/US, 2Manhasset/US

P044Comparison of Chondrocyte Behaviour on CH₃-SAMs and on Fibroin SubstratesA. Tatsumi1, S. Tatehata1, R. Hiraiwa1, Y. Arima2, Y. Tamada3, N. Tomita1, 1Kyoto-shi/JP, 2Fukuoka-shi/JP, 3Ueda-shi/JP

P045Engineered Reinforced Osteochondral Plugs Com-bining 3D Printing, Electrowriting and Cartilage Pro-genitor Cells AssemblyR. Levato1, F. Abinzano1, P. Diloksumpan1, M. De Ruijter1, M. Castilho1, I. Khan2, R. Van Weeren1, J. Malda1, 1Utrecht/NL,2Swansea/GB

P046Visible Light-responsive Gelatin Bioglues with Dual Photoreactivty for Cartilage RestorationF. Abinzano1, K. Lim2, P. Nunez-Bernal1, P. Atienza-Roca2, I. Otto1, A. Albillos1, T. Woodfi eld2, J. Malda1, R. Levato1, 1Utrecht/NL, 2Christchurch/NZ


&













79

P047Can a Meniscus-shaped PGA Scaffold Aid After Par-tial Meniscectomy?N. Sinner1, M. Endres1, J.P. Krüger1, D. Cojocaru2, J.M. Patrascu2,1Berlin/DE, 2Timisoara/RO

P048Cartilage Flow Formation Over Polymer Versus Metal Focal Resurfacing Implants: Insights From a Caprine Study.P. Van Hugten1, R. Jeuken1, A. Roth1, J. Thies2, L. Van Rhijn1, P. Emans1, 1Maastricht/NL, 2Geleen/NL

P049Bone Forms from Cartilage: An Endochondral Ossifi -cation Inspired Tissue Engineering ApproachV. Jeyakumar, N. Amraish, C. Bauer, E. Niculescu-Morzsa, D. Pahr, S. Nehrer, Krems/AT

P050Cell-free Scaffolds in Cartilage Knee Surgery: A Systematic Review and Metanalysis of Clinical Evi-dence.A. Boffa, A. Roffi , D. Reale, L. Andriolo, A. Di Martino, S. Zaffagnini, G. Filardo, Bologna/IT

P051Quantitative 3D MRI Demonstrates Durability of Re-pair After Treatment with ChondroMimetic Scaffold in an 8 Year Extension StudyM. Shive1, Á. Berta2, A. Lynn3, A. Getgood4, S. Totterman5, G. Busby6, J. Hollenstein7, G. Vásárhelyi2, I. Kéki2, L. Hangody2, 1Denver/US, 2Budapest/HU, 3Cambridge/GB, 4London/CA, 5Rochester/US, 6Glasgow/GB, 7Eden Prairie/US

P052Cell-Free Biomimetic Osteochondral Scaffold: A Pilot Prospective Clinical Study At 120 Months of Fol-low-Up.L. Andriolo, A. Di Martino, S.A. Altamura, A. Boffa, F. Perdisa, A. Sessa, S. Zaffagnini, G. Filardo, Bologna/IT

P053Biomimetic Scaffold Implantation for the Treatment of Juvenile Osteochondritis Dissecans: Clinical Result at 5 Years’ Follow-up.L. Andriolo, I. Romandini, A. Sessa, A. Di Martino, S. Zaffagnini, G. Filardo, Bologna/IT

P054Clinical Outcomes of Surgical Treatment for Osteo-chondral Defects of the KneeL. Groot Koerkamp, R. Custers, N. Van Egmond, E.C. Kester, Utrecht/NL


P056In Vivo Gait Kinematics of the Knee After Anatomi-cal and Non-anatomical Single-Bundle Anterior Cru-ciate Ligament ReconstructionW. Yan, Q. Jiang, D. Shi, Nanjing/CN

P057Different Speed of Eccentric Strength Training on Fast Strength of Lower BodyX. Miao, Y. Ao, W. Jiao, Beijing/CN

P058The Agreement Between Biofeedback Measures of Quadriceps and Gluteal Muscles in short-arc Quad-riceps and Seated Clamshell Exercises.P. Bright, Maidstone/GB

P059Pre-operative expectations Are Inversely Correlated with Rehabilitation Adherence in Patients Undergo-ing Cartilage Repair of the Knee.J. Toonstra1, J. Howard2, C. W Conley3, 1Bowling Green/US, 2Boone/US, 3Lexington/US

P060Effect of Dual Task on Gait Asymmetry in Individu-als with Anterior Cruciate Ligament ReconstructionH. Shi, H. Huang, Y. Yu, Y. Ao, Beijing/CN

P061The Clot Thickens: Pooled Plasma and Autologous Fibrin Sealants Show Similar Failure Mechanics and Repair Adhesion to Articular CartilageL. Fortier1, R. Irwin1, L. Bonassar1, I. Cohen1, A. Matuska2, J. Commins1, B. Cole3, 1Ithaca/US, 2Naples/US, 3Chicago/US

P062Comprehensive Evaluation of the Human Meniscus Using ColorimeterT. Yamanaka1, M. Ishikawa2, T. Inoue2, T. Nakasa2, S. Miyaki2, N. Kamei2, N. Adachi2, 1Kyoto/JP, 2Hiroshima/JP

P063Effects of Loading Conditions on Articular Cartilage in a Metal-on-Cartilage Tribological Set-upC. Stotter1, C. Bauer1, S. Bojana2, M. Rodríguez Ripoll2, F. Franek2, T. Klestil3, S. Nehrer1, 1Krems/AT, 2Wiener Neustadt/AT, 3Baden/AT


&













81

P064Biomechanical Comparison of Vertical Mattress and x Suture Techniques for the Treatment of Buck-et-handle Medial Meniscus TearsC. Cohen Kaleka, G. Nakama, P. Debieux, D. Astur, M. Cohen, Sao Paulo/BR

P065Evaluation of the Impact of Micro-perforations on Cryoprotectant Permeability and Mechanical Prop-erties of Porcine Articular CartilageL. Westover, K. Duong, N. Mohamed, R. Dong, K. Wu, L. Laouar, G. Hong, J. Jn Baptiste, J.A.W. Elliott, N.M. Jomha, Edmonton/CA

P066Matrix Encapsulates Chondrocytes Implantation for the Surgical Treatment of Chondral Injuries in Young AdultsA. Gantier, F.E. Villalobos Córdoba, Mexico City/MX

P067Our Experience in the Technique of Autologous Chondrocyte Implantation: 584 Treated Patients (From 1996 to 2019)P. Guillen, M. Guillen-Vicente, I. Guillen-Vicente, E. Rodriguez Iñigo, T. Fernandez-Jaen, S. Abelow, J.M. Lopez-Alcorocho, Madrid/ES

P068Single Intra-articular Lidocaine Injection is Safe for Knee Arthroscopy or Local Pain Management TherapyK. Ravnihar1, M. Drobnic2, T. Mars2, 1Ankaran/SI, 2Ljubljana/SI

P069Clinical Improvement is Signifi cantly Better after ACI Treatment with Chondrocyte Spheroids Manufac-tured with Shorter Cell Culture TimesG. Roel1, C. Eschen1, C. Kaps1, W. Widuchowski2, S. Fickert3, P. Niemeyer4, 1Teltow/DE, 2Katowice/PL, 3Straubing/DE, 4Freiburg/DE

P070Use of MACI in the US: Preliminary ExperienceJ. Carey1, A. Remmers2, D. Flanigan3, 1Philadelphia/US, 2Boulder/US, 3Columbus/US

P071Association between Degree of Preoperative Sub-chondral Bone Marrow Lesion and Postoperative Outcomes after High Tibial OsteotomyM.S. Kim, C.K. Kim, K.Y. Choi, Y. In, Seoul/KR


P072The Detrimental Impact of Delayed Implantation in Matrix Assisted Autologous Chondrocyte ImplantationD. Flanigan, J. Everhart, R. Pettit, Columbus/US

P073 Demographics in Patients Receiving Matrix-assisted Chondrocyte Implantation (MACI) in the AnkleK.T.C. Hede1, A. Gomoll2, C.B. Foldager1, 1Aarhus N/DK, 2New York/US

P074 Combined Bone Marrow Aspirate (BMAC) and Plate-let-Rich Plasma (PRP) for Cartilage Repair – Results at Two to Four-Years Follow UpK.T.C. Hede, B.B. Christensen, J. Jensen, C. Foldager, M. Lind, Aarhus N/DK

P076The Unique Role of Adipose Tissue in Cartilage Re-generation Through the LIPO-AMIC ProcedureF. Sciarretta, S. Campisi, C. Carella, M. Sanchez, Rome/IT

P077Mesenchymal Stem Cells for Cartilage Lesions and Anterior Cruciate Ligament reconstruction. A Three-year FU Comparative StudyM. Iosifi dis1, T. Kyriakidis2, E. Michalopoulos3, I. Melas1, A. Fylaktou1,C. Stavropoulos-Giokas3, 1Thessaloniki/GR, 2Brussels/BE, 3Athens/GR

P078Neutral Leg Alignment Improves Graft Survivorship After Autologous Chondrocyte Implantation with Concomitant High Tibial OsteotomyJ. Ackermann1, G. Merkely1, D. Arango1, A. Mestriner2, A. Gomoll3, 1Boston/US, 2Sao Paulo/BR, 3New York/US

P079The Modifi ed Hedgehog Technique to Repair Pure Chondral Shear-off Lesions in the Paediatric Knee.R. Jeuken1, M. Peters1, G. Vles2, P. Van Hugten1, E. Jansen3, D. Loeffen1, P. Emans1, 1Maastricht/NL, 2London/GB, 3Sittard/NL

P080Osteo-chondroisation: A Clinical Working Hypothe-sis for Pure Cartilage Defects in the Knee. Mid Term Results of a Pilot Study.J. Roland1, R. Martin2, 1Bern/CH, 2Lausanne/CH

P081Repair of Large Chondral Lesions with Single-Step Chon-drocyte and Bone Marrow Cells Co-TransplantationK. Slynarski1, L. Lipinski2, 1Warszawa/PL, 2Lodz/PL


&













83

P0821-Stage Cartilage Autograft Implantation System Using Platelet-rich Fibrin Scaffolds & Particulate Cartilaginous GraftsC. Wong, C.H. Chen, Taipei/TW

P083Therapeutic Effect of Ultra-Purifi ed Alginate Gel Containing Bone Marrow Aspirate Concentrate on Osteochondral Defects in Rabbits ModelL. Xu, A. Urita, T. Onodera, R. Hishimura, M. Hamasaki, D. Liang, Y. Tian, K. Homan, N. Iwasaki, Sapporo/JP

P084Transient Enzymatic Treatment to Improve Integra-tion of CartilageP. Lee, A. Chi, B. Chen, S. Lin, Taipei/TW

P085The Infl uence of Platelet-rich Plasma (PRP) and Me-chanical Loading on Chondrogenesis In VitroN. Pötter1, F. Westbrock1, E. Della Bella1, S. Grad1, M. Stoddart1, M. Alini1, N. Südkamp1, G. Salzmann2,3, E.J. Kubosch2, 1Davos/CH,2Freiburg/DE, 3Zurich/CH

P086Laser Etched Cryopreserved Osteochondral Al-lograft, ProChondrix® CR Maintains Consistent High Viability for 2 YearsC. Rorick, J. Mitchell, R. Sakthivel, Centennial/US

P087Matrix-Induced Autologous Chondrocyte Implan-tation (MACI) for Patellofemoral Cartilage Defects: 6-Month Radiographic ResultsS. Strickland1, A. Burge2, J. Nguyen2, A. Pyne1, 1New York City/US, 2New York/US

P088Discrimination of Meniscal Cell and Chondrocyte Phenotypes in Osteoarthritis Affected Meniscus and Cartilage.J. Wang1,2,3, S. Roberts1,2, J. Richardson1,2, W. Zhang3, K.T. Wright1,2, 1Oswestry/GB, 2Stoke-on-Trent/GB, 3Dalian/CN

P089Functional Pig Peritoneum-derived Acellular Matrix Combining Microfracture for Cartilage Repair in Rabbit ModelsQ. Meng, X. Hu, Y. Ao, Beijing/CN


P090Orchestrated Biomechanical, Structural, and Biochem-ical Stimuli for Engineering Anisotropic MeniscusZ.-Z. Zhang1, D. Jiang2, J. Yu2, 1Guangzhou/CN, 2Beijing/CN

P091Boosting Adhesion and Matrix Production by Synovi-um Cells with Hydrostatic Pressure for Meniscal RepairT. Takebayashi1,2, A. Tsuchiya3, K. Okazaki2, S. Mizuno1, 1Boston/US,2Tokyo/JP, 3Chiba/JP

P092Structured Rehabilitation Process After Osteochon-dral Repair with Demineralized Bone Matrix (DBM).J. Talikka, J. Salo, S. Kiiski, J. Kyllonen, Helsinki/FI

P093Low-Input RNA-Sequencing in Patients with Carti-lage Lesions, Osteoarthritis, and Healthy Cartilage - a Reference for Tissue EngineeringK. Wang1,2, Q.Y. Esbensen2, T.A. Karlsen1, C.N. Eftang2, A. Aroen1,2, R.B. Jakobsen1,2, 1Oslo/NO, 2Lørenskog/NO

P094Investigating the Synergistic Effects of Mesenchymal Stem Cell Exosomes and Hyaluronic Acid on Func-tional Cartilage RepairK.L.F. Wong, S. Zhang, M. Wang, A. Hassan, K.Y.-W. Teo, S.J. Chuah, S.K. Lim, J.H. Hui, E.H. Lee, W.S. Toh, Singapore/SG

P095Meniscal Repair with Concomitant Anterior Cruciate Ligament Reconstruction: Is ACL Graft Choice Predic-tive of Meniscal Repair Success?H. Salem1, A. Zajichek2, L. Huston3, J. Bravman1, E. McCarty1, M.K. Group3, K. Spindler2, R. Frank1, 1Aurora/US, 2Garfi eld Heights/US, 3Nashville/US

P096Full Regrowth of Meniscus in a 52 Y Old Male in Conjunction with Knee Osteochondral Repair with Demineralised Bone Matrix.J. Salo, Kerava/FI

P097The Occurrence of Spontaneous Osteonecrosis after Medial Meniscal Posterior Root Tear Associates with Meniscal ExtrusionS. Asai1, H. Fukuda1, T. Ogura1, K. Takahashi1, A. Tsuchiya2, 1Funabashi/JP, 2Chiba/JP


&













85

P098Prediction of Concomitant Lateral Meniscus Injury with a Tibia Plateau Fracture Based on Computed Tomography AssessmentW. Choi, Seongnam-si/KR

P099Meniscal Allograft Transplantation: Report of 18 CasesE. Ortega Orozco, J.K. Olague Franco, Guadalajara/MX

P100Cost Effectiveness of Collagen Matrix-Based Me-niscus Repair in the Perspective of Polish National Health Service and Private PatientsK. Ciemniewska-Gorzela1, T. Piontek1, T. Luczka1, M. Slomczykowski2, P. Bąkowski1, 1Poznan/PL, 2Wolhusen/CH

P101The Modifi ed Outside-in Suture for Bucket Handle Meniscus Tears. A Large Prospective Cohort Study.R. Martin1, B. Tschopp1, R. Jakob2, 1Lausanne/CH, 2Bern/CH

P102Evaluation of TGF-β Signalling Components in In-jured and Degenerative Human MenisciF. Monibi, T. Pannellini, C. Carballo, M. Otero, R. Warren, S. Rodeo, New York/US

P103Polyurethane Meniscal Scaffold Enhanced with Mes-enchymal Stem Cells: Assessment of Cartilage Qual-ity with T2 Mapping at 12 Months.A. Olivos Meza1, F.J. Pérez Jiménez2, S. Cortés González1, C. Landa Solis1, J. Granados Montiel1, C. Velasquillo Martínez1, B. Olivos Díaz2, J.D.J. Hernández León2, N. Pantanali2, C. Ibarra1, 1Mexico City/MX, 2Mexico/MX

P104Meniscus Repair in the Paediatric and Adolescent Population: A Systematic ReviewA. Tagliero, N. Kennedy, D. Leland, C. Camp, T. Milbrandt, M. Stuart, A. Krych, Rochester/US

P105Minimum 5-Year Outcomes of Arthroscopic Hip Labral Reconstruction Pair-matched to a Labral Re-pair GroupD. Maldonado1, M. Battaglia1, I. Perets2, A. Lall1, A. Chen3, V. Ortiz-Declet4, B. Domb1, 1Des Plaines/US, 2Jerusalem/IL, 3Boulder/US, 4Westwood/US


P106(Osteo)chondral Lesions in the Knee Joint Treated with a Coralline Scaffold (Cartiheal®): 2 Year Out-comes of a Prospective Case Series.W. Van Genechten1,2, K. Vuylsteke1, P. Verdonk1,3, 1Deurne/BE,2Rochester/US, 3Antwerp/BE

P107Reconstruction of Focal Osteochondral Defects of the Talus by Arthroscopically-assisted Autologous Matrix Induced ChondrogenesisF. Sciarretta1, E. Di Cave1, P. Versari2, 1Rome/IT, 2Roma/IT

P108Treating Cartilage Defects of the Proximal Tibia: A Systematic Review of Techniques, Outcomes, and Complications.H. Melugin1, C. Bernard1, C. Camp1, M. Stuart1, D.B. Saris1, N. Nakamura2, A. Krych1, 1Rochester/US, 2Osaka/JP

P109Bipolar Cartilage Lesions of the Knee: A Systematic Review of Techniques, Outcomes, and Complications.H. Melugin, C. Bernard, C. Camp, D.B. Saris, A. Krych, Rochester/US

P110Critical Role of Fibronectin in Proliferation and Dif-ferentiation of Human Infrapatellar Fat Pad Derived Stem CellsM. Pei1, Y. Wang1, Y. Fu2, Z. Yan3, X. Zhang2, 1Morgantown/US,2Loma Linda/US, 3Shanghai/CN

P111Decellularized Matrix Reverses Lineage Preference of Immortalized Stem CellsM. Pei1, Y. Wang1, X. Zhang2, Z. Yan3, 1Morgantown/US, 2Loma Linda/US, 3Shanghai/CN

P112PRP Promotes Tendon Healing Through Recruitment of Macrophages and Affects the Balance of Pro/An-ti-Infl ammatory MacrophagesH. Nishio1, Y. Saita2, Y. Kobayashi2, S. Uchino2, S. Fukusato2, Y. Takazawa1, H. Ikeda2, K. Kaneko2, 1Chiba/JP, 2Tokyo/JP

P113Anti-infl ammatory Cytokine IL1-ra is Abundantly Contained in Autologous Protein Solution (APS)S. Uchino, Y. Saita, Y. Kobayashi, H. Nishio, T. Wakayama, S. Fukusato, H. Ikeda, K. Kaneko, Bunkyo-ku/JP


&













87

P114Platelet-Rich Plasma versus Surgery for the Man-agement of Recalcitrant Greater Trochanteric Pain Syndrome: A Systematic ReviewR. Walker-Santiago1, N. Wojnowski2, A. Lall1, D. Maldonado1, S. Rabe1, B. Domb1, 1Des Plaines/US, 2Westmont/US

P115The Effi cacy of Platelet-Rich Plasma (PRP) Injection is Low in Severe Knee Osteoarthritis (OA) Regardless of Age.Y. Saita, Y. Kobayashi, H. Nishio, T. Wakayama, S. Uchino, S. Fukusato, H. Ikeda, K. Kaneko, Tokyo/JP

P116Varus Knee Deformity and High Body Mass Index Decrease the Effi cacy of Platelet-Rich Plasma Thera-py for Knee OsteoarthritisS. Fukusato1, Y. Saita1, Y. Kobayashi2, T. Wakayama1, H. Nishio1, S. Uchino3, S. Hada1, H. Ikeda1, K. Kaneko1, 1Tokyo/JP, 2Chiba/JP, 3Bunkyo-ku/JP

P117Evaluation of Clinical-Functional Results in Patients Diagnosed with Rotator Cuff Injury Infi ltrated with Platelet-Rich PlasmaJ.K. Olague Franco, E. Ortega Orozco, I. Moreno-Castillo, Guadalajara/MX

P118Up to 12 Months Improvement of Knee OA after PRP Injections; However is this of Clinical Rele-vance?J. Korpershoek, L. Vonk, J. Admiraal, E.C. Kester, T.S. De Windt, N. Van Egmond, D.B. Saris, R. Custers, Utrecht/NL

P119Do Non-steroidal Anti-infl ammatory Drugs have a Deleterious Effect on Cartilage Repair? A Systematic ReviewG. Merkely1, E. Chisari2, C.L. Rosso3, C. Lattermann1, 1Boston/US,2Catania/IT, 3California/US

P120Surgical Treatment of Chondral Knee Defects Using a Collagen Membrane (AMIC) - a Brazilian ExperienceC. Cohen Kaleka, P. Debieux, D. Astur, M. Cohen, Sao Paulo/BR

P121Intra-articular Xenogeneic Mesenchymal Stem Cell Therapy Increases CD4+CD25+ Cells in Synovial Fluid but does not Cause Pathologic ChangeC. Flynn, K. Lamers, M. Hurtig, Guelph/CA


P122Microfracture with Awls Creates Increased Subchon-dral Bone Damage and Compaction Compared to a Novel Marrow Access Device: a CT Based StudyJ. Koh1, J. Saladino2, T. Laughlin2, D. Fisher2, 1Evanston/US, 2Maple Grove/US

P123Microfracture with Awls Creates Signifi cant Surface and Deep Damage in Standard Sized DefectsJ. Koh1, J. Saladino2, T. Laughlin2, D. Fisher2, 1Evanston/US, 2Maple Grove/US

P124Can Plasma Fibronectin Enhance Cartilage Repair?J.P. Krüger, M. Endres, N. Sinner, Berlin/DE

P125Return to Sport and Work Following MicrofractureA. Beletsky, W. Skallerud, T. Tauro, J. Baker, T. Southworth, N. Naveen, J. Chahla, B. Nwachukwu, B. Cole, N. Verma, A. Yanke, Chicago/US

P128Biological Hip Resurfacing for Osteoarthritis Treat-ment in a Canine ModelB. Estes1, F. Moutos1, M. Enomoto2, D. Little3, J. Toth4, P. Eggert4, J. Stallrich2, D. Lascelles2, F. Guilak5, 1Durham/US, 2Raleigh/US, 3West Lafayette/US, 4Milwaukee/US, 5St. Louis/US

P129Evaluation of a Stepwise Loading Protocol for Vitrifi ca-tion of Porcine and Human Articular Cartilage CubesK. Wu, L. Laouar, N. Shardt, J.A.W. Elliott, N.M. Jomha, Edmonton/CA

P130Patellofemoral Stabilization with and without Carti-lage RestorationS. Sherman1, J. Rund1, J. Welsh1, L. Oladeji1, J. Worley1, B. Hinckel2, 1Columbia/US, 2San Diego/US

P131Quality of Evidence Supporting Different Genera-tions of Autologous Chondrocyte ImplantationS. Sherman1, L. Oladeji1, T. Ray1, B. Hinckel2, D. Flanigan3, 1Columbia/US, 2San Diego/US, 3Columbus/US

P132Macrophage M2 Drive on Cartilage Restoration – State of the ArtT. Fernandes1,2, A. Gomoll3, C. Lattermann2, A. Hernandez1, D. Bueno1, M. Amano1, 1São Paulo/BR, 2Boston/US, 3New York/US


&













89

P134A Magnesium Ion Sustained-releasing Micro-sized PLGA Capsule for the Treatment of OsteoarthritisL. Zheng, Q. Jiang, Nanjing/CN

P135Benefi cial Effect of Different Natural Compounds on Chondrogenic Differentiation of Primary Mesenchy-mal Stem/Stromal CellsM. Sirse1, B. Štrukelj2, S.K. Fokter1, J. Zupan2, 1Maribor/SI, 2Ljubljana/SI

P136LncRNA Regulates Thymosin β4 Expression by Func-tions as a miRNA-152 Sponge in Human OsteoarthritisQ. Liu, Y. Ao, Beijing/CN

P137Andrographolide Alleviates Pain in Osteoarthritis Rat ModelR. Wang, X. Xu, Q. Jiang, D. Shi, Nanjing/CN

P138Dendrobium Offi cinale Polysaccharide Delays Osteoar-thritis Through Anti-infl ammatory and Anti-oxidationW. Rui, X. Xu, D. Shi, Q. Jiang, Nanjing/CN

P139A Positive Effect on Chondrocyte Proliferation after Exposure of Old Murine Cartilage in a Young Systemic Environment.X. Wei1, L. Li1, L. Wei1,2, P. Li1, J. Lu1, P. Han1, 1Taiyuan/CN, 2Providence/US

P140Local Administration of Low-dose NGF Antibody Reduced Pain in Rat Osteoarthritis ModelY. Tian, T. Onodera, M.A. Terkawi, K. Iwasaki, R. Hishimura, T. Miyazaki, D. Liang, L. Xu, N. Iwasaki, Sapporo/JP

P141Diagnostic Utility of Fluorogenic Au Nanoparticle Probe Corroborated by Rabbit Model and Panel of Osteoarthritic PatientsZ. Liu, Y. Ao, Beijing/CN

P142Intraarticular Administration of Chitosan-Glutathi-one Nanoparticles on OsteoarthritisI. Zetina1, R. Díaz Torres1, M. Gómez Chavarin1, M. Masri2, M.E. Valderrama Saborio1, P. Ramirez Noguera1, 1Mexico/MX, 2Mexico City/MX


P143Blockage of BMP Signalling Pathway Counteract Hypertrophic Switch in Osteoarthritic Articular ChondrocytesI. Martin, S. Chawla, P. Occhetta, A. Barbero, Basel/CH

P144Anion Channel Activity in Chondrocytes Analyzed Using In Vitro Osteoarthritis Model.K. Kumagai1, F. Toyoda1, C. Staunton2, T. Maeda1, H. Tanigawa1, N. Okumura1, S. Imai1, R. Barrett-Jolley2, 1Otsu/JP, 2Liverpool/GB

P145Cytokine-induced Apoptosis in Rabbit Articular Chon-drocytes Inhibited by COX-2 Blocker Via Anion Chan-nel Inactivation.K. Kumagai, F. Toyoda, M. Kubo, T. Maeda, H. Tanigawa, N. Okumura, T. Mimura, T. Yayama, H. Matsuura, S. Imai, Otsu/JP

P146New Hope for Knee Osteoarthritis: IGF-1-Regulating Chimeric Peptides Showing Therapeutic Activity Are Well Tolerated In Vivo.R. Paolini1,2, R. Montjean1, C. Carelli1, C. Vêtu1, 1Romainville/FR, 2Neuville Sur Oise/FR

P147The N-Acetyl Phenylalanine Glucosamine Derivative on Osteoarthritic Joint Environment as Reproduced by In Vitro and In Vivo ModelsF. Veronesi1, S. Pagani1, R.M. Borzì1, A. Scotto D’Abusco2, M. Minguzzi1, M. Fini1, 1Bologna/IT, 2Rome/IT

P148Attenuation of the Knee Osteoarthritis Progression by Injection of Uncultured Human Adipose-derived Regenerative Cells in MiceT. Yamashita1, T. Matsushita1, N. Miyaji1, H. Iwaguro2, S. Sobajima2, R. Kuroda1, 1Kobe/JP, 2Higashiosaka/JP

P149Resistance of Cartilage to Neurovascular Invasion: Expression of the Netrin-1/UNC5B System.T. Khadija, Paris/FR

P150The Effect of PG-990 on High Density Human Chondro-cyte Micromass Cultures Activated by IL-1betaV. Can1, P. Grieco2, I. Locke1, S. Getting1, 1London/GB, 2Naples/IT


&













91

P151Predicting Joint Narrowing Risk from a Novel Joint Space Width Measure: Data from the Osteoarthritis InitiativeT. Paixao1, C. Goetz1, Z. Bertalan1, D. Ljuhar2, R. Ljuhar1, S. Nehrer3, 1Wien/AT, 2Vienna/AT, 3Krems/AT

P152Platelet Rich Plasma Supplementation and it’s Pivot-al Role on the OA Chondrocyte MicroenvironmentV. Jeyakumar, E. Niculescu-Morzsa, C. Bauer, Z. Lacza, S. Nehrer, Krems/AT

P154Comorbidities in Patients with End-stage Knee Osteoarthritis: Prevalence and Impact on Physical FunctionJ. Kim, B.R. Kim, S. Choi, C. Choi, Jeju/KR

P155The Effi cacy and Safety of Polydeoxyribonucleotide for the Treatment of Knee Osteoarthritis: Systematic Review and Meta-AnalysisM.S. Kim, C.K. Kim, K.Y. Choi, Y. In, Seoul/KR

P156Associations Between Age-related Features of Os-teoarthritis on MRI and Knee Pain Severity.A. Watanabe, Y. Aoki, T. Nakajima, M. Inoue, R. Akagi, T. Obata, S. Ohtori, T. Sasho, Chiba/JP

P157Optimizing Subject Selection in Knee Osteoarthritis Trials by Joint Space Width: Analysis from a Phase 2b Trial of Lorecivivint (SM04690)S. Kennedy1, C. Swearingen1, J. Tambiah1, P. Conaghan2, 1San Diego/US, 2Leeds/GB

P158Autologous Protein Solution as a Therapy for Mid-dle-aged Females with Patellofemoral Osteoarthri-tis: a 12-Month Clinical Study.W. Van Genechten1,2, K. Vuylsteke1, P. Rojas Martinez1, L. Swinnen1, P. Verdonk1,3, 1Deurne/BE, 2Rochester/US, 3Ant-werp/BE

P159Clinical Outcome of a Single Injection with Micro-frag-mented Autologous Adipose Tissue for Knee Osteoar-thritis: 12 Month Follow-up Study.W. Van Genechten1,2, K. Vuylsteke1, P. Rojas Martinez1, L. Swinnen1, P. Verdonk1,3, 1Deurne/BE, 2Rochester/US, 3Antwerp/BE


P160Clinical Study of the Novel FlexitSystem Implant For High Tibial Open Wedge OsteotomyN. Van Egmond1, S. Van Der Groes2, A. Van Kampen2, 1Utrecht/NL, 2Nijmegen/NL

P161Revision and Repeat Revision Rates and the Poten-tial Cost-Utility of Knee Preservation in Young Total Knee Arthroplasty PatientsM. Hevesi, C. Wyles, R. Sierra, R. Trousdale, E. Habermann, H. Maradit-Kremers, A. Krych, D.B. Saris, Rochester/US

P162Flexion Contracture is the Risk of Patellofemoral Os-teoarthritis after Open Wedge High Tibial OsteotomyS. Otsuki, K. Nakagawa, K. Ikeda, N. Okuno, Y. Okamoto, H. Wakama, T. Okayoshi, M. Neo, Osaka/JP

P163Patient Specifi c Cutting Guides for High Tibia Open-ing Wedge Osteotomy are Precise and Reliable.M. Ollivier, C. Jacquet, S. Parratte, Marseille/FR

P164Learning Curve of Patient-Specifi c High-tibial Oste-otomy Cutting-GuideM. Ollivier, C. Jacquet, A. Sharma, S. Parratte, Marseille/FR

P165AMIC in Treatment of Patients with Hallux Rigidus. Features and PossibilitiesM. Nurmukhametov, M. Makarov, S. Makarov, E. Bialik, Y. Khrennikov, V. Bialik, V. Nesterenko, Moscow/RU

P166Automated Estimation of the Mechanical Hip-Knee-Ankle Angle Using Standard Knee Radiographs.W.P. Gielis1, H. Rayegan2, V. Arbabi1, S.Y. Ahmadi Brooghani2, C. Lindner3, T.F. Cootes3, P.A. De Jong1, H. Wein-ans1, R. Custers1, 1Utrecht/NL, 2Birjand/IR, 3Manchester/GB

P167Dynamic Mechanical Markers Linked to Knee Os-teoarthritis Progression Can be Modifi ed Through Personalized Exercises: A Cluster RCTA. Cagnin1, M. Choinière1, N.J. Bureau1, M. Durand1, N. Mezghani1, N. Gaudreault2, N. Hagemeister1, 1Montreal/CA, 2Sherbrooke/CA


&













93

P168Knee Joint Distraction as Standard of Care Treat-ment for Knee Osteoarthritis: A Comparison with Clinical Trial PatientsS.C. Mastbergen, M. Jansen, M.D. Van Empelen, E.C. Kester, F.P.J.G. Lafeber, R. Custers, Utrecht/NL

P169Degenerative Patellofemoral Joint Does Not In-crease Failure after Unicompartmental Knee Arthro-plastyK. Plancher1, S. Petterson2, K. Briggs2, 1New York/US, 2Stamford/US

P170Bio-Optimized Curcuma Longa Extract is Effi cient on Knee Osteoarthritis PainY. Henrotin1, M. Malaise1, R. Wittoek2, K. De Vlam3, J.-P. Brasseur4, F. Luyten5, M. Van Den Berghe6, J. Bentin7, T. De Vroey8, Y. Dierckx-sens9, 1Liège/BE, 2Gent/BE, 3Merksem/BE, 4Yvoir/BE, 5Leuven/BE, 6Aalst/BE, 7Brussels/BE, 8Antwerpen/BE, 9Baillonville/BE

P171Effect of Placenta-Derived Mesenchymal Stem Cells and Hyaluronic Acid Composite on Articular Carti-lage Regeneration in a Rabbit ModelJ. Kim1, Y.-B. Park1, C.-W. Ha1, W.-J. Han1, H.J. Park1, M. Kim2,1Seoul/KR, 2Anyang-si/KR

P172Immortalization Approach dependent Variation in Proliferation and Differentiation of Infrapatellar Fat Pad Derived Stem CellsM. Pei1, Y. Wang1, X. Zhang2, Y. Sun3, S. Zhou1, Z. Yan4, 1Morgantown/US, 2Loma Linda/US, 3Yangzhou/CN, 4Shang-hai/CN

P173Single-Cell RNA-Seq Reveals Novel Musculoskeletal Cell Populations during Adult Axolotl Limb Regener-ation ProcessT. Qin, X. Chen, HangZhou/CN

P174The Selective Removal Method of Undifferentiated iPS Cells Using Specifi c Antibody for Cartilage Re-generative Medicine.T. Miyazaki1, T. Onodera1, L. Xu1, H. Hanamatsu1, J. Furuka-wa1, K. Homan1, M. Hamasaki1, R. Hishimura1, T. Kawasaki2, N. Iwasaki1, 1Sapporo/JP, 2Shiga/JP


P175Protective Paracrine Effect on Chondrocytes when Co-cultured with Mesenchymal Stem Cells in a Hyal-uronic Acid Hydrogel In VitroS.L. Mogensen, M.K. Rasmussen, D. Le, A.B. Nielsen, C.B. Foldager, Aarhus N/DK

P176Comparison of Mesenchymal Stem Cells of the Rab-bit: Superiority of Synovium as a Cell Source for Cartilage Tissue Engineering ProtocolsT. Sarlikiotis, D. Mastrokalos, M. Bami, D. Koulalis, E. Johnson, P. Soucacos, P. Papagelopoulos, Chaidari-Athens/GR

P177Increasing Hematocrit Reduces Mesenchymal Stem Cell Survival and Proliferation via Release of Cyto-toxic ParticlesR. Dregalla, Johnstown/US

P178TNF-α and IL-1β Primed Fetal Cartilage Stem Cell-de-rived Conditioned Media Alleviates Infl ammatory Markers in SW982 CellsD.I. Shin1, I.-S. Park1, B.H. Choi2, D.Y. Park1, B.-H. Min1, X. Yun Yin1, J.Y. Chung1, 1Suwon/KR, 2Incheon/KR

P179Novel Stem Cell Sources for Cartilage Restoration: Human Dental Pulp Stem Cells Systematic ReviewT. Fernandes1,2, J. Santanna1, I. Frisene1, J. Gazarini1, C. Pinheiro1, A. Gomoll3, C. Lattermann2, A. Hernandez1, D. Bueno1, 1São Paulo/BR, 2Boston/US, 3New York/US

P181Chondroprotective Effect of Durolane Hyaluronic Acid and Conditioned Medium of Stem Cells in an In Vitro Model of Knee OsteoarthritisM. Simental-Mendía, S. Lozano-Sepúlveda, V. Pérez-Silos, L. Fuentes-Mera, V. Peña-Martínez, C. Acosta-Olivo, F. Vilchez-Cavazos, Monterrey/MX

P182Performance-Based Clonal Expansion Using High Throughput Automation for Cartilage Cellular TherapiesV.P. Mantripragada, E. Carson, O. Krebs, G. Muschler, Cleveland/US

P183The Effect of Blood-derived Products on the Regen-erative Potential of Adipose-derived Stem Cells Originated from Different Fat LocationsM. Neubauer, O. Kuten, T. Muellner, S. Nehrer, Krems/AT


&













95

P185Intra-articular Injection of Bone Marrow Concen-trate vs Hyaluronic Acid in Bilateral Knee Osteoar-thritis: Preliminary Results of a RCTL. Andriolo, A. Di Martino, A. Poggi, R. De Filippis, A. Boffa, S. Zaffagnini, G. Filardo, Bologna/IT

P186Autologous Adipose-derived Stromal Cell Injection in the Knee: Patient Characteristics, Early Results and Complications.G. Ode, H. Greditzer, T. Warner, R. Williams Iii, New York/US

P187Early Results of Complete Cartilage Regeneration (CCR) technique for Talar Osteo-Chondral Defect (OCD)A. Chawla1, N. Makwana1, J.H. Kuiper2, S. Roberts3, A. Bing2, 1Oswestry/GB, 2Ag/GB, 3Shropshire/GB

P188Intra-articular Adipose Derived Mesenchymal Stem Cell Therapy in Combination with Arthroscopic Abrasion Arthroplasty – A Pilot Study.M. Chamberlain1, J. Freitag2, J. Wickham3, C. Norsworthy4, D. Li5, A. Tenen6, K. Shah1, 1Box Hill/AU, 2Box Hill North/AU, 3Orange/AU, 4Bundoora/AU, 5East Melbourne/AU, 6Clayton/AU

P189Evaluation of the Exploratory and Biologic Effi cacy of Regenerative Autologous Adipose Tissue Prod-ucts Used for Cartilage RepairF. Sciarretta, S. Campisi, C. Carella, M. Sanchez, Rome/IT

P190Virtual Arthroscopy of the Patient’s Knee Joint on Outpatient Clinic.J. Salo, Kerava/FI

P191PRP Therapy for Knee Osteoarthritis Improved the Articular Cartilage Condition at the Opposite Side of the Treatment Target Area in MRI.T. Wakayama1, Y. Saita1, Y. Kobayashi1, S. Hada1, H. Nishio1,2, S. Uchino1, S. Fukusato1, H. Ikeda1, K. Kaneko1, 1Tokyo/JP, 2Chiba/JP

P192Opening Wedge Distal Tuberosity Osteotomy De-creases the Incidence of Cartilage Lesion in the Pa-tellofemoral JointF. Hideaki, T. Ogura, S. Asai, Hazama Funabashi/JP


P193Short-term Outcomes of Primary Labral Reconstruc-tion in Patients with Femoroacetabular Impinge-ment, Labral Tears, and Chondral DefectsD. Maldonado1, C. Go1, J. Laseter2, A. Lall1, M. Kopscik3, B. Domb1, 1Des Plaines/US, 2Cleveland/US, 3Charleston/US

P194Perineal Pressure During Hip Arthroscopy is Re-duced by Use of Trendelenburg: A Prospective Study with Randomized Order of PositioningA. Lall1, A. Saadat2, M. Battaglia1, D. Maldonado1, I. Perets3, B. Domb1, 1Des Plaines/US, 2Chicago/US, 3Jerusalem/IL

P195Identifying the most successful Procedures in Hip Ar-throscopy: A Multivariate Analysis of 1,000 SurgeriesJ. Hammarstedt1, J. Laseter2, A. Gupta3, J. Christoforetti4, A. Lall5, B. Domb5, 1Pittsburgh/US, 2Cleveland/US, 3Woodbridge/US, 4Allen/US, 5Des Plaines/US

P196Predictors of Clinical Outcomes After Hip Arthrosco-py: 5 Year Follow- Up Analysis of 1038 PatientsA. Lall, S. Chen, C. Go, R. Walker-Santiago, D. Maldonado, B. Domb, Des Plaines/US

P197Does Failure to Meet Threshold Scores for mHHS and iHOT-12 Correlate to Reoperations Following Hip Arthroscopy?P. Rosinsky, J. Chen, D. Maldonado, J. Shapira, A. Lall, B. Domb, Des Plaines/US

P198The Evolution of Hip Arthroscopy: What Has Changed Between 2008 and 2018 - A Single Surgeon’s ExperienceP. Rosinsky, S. Chen, J. Shapira, D. Maldonado, A. Lall, B. Domb, Des Plaines/US

P199Femoral Retroversion Does not Portend Inferior Mid-Term Outcomes After Hip Arthroscopy: A Pair-Matched Controlled Cohort AnalysisA. Lall1, M. Battaglia1, D. Maldonado1, I. Perets2, J. Laseter3, B. Domb1, 1Des Plaines/US, 2Jerusalem/IL, 3Cleveland/US

P200Mid-Term Patient Reported Outcomes of Hip Arthro-plasty Following Prior Hip Arthroscopy: A Matched Case-Control Study.P. Rosinsky, J. Chen, J. Shapira, D. Maldonado, A. Lall, B. Domb, Des Plaines/US


&













97

P201Return to Play in Soccer Players Undergoing Hip Arthroscopy: Short- to Mid-Term Follow UpV. Ortiz-Declet1, L. Yuen2, G. Schwarzman3, A. Chen4, I. Perets5, B. Domb6, 1Westwood/US, 2Hanover/US, 3Chicago/US, 4Boulder/US, 5Jerusalem/IL, 6Des Plaines/US

P202A Systematic Review of Short-Term Outcomes for Circumferential and Segmental Hip Labral Recon-struction.D. Maldonado, C. Kyin, A. Lall, B. Domb, Des Plaines/US

P203Effectiveness of Femoroplasty, Labral Treatment, Iliopsoas Fractional Lengthening and Capsular Pli-cation During Hip ArthroscopyI. Perets1, J. Ornelas2, D. Rybalko3, D. Morgensteren1, D.A. Friedman1, B. Domb2, 1Jerusalem/IL, 2Des Plaines/US, 3Chicago/US

P204Tracing Outcomes and Survivorship Against Age and Gender Abstract in Hip Arthroscopy Surgery.D. Maldonado, C. Go, A. Lall, B. Domb, Des Plaines/US

P205Return to Basketball After Hip Arthroscopy: Mini-mum Two-Year Follow-upA. Chen1, B. Mu2, C. Go3, V. Ortiz-Declet4, D. Maldonado3, B. Domb3, 1Boulder/US, 2North Chicago/US, 3Des Plaines/US, 4Westwood/US

P206Return to Sport and Athletic Function in an Active Population Following Primary Arthroscopic Labral ReconstructionD. Maldonado, S. Chen, A. Lall, P. Rosinsky, R. Walker-Santiago, J. Shapira, B. Domb, Des Plaines/US

P207Arthroscopic Treatment of Hip Labral Tears and In-stability in Professional DancersS. Chandrasekaran1, N. Darwish2, J. Walsh3, P. Lodhia4, C. Suarez Ahedo5, B. Domb6, 1Melbourne/AU, 2Detroit/US, 3Des Moines/US, 4Burnaby/CA, 5Mexico City/MX, 6Des Plaines/US

P208Do Larger Acetabular Chondral Defects Portend In-ferior Outcomes in Patients Undergoing Arthroscop-ic Acetabular Microfracture?E. Chaharbakhshi1, D. Hartigan2, J. Spencer1, I. Perets3, A. Lall4, B. Domb4,1 Maywood/US, 2Rochester/US, 3Jerusalem/IL, 4Des Plaines/US


P209Mid-Term Outcomes of Iliopsoas Fractional Lengthening (IFL) for Internal Snapping as a Part of Hip ArthroscopyI. Perets1, E. Chaharbakhshi2, Y. Mansor3, L. Ashberg4, B. Mu5, M. Battaglia6, B. Domb6, 1Jerusalem/IL, 2Maywood/US, 3Ramat Gan/IL, 4Atlantis/US, 5North Chicago/US, 6Des Plaines/US

P210Arthroscopic Treatment of Labral Tears in the Hip Can Produce Outcomes that are Similar to those of a Total Hip ArthroplastyA. Lall1, E. Secretov1, M. Battaglia1, J. Laseter2, D. Maldonado1, B. Domb1, 1Des Plaines/US, 2Cleveland/US

P211The Effect of Joint Infection on the Bone Tunnel, Graft and Articular Cartilage after Arthroscopic Sin-gle-bundle ACL ReconstructionC. Nayun, Y. Ao, X. Hu, D. Li, C. Wang, Beijing/CN

P2135 Year Follow up Data of Patients Treated with Gel-rinC Reveal Substantial and Sustainable Pain and Symptom Relief.A. Dhollander1, J. Victor2, J. Bellemans3, R. Arbel4, E. Basad5, J. Van Der Bauwhede6, P. Emans7, S. Trattnig8, 1Brasschaat/BE,2Ghent/BE, 3Leuven/BE, 4Tel Aviv/IL, 5Heidelberg/DE, 6Kortrijk/BE, 7Maastricht/NL, 8Wien/AT

P214Trends in Chondral Procedures with Concurrent or Staged Osteotomies of the Knee: A Popula-tion-Based Study of a Large National DatabaseA. Shamrock, Z. Khazi, Q. An, J. Baron, R. Westermann, Iowa City/US

P215The Injection of Calcium Phosphate into the Arthritis Knee Results in 1 Year Improvement in Knee ScoresB.J.Y. Kang, P. Chang Chee Chang, K. Chua, F. Chua, D. Lie, Singapore/SG

P216In Vivo Knee Biomechanics of Patients Treated for Chondral Lesions Alongside with ACL ReconstructionM. Iosifi dis1, E. Iliopoulos1, T. Tsatalas2, S. Kalolythos2, I. Melas1, V. Sideris2, I. Giakas2, 1Thessaloniki/GR, 2Trikala/GR

P217Patient Specifi c Mini-metal Implants. The Future of Cartilage Repair for the Right Patient?T. Spalding1, J. Holz2, M. Lind3, P. Verdonk4, P. Emans5, K. Eriksson6, 1Coventry/GB, 2Hamburg/DE, 3Aarhus N/DK, 4Antwerp/BE, 5Maastricht/NL, 6Stockholm/SE


&













99

P218 Development and Validation of the Oswestry Ankle Score: A New Patient-reported Outcome Measure for Assessing Ankle SurgeryJ. Sykes, J.H. Kuiper, A. Bailey, A. Bing, N. Kuiper, N. Makwana,Ag/GB

P219PROMIS Instruments Correlate Better with Legacy Measures in Knee Cartilage Patients at Post-opera-tive than at Pre-operative AssessmentB. Nwachukwu, A. Beletsky, N. Naveen, K. Okoroha, T. Southworth,N. Verma, A. Yanke, B. Cole, Chicago/US

P220Microfracture Has Inferior Patient Reported Out-comes in Cartilage Restoration Surgery of the Knee: a Systematic Review and Meta-Analysis.T. Abraamyan, T. Kong, D. Crawford, Portland/US

P221The Need for a Standardized Protocol for Whole Leg Radiographs: The Effects of Knee Flexion, Leg Rotation and X-Ray Beam HeightC. Nguyen1, W.P. Gielis1, N. Van Egmond1, C.H. Slump2, H. Weinans1, R. Custers1, 1Utrecht/NL, 2Enschede/NL

P222Preoperative Performance of PROMIS in Patients with Articular Cartilage Defects of the KneeA. Shamrock, B. Wolf, S. Ortiz, K. Duchman, M. Bollier, Z. Khazi, C. Carender, R. Westermann, Iowa City/US

P223Early Knee Osteoarthritis of Medial Compartment- Return to Work after Knee Absorber Treatment.L. Lipinski1, K. Slynarski2, 1Lodz/PL, 2Warszawa/PL

P225Minimally Invasive Fractional Laser Procedure for Treating Degenerative Disc DiseasesE. Sobol1, A. Baskov2, I. Borshchenko2, A. Shechter2, V. Baskov2, I. Yaroslavsky1, V. Andreeva3, A. Kovalenko3, G. Altshuler1, 1Marlborough/US, 2Moscow/RU, 3Fryazino/RU

P226Patients Over Age 40 with Cam-Type Femoroace-tabular Impingement Demonstrate Increased Cell Activity in Articular ChondrocytesC. Matzko1, H. Liang2, M. Mashura2, D. Grande2, S. Bharam1, 1New York/US, 2Manhasset/US


P227Use of a Femoral Offset Guide Provides Accurate and Precise Placement of Femoral Tunnel in Anterior Cruciate Ligament ReconstructionM.S. Kim, C.K. Kim, K.Y. Choi, Y. In, Seoul/KR

P228Analysis of Private Payer Medical Policies for Osteo-chondral Allograft TransplantationS. Tabbaa1, D. Crawford2, J. Farr3, W. Bugbee4, 1San Francisco/US,2Portland/US, 3Greenwood/US, 4La Jolla/US

P229Predictors of poor pre-operative psychological sta-tus in cartilage defect patientsD. Flanigan, J. Everhart, R. Pettit, A. Dibartola, Columbus/US

P230Long Term Results After Surgical Treatment of Juve-nile Osteochondritis Dissecans of the Knee by Fixa-tion with Bioabsorbable ImplantsM. Iosifi dis, I. Melas, K. Petras, G. Gkikas, D. Metaxiotis, Thessaloniki/GR

P231User-friendliness of a Novel Dedicated Knee Joint Distraction Device: experiences from clinical practiceR. Custers, T. Struik, M. Jansen, S.C. Mastbergen, F.P.J.G. Lafeber, Utrecht/NL

P232Qualitative Compositional Analysis of ACL and PCL Using Advanced MRI. A Biomarker for Studying Ligament Biology.S.M. McDonnell, C.D.S. Ranmuthu, J.D. Kaggie, J.W. Mackay, Cambridge/GB

P233High Revision-rates but Good Clinical Outcomes in Not Revised Patients in 64 HemiCAPs in the Knee, Followed up to Ten Years.J.O. Laursen, Høruphav, Sydals/DK

P234The Effect of Early Continuous Passive Motion in Acute Septic ArthritisD. Li, H. Huang, Y. Ao, Beijing/CN

P235The Impact of Mild Synovitis on Chondrogenesis In VitroZ. Zhang, L. Schon, S. Paudel, T. Feltham, Baltimore/US


&













101

P236Bone Morphotype and Early OsteoarthritisA. Van Haver1, J. Grammens1, W. Peeters1, P. Verdonk2, 1Antwerp/BE, 2Gent-Zwijnaarde/BE

P237Treatment of Early Osteonecrosis of Femoral Head (ONFH) with Implantation of Autologous Cultured Os-teoblastC. Bhanji1, G. Palekar1, P. Sarin1, S. Archik1, K. Trivedi2, 1Mumbai/IN,2Ahmedabad/IN

P238Automated Knee Osteoarthritis Assessment Increas-es Physicians’ Agreement Rate and Accuracy: Data from the Osteoarthritis InitiativeT. Paixao1, C. Goetz1, Z. Bertalan1, R. Ljuhar1, P. Steindl2, R. Simon2, D. Maurer3, S. Nehrer4, 1Wien/AT, 2Neunkirchen/AT, 3Graz/AT, 4Krems/AT

P239Fetal Regeneration of Critical Size Articular Carti-lage DefectsF. Jenner, I. Ribitsch, M. Egerbacher, S. Gabner, S. Gültekin, M. Kandula, A. Bileck, R. Mayer, D. Kreil, C. Gerner, Vienna/AT

P240Resveratrol Enriched Iksan526 Callus Extract Induces Dedifferentiation in Chondrocytes Via the ERK-1/2 and PI3K/Akt PathwaysS.J. Kim, Gongju/KR

P241Si-HPMC/Si-Chitosan Hybrid Hydrogel for Cartilage Regenerative Medicine: From In Vitro to In Vivo As-sessmentsJ. Guicheux1, C. Boyer1, J. Lesoeur1, S. Sourice1, C. Vinatier1, G. Réthoré1, M. Fusellier1, O. Geffroy1, P. Weiss1, O. Gauthier1,2, 1Nantes/FR, 2Nantes Cedex/FR


The ICRS gratefully acknowledges all generous

contributions in support of this meeting from the

following companies:

D i a m o n d S p o n s o r s

P l a t i n u m S p o n s o r

G o l d S p o n s o r s

S i l v e r S p o n s o r s

&













103E X H I B I T O R L I S T A – Z

Companies A - Z Booth Nr.Aesculap, Inc. 18AlloSource 7Anika Therapeutics 15Arthrex 14Aspect Biosystems 31BioGend 28Biomomentum 23Cartiheal 11Collagen 1CONMED Orthopedics 9DJO Canada 30Finceramica 8Geistlich Pharma AG 4ICRS Patient Registry 27Image Biopsy Lab 25Incrediwear 29JRF Ortho 12Life Net Health 20Lipogems USA, LLC 3medi GmbH & Co. KG 13Newclip Technics 5OligoMedic Inc 32ON Foundation 26Organogenesis 22Orteq Sports Medicine 6Össur Americas, Inc 2Regen Lab SA 19SAGE Publlications 33Smith & Nephew Inc. 21Vericel Corporation 17Zimmer - Biomet 10

(See Floor Plan On Front Cover Fold Out)

E X H I B I T O R L I S T A – Z

Companies 1-33 Booth Nr.Collagen 1Össur Americas, Inc 2Lipogems USA, LLC 3Geistlich Pharma AG 4Newclip Technics 5Orteq Sports Medicine 6AlloSource 7Finceramica 8CONMED Orthopedics 9Zimmer - Biomet 10Cartiheal 11JRF Ortho 12medi GmbH & Co. KG 13Arthrex 14Anika Therapeutics 15Vericel Corporation 17Aesculap, Inc. 18Regen Lab SA 19Life Net Health 20Smith & Nephew Inc. 21Organogenesis 22Biomomentum 23Image Biopsy Lab 25ON Foundation 26ICRS Patient Registry 27BioGend 28Incrediwear 29DJO Canada 30Aspect Biosystems 31OligoMedic Inc 32

SAGE Publications 33

(See Floor Plan On Front Cover Fold Out)

&













105

Aesculap Biologics, LLC Booth Nr. 183773 Corporate ParkwayCenter Valley, PA 18034, USAwww.aesculapusa.com

Aesculap Biologics, LLC, was established in January 2012 as a division of Aesculap, Inc. and is focused on biological ap-proaches to the repair and regeneration of diseased or dam-aged tissues. Using a combination of cells, growth factors and smart biomaterial devices, Aesculap Biologics products can stimulate and support the synthesis of new tissue and enhance the body’s own regenerative power to improve the quality of patients’ lives. Aesculap, Inc., a B. Braun company, is part of a 180-year-old global organization focused on meeting the needs of an ever-changing healthcare community.

AlloSource Booth Nr. 76278 S Troy CircleCentennial, CO 80111, [email protected]

AlloSource is one of the original regenerative medicine com-panies, harnessing the power living cells found naturally in al-lografts since 1994. Over the past 25 years, the company has advanced its processes and tissue products, so surgeons have the biologics needed to heal their patients. Today AlloSource is the largest processor of cartilage tissue for joint repair, as well as cell-based biologics, remaining committed to advancing the science and use of transplantable allogenic cells and tissue through pioneering research in regenerative therapies.

Anika Therapeutics Srl Booth Nr. 15Via della Ricerca Scientifi ca 435127 PADOVA – [email protected] www.anikatherapeutics.com/

Anika Therapeutics is a global medical technology company, and a pioneer in developing therapeutic products for tissue pro-tection, healing and repair. Our products are based on hyal-uronic acid (HA), a naturally occurring polymer found through-out the body. HA enhances joint function and coats, protects, cushions and lubricates soft tissues. With more than 20 years of experience in the use of HA technology, Anika is recognized worldwide as a provider of premium HA products that are ef-fective, safe and long-lasting. We are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger, and remain active.

E X H I B I T O R ’ S G U I D E A – Z

Arthrex, Inc. Booth Nr. 141370 Creekside Blvd.Naples, FL 34110, [email protected]

As an innovation leader in sports medicine and less invasive ortho-pedics, Arthrex’s orthobiologics product lines represent the next gen-eration in orthobiologics with comprehensive solutions for the rapidly advancing fi eld of regenerative medicine. From cellular therapies and bone healing to cartilage restoration, Arthrex continues to lead the fi eld with innovative therapies and groundbreaking research. Ar-threx is a privately held company, committed to delivering uncompro-mising quality to the health care professionals who use its products and the millions of patients whose lives are impacted. Arthrex is ded-icated to its mission of Helping Surgeons Treat Their Patients Better™.

Aspect Biosystems Booth Nr. 311781 West 75th AveVancouver, BC V6P 6P2, [email protected]

Aspect Biosystems is a Canadian biotechnology company pio-neering microfl uidic-based 3D bioprinting technology to gener-ate implantable tissue therapeutics. We are focused on creating several key tissue types to address orthopaedic injuries and metabolic disorders. One of our core programs is to develop a 3D printed, customized partial meniscus replacement. We are actively partnering with academia and industry to advance our internal programs and, ultimately, enable the creation of human tissues for medical research, therapeutic discovery, and regen-erative medicine products. Learn more about our microfl uidic 3D bioprinting at www.aspectbiosystems.com.

Biogend Therapeutics Co. Ltd. Booth Nr. 284F., No.3, Park St., Nangang Dist.,Taipei City 115, [email protected]

BioGend Therapeutics was established in July 2016 with a noble vision to develop regenerative bio-orthopedic medicine to advance the clinical science of maintaining healthy joints in the skeletal sys-tem. Currently, our main product under development is a one-step autologous chondrocyte repair system: RevoCart, which is a simple one-step and effective treatment for articular cartilage defects requir-ing no cumbersome and costly cell culture and expansion. The pivot randomized, controlled clinical trial of RevoCart has successfully completed patient enrollment. A PMA submission is planned with anticipated approval from Taiwan FDA to occur in early 2020.


&













107

Biomomentum Inc. Booth Nr. 23970 Michelin, Suite 200Laval, Quebec, H7L 5C1, CanadaTel: (450) [email protected]

Biomomentum provides GLP-compliant biomechanical testing services and also manufactures and commercializes testing de-vices for the mechanical characterization of biomaterials and cartilage. The Mach-1™ multiaxial mechanical tester is the only all-in-one device designed for compression, tension, shear, fric-tion, torsion and indentation mapping. The Mach-1™ is now used in many university labs and is deemed an excellent educa-tional tool for students.

CartiHeal Booth Nr. 1117 Atir Yeda St4464313 Kfar Saba, [email protected]@cartiheal.comwww.cartiheal.com

CartiHeal, a privately held medical device company with head-quarters in Israel and USA, has developed the Agili-C™ implant for the treatment of cartilage and osteochondral defects in trau-matic and osteoarthritic joints.Agili-C™ is cell-free and off-the-shelf. The implant is bi-phasic, porous, biocompatible and resorbable, composed of natural inorganic calcium carbonate (aragonite). Agili-C™ has been implanted in over 400 patients with knee, ankle, and great toe cartilage lesions, in a series of clinical studies conducted at leading centers worldwide. CartiHeal is currently conducting an FDA (IDE) pivotal clinical study. The study is prospective, multi-center, open-label, randomized and controlled. The goal of the study is to demonstrate the superiority of the Agili-C™ implant over the current surgical standard of care (SSOC): mi-cro-fracture or debridement, for the treatment of joint surface lesions of the knee.


Collagen Solutions Plc Booth Nr. 1Europe Regional Headquarters3 Robroyston OvalNova Business ParkG33 1AP, Glasgow, Scotland, [email protected]

Collagen Solutions is a global regenerative biomaterials com-pany focused on supply, development and manufacturing of tissue-based medical devices. With locations in Minnesota, Scot-land, New Zealand and South Korea, they provide materials and services to some of the largest medical device companies in the world. Their latest development (not yet approved) is ChondroM-imetic, an off-the-shelf, biphasic osteochondral scaffold intended to be approved for use in small osteochondral defects and small focal chondral lesions. The cost-effective, all-biologic scaffold will be provided in a single-use delivery device to enable arthroscop-ic implantation and already holds 8+ years of clinical evidence.

CONMED Booth Nr. 911311 Concept BlvdLargo, FL 33773, [email protected]

CONMED is committed to helping surgeons have an easier day in the OR. As an innovative medical technology company, we are focused on empowering healthcare providers worldwide to deliver exceptional outcomes for patients. We are excited to showcase our latest solutions and demonstrate how we are redefi ning innovation and effi ciency in our industry. CONMED is the offi cial representa-tive of MTF Biologics’ Sports Medicine Allografts. MTF Biologics has provided more than 8 million allografts and minimally processed do-nor tissue to help preserve the allograft’s natural biomechanical and healing properties. CONMED. Imagine what we could do together.

DJO GLOBAL Booth Nr. 302900 Lake Vista DriveDallas, TX 75067, USAPhone: 1-800-336-6569www.djoglobal.com

DJO is a leading global medical device company providing solutions for musculoskeletal and vascular health, and pain management. The Company’s products help patients prevent injuries or rehabilitate after surgery, injury or degenerative disease. DJO’s brands include Aircast®, DonJoy®, ProCare®, CMF™, Chattanooga Group™, DJO Surgical, Cefar®-Com-pex® and Ormed®. Visit www.DJOglobal.com


&













109

Finceramica Booth Nr. 8Via Granarolo 177 / 348018 Faenza (RA) ItalyPhone: +39 0546 607 311Fax +39 0546 607 312www.fi nceramica.itinfo@fi nceramica.it

Finceramica, created in 1992 as a spin-off from the Institute of Science and Technology for Ceramics, is now an integrat-ed company which develops, produces and markets innovative therapeutic solutions in the biomedical fi eld. Finceramica rep-resents the crossover point between the thousand-year evolution of ceramic processes and the innovation in biomaterials, in bio-sciences and in “regenerative surgery”. Our research activities rotate around human beings and their specifi c necessities, as patients and as surgeons; our technology platform is a tangible answer to everyday needs that may occur in Orthopedic, Neuro and Spinal surgery.

Geistlich Pharma AG Booth Nr. 4Business Unit Surgery Bahnhofstrasse 40CH-6110 WolhusenPhone +41 41 492 55 55Fax +41 41 492 56 [email protected]

Geistlich Surgery, a business unit of Geistlich Pharma AG, pro-duces innovative bio-derived products for bone and cartilage, including Orthoss®, Orthoss Collagen®, and Chondro-Gide®. Headquartered in Switzerland and family owned since 1851, the company develops and markets medical devices for re-generative medicine and pharmaceuticals. From research and development to marketing, our operations are fully integrated under one roof, which enables us to oversee and optimize all levels of our business.


ICRS Patient Registry Booth Nr. 27c/o Cailtlin Conly Spitalstrasse 190 - House 38623 Wetzikon – SwitzerlandPhone: +41 44 503 73 [email protected] www.cartilage.org

Our mission is to create the best source of unbiased outcomes data for treatments of painful articular cartilage lesions in the world, which is paramount for improvement of existing and discovery of new car-tilage repair strategies, ultimately benefi cial for millions of patients around the world. The ICRS Patient Registry is a mechanism of allow-ing you and your doctor to track your individual progress following diagnosis and/or treatment of your knee problem. The registry is cur-rently set-up for Knee Problems but other joints will be added in due time. VISIT us at Booth Nr.xxx to sign up and receive a demonstration

ImageBiopsy Lab Booth Nr. 25Hietzinger Hauptstrasse 50/101130, Vienna, AustriaPhone: +43 1 905 12 [email protected]

Empowering physicians to support prevention of debilitating bone & joint disease by pushing the boundaries of AI. The mission of ImageBiopsy Lab is to improve the diagnostic experience of patients and to go beyond the current standard of care. Diagnoses are often too late, subjective and delay details due to time pressure. For this reason, ImageBiopsy Lab provides solutions. To solve these diffi cul-ties effi ciently, ImageBiopsy Lab uses state-of-the-art computer vision and artifi cial intelligence technology.

Incrediwear Booth Nr. 293120 Thorntree DriveChico, CA 95973, [email protected]

MISSION: To free people to live full lives, by giving effective relief from acute and chronic pain and discomfort. Incrediwear wearable anti-infl ammatory therapy is scientifi cally proven to accelerate re-covery by increasing circulation thereby reducing infl ammation & swelling, relieving pain, and signifi cantly restoring range of motion. Incrediwear’s technology incorporates semiconductor elements with-in the fabric to create cellular vibrations, bringing more oxygen and nutrients to the target area. The powerful results of Incrediwear are used by pro athletes and medical professions to alleviate symptoms from postoperative procedures, arthritis, impact injuries, and a vari-ety of other conditions. Incrediwear improves the journey to recovery allowing patients to live incredibly.


&













111

JRF Ortho Booth Nr. 126746 S Revere PkwySuite B-125Centennial, CO 80112, [email protected]

JRF Ortho specializes in providing orthopedic surgeons with the high-est viability, most widely available cartilage solutions in the industry. Our goal is to provide innovative solutions for allograft joint repair to orthopedic surgeons who specialize in helping patients regain move-ment and improve their quality of life; thus, JRF Ortho is redefi ning the standard for allograft joint repair and maximizing the gift of donation. Our unique member relationship with AlloSource® and Community Tissue Services® (CTS) enables us to offer the largest selection of spe-cialized high-viability fresh osteochondral grafts, tendons and menisci in the industry.

Mission: To improve quality of life through innovative solutions for al-lograft joint repair.Purpose: At JRF Ortho, we provide innovative solutions for allograft joint repair to orthopedic surgeons who specialize in helping patients regain movement and improve their quality of life. Through our unique member relationship with AlloSource and Community Tissue Services, we offer the largest selection of specialized high-viability fresh osteo-chondral grafts, tendons and menisci in the industry. Our approach to joint restoration maximizes tissue safety and availability for elective procedures. Through our commitment to superior clinical results and positive patient outcomes, JRF Ortho is redefi ning the standard for allograft joint repair and maximizing the gift of donation.Mantra: Beyond movement. At JRF Ortho, it’s not enough to do it the same as the next guy. Our goal is to do one better by providing the largest selection of the highest quality orthopedic-specialized grafts, tendons and cartilage possible. We know that patients with muscu-loskeletal conditions are also seeking to go further, or faster than they can presently. Like us, they are looking to go beyond today to what is possible tomorrow.

LifeNet Health Booth Nr. 201864 Concert Drive, Virginia BeachVirginia 23453, [email protected]

For over 30 years, LifeNet Health has been the world’s most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular ther-apies — a leader in the fi eld of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.


Lipogems Booth Nr. 31880 Beaver Ridge CircleNorcross, GA 30071, [email protected]

LIPOGEMS® is the best in class FDA cleared technology for patients that have tried conservative therapy and are not ready for major invasive surgery or maybe added to surgery to opti-mize recovery and healing. Lipogems is a minimally invasive procedure that washes, concentrates, and microfragments the patient’s adipose tissue to help provide cushion and support the healing process. Lipogems is FDA cleared for use in ortho-paedics and arthroscopic surgery and meets the guidelines for minimal manipulation of the tissue and is intended for homolo-gous use.

medi GmbH & Co. KG Booth Nr. 13Medicusstr. 1DE 95448 Bayreuth / Germany Contact: Vanessa [email protected]/en

Founded in Germany in 1951, medi GmbH & Co. KG has become one of the world’s leading manufacturers of medical aids. Thanks to the dedication of our international distribution partners and 1700 employees, the company exports to over 90 countries worldwide. Our orthopaedic assortment consists of supports and braces for the treatment of joint conditions and injuries for all parts of the human body such as back, shoulder/spine, hip, knee, ankle, wrist, elbow or foot. Our full range of premium-quality products are the fi rst choice of many renowned healthcare professionals all across the globe.


&













113

NEWCLIP TECHNICS Booth Nr. 545 rue des Garottières44115 Haute Goulaine, FranceContact: Lucille [email protected]

Founded in 2002, Newclip Technics is a French manufacturer of innovative osteosynthesis systems for elective surgery and traumatol-ogy. The company is already established in 38 countries with subsid-iaries in the USA, Germany, Australia and Japan.

The heart of our company’s values:• Innovation: developing innovative concepts and products protected by numerous international patents. • Quality: The reactivity and fl exibility ensures products of the hig est standards whilst adapting to market expectations.• Performance: Investing in the latest generation of CNC 5 axes machines, 3D printing and other disruptive technologies.

For Newclip Technics, each patient is unique and needs personalised care. By using CT scan protocols, we are able to provide Patient Specifi c cutting guides dedicated to each and every bone osteotomy.

OligoMedic Inc Booth Nr. 32500 Boulevard Cartier OuestLaval (Quebec) H7V 5B7, [email protected]@oligomedic.comwww.oligomedic.com

OligoMedic Inc. (Laval, Quebec) was founded in 2010 by bio-materials experts with 20 years industry experience who dis-covered the fi rst polysaccharide (Chitosan)-based thermogels. OligoMedic designs, manufactures and commercializes novel gels, with an initial focus on tissue repair. It has developed its fi rst product JointRep® as an in-situ fast forming injectable hy-drogel to treat articular cartilage defects. Designed for ease of use and seamless integration into the clinical workfl ow, it is implanted in the course of an arthroscopic procedure. Oligo-Medic employs a network of distributors to serve global mar-kets and is active in over twenty countries. OligoMedic is ISO 13485: 2016 compliant.


ON Foundation Booth Nr. 26Kapellplatz 16004 [email protected]

ON, the orthoregeneration network is an independent interna-tional foundation in the fi eld of orthopedic tissue regeneration driving the development and understanding of new treatment strategies for the well-being of the patient. The ON FOUN-DATION sets quality standards, spreads unbiased knowledge about orthoregeneration and links young professionals, experts and academic organizations all over the world. Together we build a strong network and guarantee innovation. We believe that research is the engine of development and that linking and educating passionate young professionals is the way to ad-vance the fi eld of orthoregeneration signifi cantly.

Organogenesis Booth Nr. 222641 Rocky Ridge LaneBirmingham, AL 35216, USAPhone: [email protected]

Organogenesis offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.

Orteq® Sports Medicine Ltd Booth Nr. 6535 Madison Ave, 4th FloorNY 10022 New YorkUnited States of Americawww.orteq.com

Orteq® Sports Medicine Ltd and its two core technologies Acti-fi t® and Cartione ® are now owned by Saratoga Partners LLC, a US based private equity fund. Orteq is a leader in the de-veloping fi eld of biodegradable meniscal scaffolds and single stage cartilage transplantation. Cartione, is a patented single stage ACI (STACI). It is available in the EU as a one-hour pro-cedure mixing freshly isolated chondrocytes and MNC’s. The Actifi t meniscal scaffold recently received its CE mark renewal and is re-launching globally. Positive Actifi t EU multi centre fi ve-year results are currently being presented at various Internation-al congresses and the polymer platform is being evaluated for use in the Hip and Shoulder.


&













115

Össur Americas, Inc. Booth Nr. 227051 Towne Centre DriveFoothill Ranch, CA 92610, USAPhone 800) 233-6263E-mail [email protected] www.ossur.com

Össur is a leader in non-invasive orthopaedics. We deliver advanced and innovative technologies within the fi elds of Bracing & Supports. Our Functional Healing® products include the award-winning Re-bound® PCL for complex knee injuries and Rebound® Cartilage, a protective functional solution designed to support the regeneration of knee cartilage in the post-surgical phase. Our Unloader® line of osteoarthritis bracing features the clinically proven Unloader One® knee brace that reduces pain and improves function and Unloader® Hip for the conservative treatment of hip OA. Stop by our booth to see these products along with our Rebound® Post-op Knee.

Regen Lab SA Booth Nr. 19En Budron B21052 Le [email protected] Regen Lab SA Switzerland is a global leader in Regenerative Medicine and manufacturer of Medical Devices for preparation of autologous Platelet Rich Plasma (PRP), used either alone or combined with hyaluronic acid or other autologous cells extracts from fat or bone marrow. These technologies are inherently safe and effi cient in pain management and accelerating healing; they have proven effi cacy in ageing management, wound care, mus-culoskeletal pathologies and various gynaecological conditions.

SAGE Publishing Booth Nr. 33Journal “Cartilage”2455 Teller RoadThousand Oaks, CA 91320, USAwww.sagepublishing.com

Sara Miller McCune founded SAGE Publishing in 1965 to support the dissemination of usable knowledge and educate a global com-munity. SAGE publishes more than 1,000 journals and over 800 new books each year, spanning a wide range of subject areas. Our growing selection of library products includes archives, data, case studies and video. SAGE remains majority owned by our founder and after her lifetime will become owned by a charitable trust that secures the company’s continued independence. Principal offi ces are located in Los Angeles, London, New Delhi, Singapore, Washington DC and Melbourne. www.sagepublishing.com


Smith & Nephew Inc. Booth Nr. 21150 Minuteman RoadAndover, MA 01810, USAPhone: +1 978 749 1000Fax: + 1 978 749 1407www.global.smith-nephew.com

Smith & Nephew is a portfolio medical technology business with leadership positions in:

• Orthopaedic Reconstruction - Joint replacement systems for knees and hips • Sports Medicine - Minimally invasive surgery of the joint• Trauma & Extremities • Advanced Wound Management

Smith & Nephew supports healthcare professionals in their dai-ly efforts to improve the lives of their patients. We do this by taking a pioneering approach to the design of our advanced medical products and services, by securing wider access to our diverse technologies for more customers globally, and by enabling better outcomes for patients and healthcare systems. Smith & Nephew has more than 16,000 employees and a pres-ence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

Vericel Corporation Booth Nr. 1764 Sidney StCambridge, MA 02139, [email protected]

Vericel develops, manufactures, and markets autologous cell-based therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients.


&













117BerlinGermany May 26–29, 2021

16th World Congressof the International Cartilage Regeneration & Joint Preservation Society


Mark your agenda!

www.cartilage.org

Zimmer Biomet Booth Nr. 101800 West Center StWarsaw, Indiana 46580 Phone: 1-800-253-6190 [email protected]

Zimmer Biomet has been based in Warsaw, Indiana since it was founded in 1927. Today, Zimmer Biomet has operations in more than 25 countries around the world and sells products in more than 100 countries. Our global team designs, manu-factures and markets effective, innovative solutions that support orthopaedic surgeons and clinicians in alleviating pain and improving the quality of life for people around the world. Our musculoskeletal technologies and a wide range of related prod-ucts and services make us partners to healthcare providers in more than 100 countries. We’re building on a strong history of success to enhance the value we provide to healthcare pro-viders and their patients. Zimmer Biomet maintains world-class scientifi c facilities and resources and collaborates with leading clinicians and researchers around the world. We share a com-mitment with healthcare providers to fi nd the best technologies, treatments and solutions to deliver high quality, cost-effective patient care.


Our mission is to improve quality of life through innovative solutions for allograft joint repair.

DISCOVER HOW JRF ORTHO CAN MOVE YOU. VISIT US AT BOOTH #12 IN VANCOUVER!

JRFORTHO.org

THOUGHT LEADER AND INNOVATOR

FRESH OCA CORES

⊲ Provide intact hyaline cartilage, viable chondrocytes, and subchondral bone

⊲ Single step treatment with no patient size matching required

⊲ A great alternative for small focal lesions

FEMORAL CONDYLE

⊲ Proprietary processing methods shown to maintain 80% cartilage viability1

⊲ Sized matched per patient

⊲ Shortest wait times in the industry

DISTAL TIBIA

⊲ Restores glenoid with live cartilage and strong bone

⊲ No size match required

⊲ Eliminates morbidity of autograft latarjet

1. Data on file, JRF Ortho

beyond movement

NOW AVAILABLE

IN 16 m

m

INTERNATIONAL CARTILAGE REGENERATION INTERNATIONAL ... · 16.15 Opening Ceremony & Award Session...

Documents

Transcript of INTERNATIONAL CARTILAGE REGENERATION INTERNATIONAL ... · 16.15 Opening Ceremony & Award Session...